51
|
Roberts BR, Laffoon SB, Roberts AM, Porter T, Fowler C, Masters CL, Dratz EA, Laws SM. Discovery of a Missense Mutation (Q222K) of the APOE Gene from the Australian Imaging, Biomarker and Lifestyle Study. J Alzheimers Dis Rep 2023; 7:165-172. [PMID: 36891255 PMCID: PMC9986708 DOI: 10.3233/adr-220075] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/19/2022] [Accepted: 01/04/2023] [Indexed: 02/05/2023] Open
Abstract
After age, polymorphisms of the Apolipoprotein E (APOE) gene are the biggest risk factor for the development of Alzheimer's disease (AD). During our investigation to discovery biomarkers in plasma, using 2D gel electrophoresis, we found an individual with and unusual apoE isoelectric point compared to APOE ɛ2, ɛ3, and ɛ4 carriers. Whole exome sequencing of APOE from the donor confirmed a single nucleotide polymorphism (SNP) in exon 4, translating to a rare Q222K missense mutation. The apoE ɛ4 (Q222K) mutation did not form dimers or complexes observed for apoE ɛ2 & ɛ3 proteins.
Collapse
Affiliation(s)
- Blaine R Roberts
- Emory School of Medicine, Department of Biochemistry, Department of Neurology, Atlanta, GA, USA.,Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, VIC, Australia.,Department of Chemistry and Biochemistry, Montana State University, Bozeman, MT, USA
| | - Scott B Laffoon
- Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, VIC, Australia.,Department of Chemistry and Biochemistry, Montana State University, Bozeman, MT, USA
| | - Anne M Roberts
- Emory School of Medicine, Department of Biochemistry, Department of Neurology, Atlanta, GA, USA.,Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, VIC, Australia
| | - Tenielle Porter
- Centre for Precision Health, Edith Cowan University, Joondalup, WA, Australia.,Collaborative Genomics and Translation Group, School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia
| | - Chris Fowler
- Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, VIC, Australia
| | - Colin L Masters
- Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, VIC, Australia
| | - Edward A Dratz
- Department of Chemistry and Biochemistry, Montana State University, Bozeman, MT, USA
| | - Simon M Laws
- Centre for Precision Health, Edith Cowan University, Joondalup, WA, Australia.,Collaborative Genomics and Translation Group, School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia
| |
Collapse
|
52
|
Luckett PH, Chen C, Gordon BA, Wisch J, Berman SB, Chhatwal JP, Cruchaga C, Fagan AM, Farlow MR, Fox NC, Jucker M, Levin J, Masters CL, Mori H, Noble JM, Salloway S, Schofield PR, Brickman AM, Brooks WS, Cash DM, Fulham MJ, Ghetti B, Jack CR, Vöglein J, Klunk WE, Koeppe R, Su Y, Weiner M, Wang Q, Marcus D, Koudelis D, Mathurin NJ, Cash L, Hornbeck R, Xiong C, Perrin RJ, Karch CM, Hassenstab J, McDade E, Morris JC, Benzinger TL, Bateman RJ, Ances BM. Biomarker clustering in autosomal dominant Alzheimer's disease. Alzheimers Dement 2023; 19:274-284. [PMID: 35362200 PMCID: PMC9525451 DOI: 10.1002/alz.12661] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2021] [Revised: 02/20/2022] [Accepted: 02/22/2022] [Indexed: 01/18/2023]
Abstract
INTRODUCTION As the number of biomarkers used to study Alzheimer's disease (AD) continues to increase, it is important to understand the utility of any given biomarker, as well as what additional information a biomarker provides when compared to others. METHODS We used hierarchical clustering to group 19 cross-sectional biomarkers in autosomal dominant AD. Feature selection identified biomarkers that were the strongest predictors of mutation status and estimated years from symptom onset (EYO). Biomarkers identified included clinical assessments, neuroimaging, cerebrospinal fluid amyloid, and tau, and emerging biomarkers of neuronal integrity and inflammation. RESULTS Three primary clusters were identified: neurodegeneration, amyloid/tau, and emerging biomarkers. Feature selection identified amyloid and tau measures as the primary predictors of mutation status and EYO. Emerging biomarkers of neuronal integrity and inflammation were relatively weak predictors. DISCUSSION These results provide novel insight into our understanding of the relationships among biomarkers and the staging of biomarkers based on disease progression.
Collapse
Affiliation(s)
| | - Charlie Chen
- Washington University in St. Louis, St. Louis, Missouri, USA
| | - Brian A. Gordon
- Washington University in St. Louis, St. Louis, Missouri, USA
| | - Julie Wisch
- Washington University in St. Louis, St. Louis, Missouri, USA
| | | | - Jasmeer P. Chhatwal
- Brigham and Women’s Hospital, Massachusetts General Hospital, Boston, Massachusetts, USA
| | - Carlos Cruchaga
- Washington University in St. Louis, St. Louis, Missouri, USA
| | - Anne M. Fagan
- Washington University in St. Louis, St. Louis, Missouri, USA
| | | | - Nick C. Fox
- Dementia Research Centre, UCL Queen Square Institute of Neurology, London, UK
| | - Mathias Jucker
- German Center for Neurodegenerative Disease, Tübingen, Germany
- Hertie-Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany
| | - Johannes Levin
- Department of Neurology, Ludwig-Maximilians-Universität München, Munich, Germany
- German Center for Neurodegenerative Diseases, Munich, Germany
- Munich Cluster for Systems Neurology (SyNergy), Munich, Germany
| | - Colin L. Masters
- Florey Institute, The University of Melbourne, Parkville, Victoria, Australia
| | - Hiroshi Mori
- Osaka City University Medical School, Nagaoka Sutoku University, Abenoku, Osaka, Japan
| | - James M. Noble
- Taub Institute for Research on Alzheimer’s Disease and the Aging Brain, G.H. Sergievsky Center, and Department of Neurology, Columbia University Irving Medical Center, New York, New York, USA
| | - Stephen Salloway
- Butler Hospital and Warren Alpert Medical School of Brown University, Providence, Rhode Island, USA
| | - Peter R. Schofield
- Neuroscience Research Australia, Randwick, New South Wales, Australia
- School of Medical Sciences, University of New South Wales, Sydney, New South Wales, Australia
| | - Adam M. Brickman
- Department of Molecular Imaging, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia
- The University of Sydney, Sydney, New South Wales, Australia
| | - William S. Brooks
- Neuroscience Research Australia, Randwick, New South Wales, Australia
- School of Medical Sciences, University of New South Wales, Sydney, New South Wales, Australia
| | - David M. Cash
- Dementia Research Centre, UCL Queen Square Institute of Neurology, London, UK
| | - Michael J. Fulham
- Department of Molecular Imaging, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia
- The University of Sydney, Sydney, New South Wales, Australia
| | | | | | - Jonathan Vöglein
- Department of Neurology, Ludwig-Maximilians-Universität München, Munich, Germany
- German Center for Neurodegenerative Diseases (DZNE), Munich, Germany
| | | | | | - Yi Su
- Banner Alzheimer Institute, Phoenix, Arizona, USA
| | - Michael Weiner
- University of California San Francisco, San Francisco, California, USA
- San Francisco Veterans Affairs Medical Center, San Francisco, California, USA
| | - Qing Wang
- Washington University in St. Louis, St. Louis, Missouri, USA
| | - Daniel Marcus
- Washington University in St. Louis, St. Louis, Missouri, USA
| | | | | | - Lisa Cash
- Washington University in St. Louis, St. Louis, Missouri, USA
| | - Russ Hornbeck
- Washington University in St. Louis, St. Louis, Missouri, USA
| | - Chengjie Xiong
- Washington University in St. Louis, St. Louis, Missouri, USA
| | | | | | | | - Eric McDade
- Washington University in St. Louis, St. Louis, Missouri, USA
| | - John C. Morris
- Washington University in St. Louis, St. Louis, Missouri, USA
| | | | | | - Beau M. Ances
- Washington University in St. Louis, St. Louis, Missouri, USA
| |
Collapse
|
53
|
Luo J, Agboola F, Grant E, Morris JC, Masters CL, Albert MS, Johnson SC, McDade EM, Fagan AM, Benzinger TLS, Hassenstab J, Bateman RJ, Perrin RJ, Wang G, Li Y, Gordon B, Cruchaga C, Day GS, Levin J, Vöglein J, Ikeuchi T, Suzuki K, Allegri RF, Xiong C. Accelerated longitudinal changes and ordering of Alzheimer disease biomarkers across the adult lifespan. Brain 2022; 145:4459-4473. [PMID: 35925685 PMCID: PMC10200301 DOI: 10.1093/brain/awac238] [Citation(s) in RCA: 11] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/29/2021] [Revised: 04/15/2022] [Accepted: 06/11/2022] [Indexed: 01/25/2023] Open
Abstract
The temporal evolutions and relative orderings of Alzheimer disease biomarkers, including CSF amyloid-β42 (Aβ42), Aβ40, total tau (Tau) and phosphorylated tau181 (pTau181), standardized uptake value ratio (SUVR) from the molecular imaging of cerebral fibrillar amyloid-β with PET using the 11C-Pittsburgh Compound-B (PiB), MRI-based hippocampal volume and cortical thickness and cognition have been hypothesized but not yet fully tested with longitudinal data for all major biomarker modalities among cognitively normal individuals across the adult lifespan starting from 18 years. By leveraging a large harmonized database from 8 biomarker studies with longitudinal data from 2609 participants in cognition, 873 in MRI biomarkers, 519 in PET PiB imaging and 475 in CSF biomarkers for a median follow-up of 5-6 years, we estimated the longitudinal trajectories of all major Alzheimer disease biomarkers as functions of baseline age that spanned from 18 to 103 years, located the baseline age window at which the longitudinal rates of change accelerated and further examined possible modifying effects of apolipoprotein E (APOE) genotype. We observed that participants 18-45 years at baseline exhibited learning effects on cognition and unexpected directions of change on CSF and PiB biomarkers. The earliest acceleration of longitudinal change occurred for CSF Aβ42 and Aβ42/Aβ40 ratio (with an increase) and for Tau, and pTau181 (with a decrease) at the next baseline age interval of 45-50 years, followed by an accelerated increase for PiB SUVR at the baseline age of 50-55 years and an accelerated decrease for hippocampal volume at the baseline age of 55-60 years and finally by an accelerated decline for cortical thickness and cognition at the baseline age of 65-70 years. Another acceleration in the rate of change occurred at the baseline age of 65-70 years for Aβ42/Aβ40 ratio, Tau, pTau181, PiB SUVR and hippocampal volume. Accelerated declines in hippocampal volume and cognition continued after 70 years. For participants 18-45 years at baseline, significant increases in Aβ42 and Aβ42/Aβ40 ratio and decreases in PiB SUVR occurred in APOE ɛ4 non-carriers but not carriers. After age 45 years, APOE ɛ4 carriers had greater magnitudes than non-carriers in the rates of change for all CSF biomarkers, PiB SUVR and cognition. Our results characterize the temporal evolutions and relative orderings of Alzheimer disease biomarkers across the adult lifespan and the modification effect of APOE ɛ4. These findings may better inform the design of prevention trials on Alzheimer disease.
Collapse
Affiliation(s)
- Jingqin Luo
- Division of Public Health Sciences, Department of Surgery, Washington University School of Medicine, St. Louis, MO 63110, USA
- Siteman Cancer Center Biostatistics Core, Washington University School of Medicine, St. Louis, MO 63110, USA
- Division of Biostatistics, Washington University School of Medicine, St. Louis, MO, USA
| | - Folasade Agboola
- Division of Biostatistics, Washington University School of Medicine, St. Louis, MO, USA
- Knight Alzheimer Disease Research Center, Washington University School of Medicine, St. Louis, MO, USA
| | - Elizabeth Grant
- Division of Biostatistics, Washington University School of Medicine, St. Louis, MO, USA
- Knight Alzheimer Disease Research Center, Washington University School of Medicine, St. Louis, MO, USA
| | - John C Morris
- Knight Alzheimer Disease Research Center, Washington University School of Medicine, St. Louis, MO, USA
- Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA
- Departments of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA
| | - Colin L Masters
- The Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, VIC, Australia
| | - Marilyn S Albert
- Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
| | - Sterling C Johnson
- Wisconsin Alzheimer’s Institute and Alzheimer’s Disease Research Center, University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI, USA
- Geriatric Research Education and Clinical Center, William S. Middleton Veterans Memorial Hospital, Madison, WI, USA
| | - Eric M McDade
- Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA
| | - Anne M Fagan
- Knight Alzheimer Disease Research Center, Washington University School of Medicine, St. Louis, MO, USA
- Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA
| | - Tammie L S Benzinger
- Knight Alzheimer Disease Research Center, Washington University School of Medicine, St. Louis, MO, USA
- Department of Radiology, Washington University School of Medicine, St. Louis, MO, USA
| | - Jason Hassenstab
- Knight Alzheimer Disease Research Center, Washington University School of Medicine, St. Louis, MO, USA
- Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA
| | - Randall J Bateman
- Knight Alzheimer Disease Research Center, Washington University School of Medicine, St. Louis, MO, USA
- Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA
| | - Richard J Perrin
- Knight Alzheimer Disease Research Center, Washington University School of Medicine, St. Louis, MO, USA
- Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA
- Departments of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA
| | - Guoqiao Wang
- Division of Biostatistics, Washington University School of Medicine, St. Louis, MO, USA
- Knight Alzheimer Disease Research Center, Washington University School of Medicine, St. Louis, MO, USA
| | - Yan Li
- Division of Biostatistics, Washington University School of Medicine, St. Louis, MO, USA
- Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA
| | - Brian Gordon
- Knight Alzheimer Disease Research Center, Washington University School of Medicine, St. Louis, MO, USA
- Department of Radiology, Washington University School of Medicine, St. Louis, MO, USA
| | - Carlos Cruchaga
- Knight Alzheimer Disease Research Center, Washington University School of Medicine, St. Louis, MO, USA
- Department of Psychiatry, Washington University School of Medicine, St Louis, MO, USA
| | - Gregory S Day
- Department of Neurology, Mayo Clinic, Jacksonville, FL, USA
| | - Johannes Levin
- German Center for Neurodegenerative Diseases (DZNE), Munich, Germany
- Department of Neurology, Ludwig-Maximilians-Universität München, Munich, Germany
- Munich Cluster for Systems Neurology (SyNergy), Munich, Germany
| | - Jonathan Vöglein
- German Center for Neurodegenerative Diseases (DZNE), Munich, Germany
- Department of Neurology, Ludwig-Maximilians-Universität München, Munich, Germany
| | - Takeshi Ikeuchi
- Department of Molecular Genetics, Brain Research Institute, Niigata University, Niigata 951-8585, Japan
| | - Kazushi Suzuki
- Unit for Early and Exploratory Clinical Development, The University of Tokyo, Tokyo, Japan
| | - Ricardo F Allegri
- Department of Cognitive Neurology, Institute for Neurological Research Fleni, Buenos Aires, Argentina
| | - Chengjie Xiong
- Division of Biostatistics, Washington University School of Medicine, St. Louis, MO, USA
- Knight Alzheimer Disease Research Center, Washington University School of Medicine, St. Louis, MO, USA
| | | |
Collapse
|
54
|
Dhiman K, Villemagne VL, Fowler C, Bourgeat P, Li Q, Collins S, Rowe CC, Masters CL, Ames D, Blennow K, Zetterberg H, Martins RN, Gupta V. Cerebrospinal fluid levels of fatty acid-binding protein 3 are associated with likelihood of amyloidopathy in cognitively healthy individuals. Alzheimers Dement (Amst) 2022; 14:e12377. [PMID: 36479019 PMCID: PMC9719998 DOI: 10.1002/dad2.12377] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Received: 05/04/2021] [Revised: 10/05/2022] [Accepted: 10/19/2022] [Indexed: 12/12/2022]
Abstract
INTRODUCTION Fatty acid-binding protein 3 (FABP3) is a biomarker of neuronal membrane disruption, associated with lipid dyshomeostasis-a notable Alzheimer's disease (AD) pathophysiological change. We assessed the association of cerebrospinal fluid (CSF) FABP3 levels with brain amyloidosis and the likelihood/risk of developing amyloidopathy in cognitively healthy individuals. METHODS FABP3 levels were measured in CSF samples of cognitively healthy participants, > 60 years of age (n = 142), from the Australian Imaging, Biomarkers & Lifestyle Flagship Study of Ageing (AIBL). RESULTS FABP3 levels were positively associated with baseline brain amyloid beta (Aβ) load as measured by standardized uptake value ratio (SUVR, standardized β = 0.22, P = .009) and predicted the change in brain Aβ load (standardized β = 0.32, P = .004). Higher levels of CSF FABP3 (above median) were associated with a likelihood of amyloidopathy (odds ratio [OR] 2.28, 95% confidence interval [CI] 1.12 to 4.65, P = .023). DISCUSSION These results support inclusion of CSF FABP3 as a biomarker in risk-prediction models of AD.
Collapse
Affiliation(s)
- Kunal Dhiman
- IMPACT – The Institute for Mental and Physical Health and Clinical TranslationSchool of MedicineDeakin UniversityGeelongVictoriaAustralia,Western Health PartnershipSchool of Nursing and Midwifery (Centre for Quality and Patient Safety Research in the Institute of Health Transformation)Faculty of HealthDeakin UniversityMelbourneVictoriaAustralia,School of Medical and Health SciencesEdith Cowan UniversityJoondalupWestern AustraliaAustralia
| | - Victor L. Villemagne
- Department of PsychiatryUniversity of PittsburghPittsburghPennsylvaniaUSA,Department of Molecular Imaging & Therapy and Centre for PETAustin HealthHeidelbergVictoriaAustralia,Department of MedicineThe University of MelbourneMelbourneVictoriaAustralia
| | - Christopher Fowler
- The Florey Institute of Neuroscience and Mental HealthThe University of MelbourneParkvilleVictoriaAustralia
| | - Pierrick Bourgeat
- Australian e‐Health Research CentreCSIRO Health and BiosecurityBrisbaneQueenslandAustralia
| | - Qiao‐Xin Li
- The Florey Institute of Neuroscience and Mental HealthThe University of MelbourneParkvilleVictoriaAustralia
| | - Steven Collins
- Department of MedicineThe University of MelbourneMelbourneVictoriaAustralia,The Florey Institute of Neuroscience and Mental HealthThe University of MelbourneParkvilleVictoriaAustralia
| | - Christopher C. Rowe
- Department of Molecular Imaging & Therapy and Centre for PETAustin HealthHeidelbergVictoriaAustralia,Department of MedicineThe University of MelbourneMelbourneVictoriaAustralia
| | - Colin L. Masters
- The Florey Institute of Neuroscience and Mental HealthThe University of MelbourneParkvilleVictoriaAustralia
| | - David Ames
- National Ageing Research InstituteParkvilleVictoriaAustralia,Academic Unit for Psychiatry of Old ageSt. George's HospitalThe University of MelbourneMelbourneVictoriaAustralia
| | - Kaj Blennow
- Department of Psychiatry and NeurochemistryInstitute of Neuroscience and Physiologythe Sahlgrenska Academy at the University of GothenburgGothenburgSweden,Clinical Neurochemistry LaboratorySahlgrenska University HospitalGothenburgSweden
| | - Henrik Zetterberg
- Department of Psychiatry and NeurochemistryInstitute of Neuroscience and Physiologythe Sahlgrenska Academy at the University of GothenburgGothenburgSweden,Clinical Neurochemistry LaboratorySahlgrenska University HospitalGothenburgSweden,Department of Neurodegenerative DiseaseUCL Queen Square Institute of NeurologyLondonUK,UK Dementia Research Institute at UCLLondonUK,Hong Kong Center for Neurodegenerative DiseasesHong KongChina
| | - Ralph N. Martins
- School of Medical and Health SciencesEdith Cowan UniversityJoondalupWestern AustraliaAustralia,Australian Alzheimer's Research FoundationRalph and Patricia Sarich Neuroscience Research InstituteNedlandsWestern AustraliaAustralia,Department of Biomedical SciencesMacquarie UniversitySydneyNew South WalesAustralia,School of Psychiatry and Clinical NeurosciencesUniversity of Western AustraliaPerthWestern AustraliaAustralia,KaRa Institute of Neurological DiseasesSydneyNew South WalesAustralia,Co‐operative Research Centre for Mental HealthCarltonVictoriaAustralia
| | - Veer Gupta
- IMPACT – The Institute for Mental and Physical Health and Clinical TranslationSchool of MedicineDeakin UniversityGeelongVictoriaAustralia,School of Medical and Health SciencesEdith Cowan UniversityJoondalupWestern AustraliaAustralia
| |
Collapse
|
55
|
Sewell KR, Rainey‐Smith S, Villemagne VL, Peiffer JJ, Sohrabi HR, Taddei K, Ames D, Maruff P, Laws SM, Masters CL, Rowe C, Martins RN, Erickson KI, Brown BM. Objectively measured physical activity and cognition in cognitively normal older adults: A longitudinal analysis of the Australian Imaging Biomarkers and Lifestyle (AIBL) study. Alzheimers Dement 2022. [DOI: 10.1002/alz.064392] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Affiliation(s)
| | - Stephanie Rainey‐Smith
- Murdoch University, Murdoch Western Australia Australia
- Edith Cowan University, Joondalup Western Australia Australia
| | - Victor L Villemagne
- Department of Molecular Imaging and Therapy, Austin Health Heidelberg VIC Australia
- Department of Psychiatry, University of Pittsburgh Pittsburgh PA USA
| | | | - Hamid R Sohrabi
- Centre for Healthy Ageing, Murdoch University, Murdoch Western Australia Australia
- Australian Alzheimer’s Research Foundation, Perth Western Australia Australia
- Department of Biomedical Sciences, Macquarie University Sydney NSW Australia
| | | | - David Ames
- The University of Melbourne Melbourne VIC Australia
- National Ageing Research Institute Melbourne VIC Australia
| | - Paul Maruff
- Cogstate Ltd. Melbourne VIC Australia
- The Florey Institute of Neuroscience and Mental Health Melbourne VIC Australia
| | - Simon M Laws
- Edith Cowan University Joondalup Australia
- Curtin University Perth Australia
- School of Medical and Health Sciences, Edith Cowan University Joondalup Australia
| | - Colin L. Masters
- National Dementia Diagnostics Laboratory, The Florey Institute of Neuroscience and Mental Health Parkville VIC Australia
| | - Christopher Rowe
- Department of Molecular Imaging, Austin Health Melbourne VIC Australia
- Florey Institute of Neuroscience and Mental Health Parkville VIC Australia
| | - Ralph N Martins
- Edith Cowan University, Joondalup Western Australia Australia
- Australian Alzheimer’s Research Foundation Nedlands Australia
- Department of Biomedical Sciences, Macquarie University Macquarie Park NSW Australia
| | | | - Belinda M Brown
- Edith Cowan University, Joondalup Western Australia Australia
- Australian Alzheimer’s Research Foundation, Perth Western Australia Australia
- Centre for Healthy Ageing, Murdoch University, Perth Western Australia Australia
| |
Collapse
|
56
|
Roberts BR, Roberts AM, Cortes L, Fowler C, Villemagne VL, Masters CL, Ryan TM. Altered levels of plasma kallikrein‐7 in prodromal Alzheimer’s disease. Alzheimers Dement 2022. [DOI: 10.1002/alz.065881] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Affiliation(s)
| | | | - Laura Cortes
- The University of Melbourne parkville VIC Australia
| | - Christopher Fowler
- University of Melbourne Melbourne VIC Australia
- Florey Institute of Neuroscience and Mental Health Parkville VIC Australia
| | | | | | | |
Collapse
|
57
|
Rabe C, Bittner T, Mertes M, Riley K, Jethwa A, Schrurs I, Babitzki G, Stomrud E, Palmqvist S, Sperling RA, Aisen P, Rissman RA, Masters CL, Fontoura P, Ostrowitzki S, Hansson O, Doody RS. Blood‐based biomarker prescreening in the SKYLINE secondary prevention study with gantenerumab. Alzheimers Dement 2022. [DOI: 10.1002/alz.062144] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Affiliation(s)
| | - Tobias Bittner
- Genentech, Inc. South San Francisco CA USA
- F. Hoffmann‐La Roche Ltd Basel Switzerland
| | | | | | | | | | | | - Erik Stomrud
- Memory Clinic, Skåne University Hospital Malmö Sweden
- Clinical Memory Research Unit, Lund University Malmö Sweden
| | - Sebastian Palmqvist
- Memory Clinic, Skåne University Hospital Malmö Sweden
- Clinical Memory Research Unit, Lund University Malmö Sweden
| | - Reisa A. Sperling
- Center for Alzheimer’s Research and Treatment, Brigham and Women’s Hospital/Harvard Medical School Boston MA USA
| | - Paul Aisen
- Alzheimer's Therapeutic Research Institute, University of Southern California San Diego CA USA
| | - Robert A. Rissman
- Alzheimer's Therapeutic Research Institute, University of Southern California San Diego CA USA
- Department of Neurosciences, University of California San Diego CA USA
| | - Colin L Masters
- The Florey Institute of Neuroscience and Mental Health, University of Melbourne Melbourne VIC Australia
| | | | | | - Oskar Hansson
- Memory Clinic, Skåne University Hospital Malmö Sweden
- Clinical Memory Research Unit, Lund University Malmö Sweden
| | - Rachelle S. Doody
- Genentech, Inc. South San Francisco CA USA
- F. Hoffmann‐La Roche Ltd Basel Switzerland
| |
Collapse
|
58
|
Lee K, Huynh A, Moe T, Amadoru S, Zisis G, Raman R, Aisen P, Ernstrom K, Sperling RA, Masters CL, Yates PA. Prevalence and Associations of Frailty in Preclinical Alzheimer’s Disease. Alzheimers Dement 2022. [DOI: 10.1002/alz.069147] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Affiliation(s)
| | - Andrew Huynh
- Austin Health Melbourne VIC Australia
- The Florey Institute of Neuroscience and Mental Health Melbourne VIC Australia
| | | | | | - Georgios Zisis
- The Florey Institute of Neuroscience and Mental Health Melbourne VIC Australia
- University of Melbourne Melbourne VIC Australia
| | - Rema Raman
- Alzheimer’s Therapeutic Research Institute, University of Southern California San Diego CA USA
| | - Paul Aisen
- Alzheimer’s Therapeutic Research Institute, University of Southern California San Diego CA USA
| | - Karin Ernstrom
- Alzheimer’s Therapeutic Research Institute, University of Southern California San Diego CA USA
| | | | - Colin L. Masters
- The Florey Institute of Neuroscience and Mental Health Melbourne VIC Australia
- University of Melbourne Melbourne VIC Australia
| | - Paul A Yates
- Austin Health Melbourne VIC Australia
- The Florey Institute of Neuroscience and Mental Health Melbourne VIC Australia
- University of Melbourne Melbourne VIC Australia
| |
Collapse
|
59
|
Govindarajan ST, Mamourian E, Erus G, Abdulkadir A, Melhem R, Doshi J, Pomponio R, Tosun D, Bilgel M, An Y, Sotiras A, Marcus DS, LaMontagne PJ, Espeland MA, Masters CL, Maruff P, Launer LJ, Fripp J, Johnson SC, Morris JC, Albert MS, Bryan RN, Resnick SM, Habes M, Shou H, Wolk DA, Nasrallah IM, Davatzikos C. Machine‐learning based MRI neuro‐anatomical signatures associated with cardiovascular and metabolic risk factors. Alzheimers Dement 2022. [DOI: 10.1002/alz.061530] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Affiliation(s)
| | - Elizabeth Mamourian
- Center for Biomedical Image Computing and Analytics, University of Pennsylvania Philadelphia PA USA
| | - Guray Erus
- Center for Biomedical Image Computing and Analytics, University of Pennsylvania Philadelphia PA USA
| | - Ahmed Abdulkadir
- Center for Biomedical Image Computing and Analytics, University of Pennsylvania Philadelphia PA USA
| | - Randa Melhem
- Center for Biomedical Image Computing and Analytics, University of Pennsylvania Philadelphia PA USA
| | - Jimit Doshi
- Center for Biomedical Image Computing and Analytics, University of Pennsylvania Philadelphia PA USA
| | - Raymond Pomponio
- Center for Biomedical Image Computing and Analytics, University of Pennsylvania Philadelphia PA USA
| | - Duygu Tosun
- University of California, San Francisco San Francisco CA USA
| | - Murat Bilgel
- Laboratory of Behavioral Neuroscience, National Institute on Aging, Intramural Research Program Baltimore MD USA
| | - Yang An
- Laboratory of Behavioral Neuroscience, National Institute on Aging, Intramural Research Program Baltimore MD USA
| | | | - Daniel S. Marcus
- Washington University in St. Louis School of Medicine St. Louis MO USA
| | | | | | - Colin L. Masters
- Florey Institute of Neuroscience and Mental Health Parkville VIC Australia
| | - Paul Maruff
- The Florey Institute of Neuroscience and Mental Health Melbourne VIC Australia
| | - Lenore J. Launer
- Laboratory of Epidemiology and Population Sciences, National Institute on Aging Baltimore MD USA
| | - Jurgen Fripp
- CSIRO Health and Biosecurity, Australian E‐Health Research Centre Brisbane QLD Australia
| | - Sterling C. Johnson
- Wisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health Madison WI USA
| | - John C. Morris
- Knight Alzheimer Disease Research Center St. Louis MO USA
| | - Marilyn S. Albert
- Department of Neurology, Division of Cognitive Neuroscience, John’s Hopkins University School of Medicine Baltimore MD USA
| | | | - Susan M. Resnick
- Laboratory of Behavioral Neuroscience, National Institute on Aging, Intramural Research Program Baltimore MD USA
| | - Mohamad Habes
- Neuroimage Analytics Laboratory (NAL) and the Biggs Institute Neuroimaging Core (BINC), Glenn Biggs Institute for Alzheimer’s & Neurodegenerative Diseases, University of Texas Health Sciences Center San Antonio TX USA
| | - Haochang Shou
- Penn Statistics in Imaging and Visualization Center, University of Pennsylvania Philadelphia PA USA
| | - David A. Wolk
- Department of Neurology, University of Pennsylvania School of Medicine Philadelphia PA USA
| | - Ilya M. Nasrallah
- Center for Biomedical Image Computing and Analytics, University of Pennsylvania Philadelphia PA USA
- Department of Radiology, Perelman School of Medicine, University of Pennsylvania Philadelphia PA USA
| | - Christos Davatzikos
- Center for Biomedical Image Computing and Analytics, University of Pennsylvania Philadelphia PA USA
| |
Collapse
|
60
|
Gillis C, Cespedes MI, Maserejian NN, Dore V, Maruff P, Fowler C, Rainey‐Smith S, Villemagne VL, Rowe C, Martins RN, Vacher M, Masters CL, Doecke JD. Alzheimer’s disease specific MRI brain regions are differentially associated with accelerated decline as defined using sigmoidal cognitive turning point methodology in amyloid‐positive AIBL participants. Alzheimers Dement 2022. [DOI: 10.1002/alz.064503] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Affiliation(s)
| | | | | | - Vincent Dore
- Australian E‐Health Research Centre, CSIRO Parkville VIC Australia
| | - Paul Maruff
- Cogstate Pty. Ltd New Haven CT USA
- University of Melbourne Melbourne VIC Australia
| | - Christopher Fowler
- Florey Institute of Neuroscience and Mental Health Parkville VIC Australia
| | - Stephanie Rainey‐Smith
- Centre for Healthy Ageing, Murdoch University Perth Western Australia Australia
- Centre of Excellence for Alzheimer’s Disease Research and Care, School of Medical and Health Sciences, Edith Cowan University Joondalup Western Australia Australia
| | - Victor L Villemagne
- Department of Molecular Imaging and Therapy, Austin Health Heidelberg VIC Australia
- Department of Psychiatry, University of Pittsburgh Pittsburgh PA USA
| | - Christopher Rowe
- Florey Institute of Neuroscience and Mental Health Parkville VIC Australia
- Department of Biomedical Sciences, Faculty of Medicine, Health and Human Sciences, Macquarie University Sydney NSW Australia
| | - Ralph N Martins
- Centre of Excellence for Alzheimer’s Disease Research and Care, School of Medical and Health Sciences, Edith Cowan University Joondalup Western Australia Australia
- Department of Biomedical Sciences, Faculty of Medicine, Health and Human Sciences, Macquarie University Sydney NSW Australia
- Sir James McCusker Alzheimer's Disease Research Unit (Hollywood Private Hospital) Perth Western Australia Australia
| | - Michael Vacher
- Australian E‐Health Research Centre, CSIRO Perth Western Australia Australia
| | - Colin L Masters
- The Florey Institute of Neuroscience and Mental Health, University of Melbourne Parkville VIC Australia
| | - James D Doecke
- Australian E‐Health Research Centre, CSIRO Herston QLD Australia
| |
Collapse
|
61
|
Cox T, Bourgeat P, Dore V, Doecke JD, Fripp J, Chatterjee P, Schindler EE, Benzinger TL, Rowe C, Villemagne VL, Weiner MW, Morris JC, Masters CL. Comparing the longitudinal progression of CSF biomarkers with PET Amyloid biomarkers for Alzheimer’s disease. Alzheimers Dement 2022. [DOI: 10.1002/alz.068082] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Affiliation(s)
- Timothy Cox
- The Australian e‐Health Research Centre, CSIRO Canberra ACT Australia
| | - Pierrick Bourgeat
- CSIRO Health and Biosecurity, Australian E‐Health Research Centre Brisbane QLD Australia
| | - Vincent Dore
- Department of Molecular Imaging & Therapy, Austin Health Heidelberg VIC Australia
- Australian E‐Health Research Centre, CSIRO Parkville VIC Australia
| | - James D Doecke
- Australian E‐Health Research Centre, CSIRO Herston QLD Australia
| | - Jurgen Fripp
- CSIRO Health and Biosecurity, Australian E‐Health Research Centre Brisbane QLD Australia
| | | | | | | | - Christopher Rowe
- Department of Molecular Imaging, Austin Health Melbourne VIC Australia
- Florey Institute of Neuroscience and Mental Health Parkville VIC Australia
- The University of Melbourne Melbourne VIC Australia
| | | | | | - John C. Morris
- Washington University School of Medicine St. Louis MO USA
| | - Colin L. Masters
- Florey Institute of Neuroscience and Mental Health Parkville VIC Australia
- The University of Melbourne Melbourne VIC Australia
| |
Collapse
|
62
|
Piccirella S, Van Neste L, Fowler C, Masters CL, Fripp J, Doecke JD, Xiong C, Uberti D, Kinnon P. AlzoSure® Predict, a simple minimally‐invasive blood test to predict the early onset of Alzheimer’s disease before the manifestation of clinical symptoms. Alzheimers Dement 2022. [DOI: 10.1002/alz.069262] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Affiliation(s)
| | | | - Christopher Fowler
- Florey Institute of Neuroscience and Mental Health Parkville VIC Australia
| | - Colin L Masters
- The Florey Institute of Neuroscience and Mental Health, University of Melbourne Parkville VIC Australia
| | - Jurgen Fripp
- CSIRO Health and Biosecurity, Australian E‐Health Research Centre Brisbane QLD Australia
| | - James D Doecke
- Australian E‐Health Research Centre, CSIRO Herston QLD Australia
| | - Chengjie Xiong
- Washington University School of Medicine Saint Louis MO USA
| | - Daniela Uberti
- Molecular Markers Laboratory, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli Brescia Italy
| | | |
Collapse
|
63
|
Saint‐Jalmes M, Goudey B, Beck D, Masters CL, Fedyashov V. On the evaluation of disease progression modelling in Alzheimer's Disease. Alzheimers Dement 2022. [DOI: 10.1002/alz.064377] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Affiliation(s)
- Martin Saint‐Jalmes
- The University of Melbourne Melbourne VIC Australia
- ARC Training Centre in Cognitive Computing for Medical Technologies Melbourne VIC Australia
| | - Benjamin Goudey
- The University of Melbourne Melbourne VIC Australia
- ARC Training Centre in Cognitive Computing for Medical Technologies Melbourne VIC Australia
| | - Daniel Beck
- The University of Melbourne Melbourne VIC Australia
- ARC Training Centre in Cognitive Computing for Medical Technologies Melbourne VIC Australia
| | - Colin L. Masters
- ARC Training Centre in Cognitive Computing for Medical Technologies Melbourne VIC Australia
- University of Melbourne Melbourne VIC Australia
- Florey Institute of Neuroscience and Mental Health Parkville VIC Australia
| | - Victor Fedyashov
- The University of Melbourne Melbourne VIC Australia
- ARC Training Centre in Cognitive Computing for Medical Technologies Melbourne VIC Australia
| |
Collapse
|
64
|
Chatterjee P, Dore V, Pedrini S, Krishnadas N, Thota RN, Bourgeat P, Rainey‐Smith S, Burnham SC, Fowler C, Taddei K, Mulligan RS, Ames D, Masters CL, Fripp J, Rowe C, Martins RN, Villemagne VL. Plasma glial fibrillary acidic protein is associated with reactive astrogliosis assessed via
18
F‐SMBT‐1 PET. Alzheimers Dement 2022. [DOI: 10.1002/alz.068749] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Affiliation(s)
- Pratishtha Chatterjee
- School of Medical and Health Sciences, Edith Cowan University Joondalup Australia
- Macquarie University North Ryde NSW Australia
| | - Vincent Dore
- CSIRO Health and Biosecurity, Australian E‐Health Research Centre Parkville VIC Australia
- Department of Molecular Imaging & Therapy, Austin Health Heidelberg VIC Australia
| | - Steve Pedrini
- Edith Cowan University Joondalup Western Australia Australia
| | - Natasha Krishnadas
- Department of Molecular Imaging & Therapy, Austin Health Heidelberg VIC Australia
- Florey Department of Neuroscience and Mental Health, The University of Melbourne Parkville VIC Australia
| | - Rohith N Thota
- Macquarie University North Ryde NSW Australia
- The University of Newcastle Newcastle NSW Australia
- Massey University Palmerston North New Zealand
| | - Pierrick Bourgeat
- CSIRO Health and Biosecurity, Australian E‐Health Research Centre Brisbane QLD Australia
| | - Stephanie Rainey‐Smith
- Edith Cowan University Joondalup Western Australia Australia
- Murdoch University, Murdoch, Western Australia Australia
| | | | - Christopher Fowler
- University of Melbourne Melbourne VIC Australia
- Florey Institute of Neuroscience and Mental Health Parkville VIC Australia
| | - Kevin Taddei
- McCusker Alzheimer's Research Foundation Perth Australia
- Edith Cowan University Joondalup Australia
| | | | - David Ames
- The University of Melbourne Parkville Australia
| | - Colin L. Masters
- The University of Melbourne Melbourne VIC Australia
- The Florey Institute of Neuroscience and Mental Health Melbourne VIC Australia
| | - Jurgen Fripp
- CSIRO Health and Biosecurity, Australian E‐Health Research Centre Brisbane QLD Australia
| | - Christopher Rowe
- Florey Institute of Neuroscience and Mental Health Parkville VIC Australia
- Department of Molecular Imaging, Austin Health Melbourne VIC Australia
- The University of Melbourne Parkville VIC Australia
| | - Ralph N Martins
- Macquarie University North Ryde NSW Australia
- Edith Cowan University Joondalup Western Australia Australia
- Australian Alzheimer's Research Foundation Nedlands Australia
| | - Victor L Villemagne
- The University of Melbourne Melbourne VIC Australia
- The University of Pittsburgh Pittsburgh PA USA
- Department of Molecular Imaging and Therapy, Austin Health Melbourne VIC Australia
| |
Collapse
|
65
|
Keem MH, Eratne D, Lewis C, Kang M, Walterfang M, Loi SM, Kelso W, Cadwallader C, Berkovic SF, Li Q, Masters CL, Collins S, Santillo A, Velakoulis D. Cerebrospinal fluid neurofilament light chain differentiates behavioural variant frontotemporal dementia progressors from ‘phenocopy’ non‐progressors. Alzheimers Dement 2022. [DOI: 10.1002/alz.065333] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Affiliation(s)
- Michael H Keem
- Neuropsychiatry, The Royal Melbourne Hospital Parkville VIC Australia
- University of Melbourne Parkville VIC Australia
| | - Dhamidhu Eratne
- Neuropsychiatry, The Royal Melbourne Hospital Parkville VIC Australia
- University of Melbourne Parkville VIC Australia
- Melbourne Neuropsychiatry Centre, University of Melbourne and Melbourne Health Parkville VIC Australia
- National Dementia Diagnostics Laboratory, The Florey Institute of Neuroscience and Mental Health Parkville VIC Australia
| | - Courtney Lewis
- Neuropsychiatry, The Royal Melbourne Hospital Parkville VIC Australia
| | - Matthew Kang
- Neuropsychiatry, The Royal Melbourne Hospital Parkville VIC Australia
- Melbourne Neuropsychiatry Centre, University of Melbourne and Melbourne Health Parkville VIC Australia
- Alfred Health Prahran VIC Australia
| | - Mark Walterfang
- Neuropsychiatry, The Royal Melbourne Hospital Parkville VIC Australia
- Melbourne Neuropsychiatry Centre, University of Melbourne and Melbourne Health Parkville VIC Australia
| | - Samantha M Loi
- Neuropsychiatry, The Royal Melbourne Hospital Parkville VIC Australia
- Melbourne Neuropsychiatry Centre, University of Melbourne and Melbourne Health Parkville VIC Australia
| | - Wendy Kelso
- Neuropsychiatry, The Royal Melbourne Hospital Parkville VIC Australia
- Melbourne Neuropsychiatry Centre, University of Melbourne and Melbourne Health Parkville VIC Australia
| | | | - Samuel F Berkovic
- University of Melbourne Parkville VIC Australia
- Epilepsy Research Centre Health, Austin Heidelberg VIC Australia
| | - Qiao‐Xin Li
- University of Melbourne Parkville VIC Australia
- National Dementia Diagnostics Laboratory, The Florey Institute of Neuroscience and Mental Health Parkville VIC Australia
| | - Colin L. Masters
- National Dementia Diagnostics Laboratory, The Florey Institute of Neuroscience and Mental Health Parkville VIC Australia
- University of Melbourne Melbourne VIC Australia
| | - Steven Collins
- University of Melbourne Parkville VIC Australia
- National Dementia Diagnostics Laboratory, The Florey Institute of Neuroscience and Mental Health Parkville VIC Australia
| | | | - Dennis Velakoulis
- Neuropsychiatry, The Royal Melbourne Hospital Parkville VIC Australia
- University of Melbourne Parkville VIC Australia
- Melbourne Neuropsychiatry Centre, University of Melbourne and Melbourne Health Parkville VIC Australia
| | | |
Collapse
|
66
|
Pivac LN, Brown BM, Sewell KR, Doecke JD, Villemagne VL, Dore V, Weinborn M, Sohrabi HR, Gardener SL, Bucks RS, Masters CL, Rowe C, Martins RN, Rainey‐Smith S. Suboptimal sleep efficiency and duration predicts rate of accumulation of Aβ‐ Amyloid in cognitively normal older adults. Alzheimers Dement 2022. [DOI: 10.1002/alz.060975] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Affiliation(s)
| | - Belinda M Brown
- Centre for Healthy Ageing, Murdoch University Perth Western Australia Australia
- Australian Alzheimer's Research Foundation Perth Western Australia Australia
| | | | - James D Doecke
- Australian E‐Health Research Centre, CSIRO Herston QLD Australia
| | | | - Vincent Dore
- Department of Molecular Imaging, Austin Health Melbourne VIC Australia
| | - Michael Weinborn
- University of Western Australia Perth Western Australia Australia
| | - Hamid R Sohrabi
- Australian Alzheimer's Research Foundation Perth Western Australia Australia
- Centre for Healthy Ageing, Murdoch University Murdoch Western Australia Australia
| | | | - Romola S Bucks
- University of Western Australia Perth Western Australia Australia
| | - Colin L Masters
- The Florey Institute of Neuroscience and Mental Health, University of Melbourne Melbourne VIC Australia
| | - Christopher Rowe
- Department of Molecular Imaging, Austin Health Melbourne VIC Australia
- Florey Institute of Neuroscience and Mental Health Parkville VIC Australia
| | - Ralph N Martins
- Edith Cowan University Joondalup Western Australia Australia
| | - Stephanie Rainey‐Smith
- Centre for Healthy Ageing, Murdoch University Perth Western Australia Australia
- Australian Alzheimer's Research Foundation Perth Western Australia Australia
| |
Collapse
|
67
|
Blennow K, Kurka H, Suridjan I, Jethwa A, Hastreiter M, Carboni M, Kollmorgen G, Rabe C, Bittner T, Fowler C, Masters CL, Zetterberg H, Hansson O. Clinical performance and robustness of blood‐based biomarkers for early detection of amyloid pathology associated with Alzheimer’s disease. Alzheimers Dement 2022. [DOI: 10.1002/alz.069052] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Affiliation(s)
- Kaj Blennow
- Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital Mölndal Sweden
- Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg Mölndal Sweden
| | | | | | | | | | | | | | | | - Tobias Bittner
- Genentech, Inc. South San Francisco CA USA
- F. Hoffmann‐La Roche Ltd Basel Switzerland
| | - Christopher Fowler
- The Florey Institute of Neuroscience and Mental Health, The University of Melbourne Melbourne VIC Australia
| | - Colin L. Masters
- The Florey Institute of Neuroscience and Mental Health, The University of Melbourne Melbourne VIC Australia
| | - Henrik Zetterberg
- Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital Mölndal Sweden
- Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg Mölndal Sweden
- Department of Neurodegenerative Disease, UCL Institute of Neurology London United Kingdom
- UK Dementia Research Institute at UCL London United Kingdom
| | - Oskar Hansson
- Clinical Memory Research Unit, Department of Clinical Sciences Mälmo, Lund University Malmö Sweden
- Memory Clinic, Skåne University Hospital Malmö Sweden
| |
Collapse
|
68
|
Bourgeat P, Dore V, Benzinger TL, Tosun D, Li S, Goyal MS, LaMontagne P, Jin L, Rowe C, Weiner MW, Morris JC, Masters CL, Fripp J, Villemagne VL. Investigating a new neocortical mask for Centiloid quantification. Alzheimers Dement 2022. [DOI: 10.1002/alz.069029] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Affiliation(s)
- Pierrick Bourgeat
- CSIRO Health and Biosecurity, Australian E‐Health Research Centre Brisbane QLD Australia
| | - Vincent Dore
- CSIRO Health and Biosecurity, Australian E‐Health Research Centre Parkville VIC Australia
- Austin Health Melbourne Australia
| | | | - Duygu Tosun
- University of California, San Francisco San Francisco CA USA
| | - Shenpeng Li
- CSIRO Health and Biosecurity, Australian E‐Health Research Centre Parkville VIC Australia
| | | | | | - Liang Jin
- Florey Institute of Neuroscience and Mental Health Parkville VIC Australia
| | - Christopher Rowe
- Florey Institute of Neuroscience and Mental Health Parkville VIC Australia
- Department of Molecular Imaging, Austin Health Melbourne VIC Australia
| | | | - John C. Morris
- Washington University School of Medicine St. Louis MO USA
| | - Colin L Masters
- The Florey Institute of Neuroscience and Mental Health, University of Melbourne Parkville VIC Australia
| | - Jurgen Fripp
- CSIRO Health and Biosecurity, Australian E‐Health Research Centre Brisbane QLD Australia
| | | |
Collapse
|
69
|
Maruff P, Lim YY, Masters CL, Robertson J. Validity of a remote supervised preclinical Alzheimer’s disease cognitive composite (PACC) score in preclinical and prodromal Alzheimer’s disease. Alzheimers Dement 2022. [DOI: 10.1002/alz.068363] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Affiliation(s)
| | - Yen Ying Lim
- Turner Institute for Brain and Mental Health, Monash University Melbourne VIC Australia
| | - Colin L. Masters
- Florey Institute of Neuroscience and Mental Health Parkville VIC Australia
| | - Joanne Robertson
- Florey Institute of Neuroscience and Mental Health Parkville VIC Australia
| |
Collapse
|
70
|
Fowler C, Stoops E, Rainey‐Smith S, Vanmechelen E, Vanbrabant J, Dewit N, Mauroo K, Rowe C, Fripp J, Li Q, Bourgeat P, Collins S, Martins RN, Masters CL, Maruff P, Doecke JD. Plasma pTau181/Aβ42 identifies cognitive change earlier than CSF pTau181/Ab42. Alzheimers Dement 2022. [DOI: 10.1002/alz.064341] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Affiliation(s)
- Christopher Fowler
- Florey Institute of Neuroscience and Mental Health Parkville VIC Australia
| | - Erik Stoops
- ADx NeuroSciences NV, Technologiepark 94 Ghent 9052 Belgium
| | - Stephanie Rainey‐Smith
- Murdoch University, Murdoch Western Australia Australia
- Australian Alzheimer's Research Foundation Perth Western Australia Australia
- Ageing, Cognition and Exercise Research Group Murdoch Australia
| | - Eugeen Vanmechelen
- ADx NeuroSciences NV, Technologiepark 94 Ghent 9052 Belgium
- ADx NeuroSciences Ghent Belgium
| | | | | | | | - Christopher Rowe
- Departments of Medicine and Molecular Imaging, University of Melbourne Health, Austin Melbourne VIC Australia
| | - Jurgen Fripp
- CSIRO Health and Biosecurity, Australian E‐Health Research Centre Brisbane QLD Australia
| | - Qiao‐Xin Li
- The Florey Institute of Neuroscience, University of Melbourne PARKVILLE VIC Australia
| | - Pierrick Bourgeat
- CSIRO Health and Biosecurity, Australian E‐Health Research Centre Brisbane QLD Australia
| | - Steven Collins
- National Dementia Diagnostics Laboratory, The Florey Institute of Neuroscience and Mental Health Parkville VIC Australia
| | - Ralph N Martins
- KaRa Institute of Neurological Diseases Sydney NSW Australia
- Australian Alzheimer's Research Foundation Nedlands Australia
- Edith Cowan University, Joondalup Western Australia Australia
- Sir James McCusker Alzheimer's Disease Research Unit (Hollywood Private Hospital) Perth Western Australia Australia
- Department of Biomedical Sciences, Macquarie University Macquarie Park NSW Australia
| | - Colin L Masters
- The Florey Institute of Neuroscience and Mental Health, University of Melbourne Melbourne VIC Australia
| | - Paul Maruff
- Cogstate Ltd. Melbourne VIC Australia
- The Florey Institute of Neuroscience and Mental Health Melbourne VIC Australia
| | - James D Doecke
- Australian E‐Health Research Centre, CSIRO Herston QLD Australia
| |
Collapse
|
71
|
Goudey B, Fedyashov V, Fripp J, Rowe C, Maruff P, Masters CL. Understanding the impact of PET amyloid cutpoints on prognostic modelling for cognitively normal individuals. Alzheimers Dement 2022. [DOI: 10.1002/alz.067418] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Affiliation(s)
| | - Victor Fedyashov
- University of Melbourne Mlebourne VIC Australia
- ARC Training Centre in Cognitive Computing for Medical Technologies Carlton VIC Australia
| | - Jurgen Fripp
- CSIRO Health and Biosecurity, Australian E‐Health Research Centre Brisbane QLD Australia
| | - Christopher Rowe
- Department of Molecular Imaging, Austin Health Melbourne VIC Australia
- The University of Melbourne Parkville VIC Australia
| | - Paul Maruff
- University of Melbourne Melbourne VIC Australia
- Cogstate Ltd. Melbourne VIC Australia
| | - Colin L Masters
- The Florey Institute of Neuroscience and Mental Health, University of Melbourne Parkville VIC Australia
| |
Collapse
|
72
|
Bourgeat P, Doré V, Burnham SC, Benzinger T, Tosun D, Li S, Goyal M, LaMontagne P, Jin L, Rowe CC, Weiner MW, Morris JC, Masters CL, Fripp J, Villemagne VL. β-amyloid PET harmonisation across longitudinal studies: Application to AIBL, ADNI and OASIS3. Neuroimage 2022; 262:119527. [PMID: 35917917 PMCID: PMC9550562 DOI: 10.1016/j.neuroimage.2022.119527] [Citation(s) in RCA: 8] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2022] [Revised: 07/11/2022] [Accepted: 07/28/2022] [Indexed: 10/31/2022] Open
Abstract
INTRODUCTION The Centiloid scale was developed to harmonise the quantification of β-amyloid (Aβ) PET images across tracers, scanners, and processing pipelines. However, several groups have reported differences across tracers and scanners even after centiloid conversion. In this study, we aim to evaluate the impact of different pre and post-processing harmonisation steps on the robustness of longitudinal Centiloid data across three large international cohort studies. METHODS All Aβ PET data in AIBL (N = 3315), ADNI (N = 3442) and OASIS3 (N = 1398) were quantified using the MRI-based Centiloid standard SPM pipeline and the PET-only pipeline CapAIBL. SUVR were converted into Centiloids using each tracer's respective transform. Global Aβ burden from pre-defined target cortical regions in Centiloid units were quantified for both raw PET scans and PET scans smoothed to a uniform 8 mm full width half maximum (FWHM) effective smoothness. For Florbetapir, we assessed the performance of using both the standard Whole Cerebellum (WCb) and a composite white matter (WM)+WCb reference region. Additionally, our recently proposed quantification based on Non-negative Matrix Factorisation (NMF) was applied to all spatially and SUVR normalised images. Correlation with clinical severity measured by the Mini-Mental State Examination (MMSE) and effect size, as well as tracer agreement in 11C-PiB-18F-Florbetapir pairs and longitudinal consistency were evaluated. RESULTS The smoothing to a uniform resolution partially reduced longitudinal variability, but did not improve inter-tracer agreement, effect size or correlation with MMSE. Using a Composite reference region for 18F-Florbetapir improved inter-tracer agreement, effect size, correlation with MMSE, and longitudinal consistency. The best results were however obtained when using the NMF method which outperformed all other quantification approaches in all metrics used. CONCLUSIONS FWHM smoothing has limited impact on longitudinal consistency or outliers. A Composite reference region including subcortical WM should be used for computing both cross-sectional and longitudinal Florbetapir Centiloid. NMF improves Centiloid quantification on all metrics examined.
Collapse
Affiliation(s)
| | - Vincent Doré
- CSIRO Health and Biosecurity, Brisbane, Australia; Department of Molecular Imaging & Therapy, Austin Health, Melbourne, Australia
| | | | | | - Duygu Tosun
- San Francisco Veterans Affairs Medical Center, San Francisco, CA, USA,; Department of Radiology and Biomedical Imaging, University of California, San Francisco, CA, USA
| | - Shenpeng Li
- CSIRO Health and Biosecurity, Brisbane, Australia
| | - Manu Goyal
- Mallinckrodt Institute of Radiology, Washington University School of Medicine, St Louis, USA
| | - Pamela LaMontagne
- Mallinckrodt Institute of Radiology, Washington University School of Medicine, St Louis, USA
| | - Liang Jin
- The Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, Melbourne, Australia
| | - Christopher C Rowe
- Department of Molecular Imaging & Therapy, Austin Health, Melbourne, Australia; The Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, Melbourne, Australia
| | - Michael W Weiner
- San Francisco Veterans Affairs Medical Center, San Francisco, CA, USA,; Department of Radiology and Biomedical Imaging, University of California, San Francisco, CA, USA
| | - John C Morris
- Washington University in St. Louis, St. Louis, MO, USA
| | - Colin L Masters
- The Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, Melbourne, Australia
| | - Jurgen Fripp
- CSIRO Health and Biosecurity, Brisbane, Australia
| | - Victor L Villemagne
- Department of Molecular Imaging & Therapy, Austin Health, Melbourne, Australia; Department of Psychiatry, The University of Pittsburgh, Pittsburgh, PA, USA
| |
Collapse
|
73
|
Eratne D, Keem M, Lewis C, Kang M, Walterfang M, Farrand S, Loi S, Kelso W, Cadwallader C, Berkovic SF, Li QX, Masters CL, Collins S, Santillo A, Velakoulis D. Cerebrospinal fluid neurofilament light chain differentiates behavioural variant frontotemporal dementia progressors from non-progressors. J Neurol Sci 2022; 442:120439. [PMID: 36201960 DOI: 10.1016/j.jns.2022.120439] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2022] [Revised: 09/05/2022] [Accepted: 09/25/2022] [Indexed: 11/18/2022]
Abstract
BACKGROUND Distinguishing behavioural variant frontotemporal dementia (bvFTD) from non-neurodegenerative 'non-progressor' mimics of frontal lobe dysfunction, can be one of the most challenging clinical dilemmas. A biomarker of neuronal injury, neurofilament light chain (NfL), could reduce misdiagnosis and delay. METHODS Cerebrospinal fluid (CSF) NfL, amyloid beta 1-42 (AB42), total and phosphorylated tau (T-tau, P-tau) levels were examined in patients with an initial diagnosis of bvFTD. Based on follow-up information, patients were categorised as Progressors or Non-Progressors: further subtyped into Non-Progressor Revised (non-neurological/neurodegenerative final diagnosis), and Non-Progressor Static (static deficits, not fully explained by non-neurological/neurodegenerative causes). RESULTS Forty-three patients were included: 20 Progressors, 23 Non-Progressors (15 Non-Progressor Revised, 8 Non-Progressor Static), and 20 controls. NfL concentrations were lower in Non-Progressors (Non-Progressors Mean, M = 554 pg/mL, 95%CI:[461, 675], Non-Progressor Revised M = 459 pg/mL, 95%CI:[385, 539], and Non-Progressor Static M = 730 pg/mL, 95%CI:[516, 940]), compared to Progressors (M = 2397 pg/mL, 95%CI:[1607, 3332]). NfL distinguished Progressors from Non-Progressors with the highest accuracy (area under the curve 0.92, 90%/87% sensitivity/specificity, 86%/91% positive/negative predictive value, 88% accuracy). Non-Progressor Static tended to have higher T-tau and P-tau levels compared to Non-Progressor Revised Diagnoses. CONCLUSION This study demonstrated strong diagnostic utility of CSF NfL to distinguish bvFTD from non-progressor variants, at baseline, with high accuracy, in a real-world clinical setting. This has important clinical implications, to improve outcomes for patients and clinicians facing this challenging clinical dilemma, healthcare services, and clinical trials. Further research is required to investigate heterogeneity within the non-progressor group and potential diagnostic algorithms, and prospective studies are underway assessing plasma NfL.
Collapse
Affiliation(s)
- Dhamidhu Eratne
- Neuropsychiatry, Royal Melbourne Hospital, Parkville, VIC, Australia; Melbourne Neuropsychiatry Centre & Department of Psychiatry, University of Melbourne, Parkville, VIC, Australia; National Dementia Diagnostics Laboratory, The Florey Institute of Neuroscience and Mental Health, Parkville, VIC, Australia.
| | - Michael Keem
- Neuropsychiatry, Royal Melbourne Hospital, Parkville, VIC, Australia; Melbourne Neuropsychiatry Centre & Department of Psychiatry, University of Melbourne, Parkville, VIC, Australia
| | - Courtney Lewis
- Neuropsychiatry, Royal Melbourne Hospital, Parkville, VIC, Australia; Melbourne Neuropsychiatry Centre & Department of Psychiatry, University of Melbourne, Parkville, VIC, Australia
| | - Matthew Kang
- Neuropsychiatry, Royal Melbourne Hospital, Parkville, VIC, Australia; Melbourne Neuropsychiatry Centre & Department of Psychiatry, University of Melbourne, Parkville, VIC, Australia
| | - Mark Walterfang
- Neuropsychiatry, Royal Melbourne Hospital, Parkville, VIC, Australia; Melbourne Neuropsychiatry Centre & Department of Psychiatry, University of Melbourne, Parkville, VIC, Australia; National Dementia Diagnostics Laboratory, The Florey Institute of Neuroscience and Mental Health, Parkville, VIC, Australia
| | - Sarah Farrand
- Neuropsychiatry, Royal Melbourne Hospital, Parkville, VIC, Australia; Melbourne Neuropsychiatry Centre & Department of Psychiatry, University of Melbourne, Parkville, VIC, Australia
| | - Samantha Loi
- Neuropsychiatry, Royal Melbourne Hospital, Parkville, VIC, Australia; Melbourne Neuropsychiatry Centre & Department of Psychiatry, University of Melbourne, Parkville, VIC, Australia
| | - Wendy Kelso
- Neuropsychiatry, Royal Melbourne Hospital, Parkville, VIC, Australia
| | | | - Samuel F Berkovic
- Epilepsy Research Centre, Department of Medicine, Austin Health, The University of Melbourne, Heidelberg, VIC, Australia
| | - Qiao-Xin Li
- National Dementia Diagnostics Laboratory, The Florey Institute of Neuroscience and Mental Health, Parkville, VIC, Australia
| | - Colin L Masters
- National Dementia Diagnostics Laboratory, The Florey Institute of Neuroscience and Mental Health, Parkville, VIC, Australia
| | - Steven Collins
- National Dementia Diagnostics Laboratory, The Florey Institute of Neuroscience and Mental Health, Parkville, VIC, Australia
| | - Alexander Santillo
- Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University, Sölvegatan 18, Sweden
| | - Dennis Velakoulis
- Neuropsychiatry, Royal Melbourne Hospital, Parkville, VIC, Australia; Melbourne Neuropsychiatry Centre & Department of Psychiatry, University of Melbourne, Parkville, VIC, Australia
| |
Collapse
|
74
|
Eratne D, Loi SM, Li QX, Stehmann C, Malpas CB, Santillo A, Janelidze S, Cadwallader C, Walia N, Ney B, Lewis V, Senesi M, Fowler C, McGlade A, Varghese S, Ravanfar P, Kelso W, Farrand S, Keem M, Kang M, Goh AMY, Dhiman K, Gupta V, Watson R, Yassi N, Kaylor-Hughes C, Kanaan R, Perucca P, Dobson H, Vivash L, Ali R, O'Brien TJ, Hansson O, Zetterberg H, Blennow K, Walterfang M, Masters CL, Berkovic SF, Collins S, Velakoulis D. Cerebrospinal fluid neurofilament light chain differentiates primary psychiatric disorders from rapidly progressive, Alzheimer's disease and frontotemporal disorders in clinical settings. Alzheimers Dement 2022; 18:2218-2233. [PMID: 35102694 DOI: 10.1002/alz.12549] [Citation(s) in RCA: 18] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/04/2021] [Revised: 10/26/2021] [Accepted: 11/01/2021] [Indexed: 01/31/2023]
Abstract
INTRODUCTION Many patients with cognitive and neuropsychiatric symptoms face diagnostic delay and misdiagnosis. We investigated whether cerebrospinal fluid (CSF) neurofilament light (NfL) and total-tau (t-tau) could assist in the clinical scenario of differentiating neurodegenerative (ND) from psychiatric disorders (PSY), and rapidly progressive disorders. METHODS Biomarkers were examined in patients from specialist services (ND and PSY) and a national Creutzfeldt-Jakob registry (Creutzfeldt-Jakob disease [CJD] and rapidly progressive dementias/atypically rapid variants of common ND, RapidND). RESULTS A total of 498 participants were included: 197 ND, 67 PSY, 161 CJD, 48 RapidND, and 20 controls. NfL was elevated in ND compared to PSY and controls, with highest levels in CJD and RapidND. NfL distinguished ND from PSY with 95%/78% positive/negative predictive value, 92%/87% sensitivity/specificity, 91% accuracy. NfL outperformed t-tau in most real-life clinical diagnostic dilemma scenarios, except distinguishing CJD from RapidND. DISCUSSION We demonstrated strong generalizable evidence for the diagnostic utility of CSF NfL in differentiating ND from psychiatric disorders, with high accuracy.
Collapse
Affiliation(s)
- Dhamidhu Eratne
- Neuropsychiatry, Royal Melbourne Hospital, Parkville, Victoria, Australia.,Department of Psychiatry & Melbourne Neuropsychiatry Centre, University of Melbourne, Parkville, Victoria, Australia.,National Dementia Diagnostics Laboratory, The Florey Institute of Neuroscience and Mental Health, Parkville, Victoria, Australia
| | - Samantha M Loi
- Neuropsychiatry, Royal Melbourne Hospital, Parkville, Victoria, Australia.,Department of Psychiatry & Melbourne Neuropsychiatry Centre, University of Melbourne, Parkville, Victoria, Australia.,National Dementia Diagnostics Laboratory, The Florey Institute of Neuroscience and Mental Health, Parkville, Victoria, Australia
| | - Qiao-Xin Li
- National Dementia Diagnostics Laboratory, The Florey Institute of Neuroscience and Mental Health, Parkville, Victoria, Australia
| | - Christiane Stehmann
- National Dementia Diagnostics Laboratory, The Florey Institute of Neuroscience and Mental Health, Parkville, Victoria, Australia.,Australian National Creutzfeldt-Jakob Disease Registry, Florey Institute of Neuroscience and Mental Health and Department of Medicine, The University of Melbourne, Parkville, Victoria, Australia
| | - Charles B Malpas
- Department of Medicine, Department of Neurology, Clinical Outcomes Research Unit (CORe), Royal Melbourne Hospital, Parkville, Victoria, Australia
| | - Alexander Santillo
- Department of Clinical Sciences Malmö, Clinical Memory Research Unit, Lund University, Lund, Sweden.,Memory Clinic, Skåne University Hospital, Malmo, Sweden
| | - Shorena Janelidze
- Department of Clinical Sciences Malmö, Clinical Memory Research Unit, Lund University, Lund, Sweden.,Memory Clinic, Skåne University Hospital, Malmo, Sweden
| | - Claire Cadwallader
- Neuropsychiatry, Royal Melbourne Hospital, Parkville, Victoria, Australia
| | - Nirbaanjot Walia
- Neuropsychiatry, Royal Melbourne Hospital, Parkville, Victoria, Australia
| | - Blair Ney
- The Florey Institute of Neuroscience and Mental Health, Parkville, Victoria, Australia.,St. Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia
| | - Victoria Lewis
- Australian National Creutzfeldt-Jakob Disease Registry, Florey Institute of Neuroscience and Mental Health and Department of Medicine, The University of Melbourne, Parkville, Victoria, Australia
| | - Matteo Senesi
- Australian National Creutzfeldt-Jakob Disease Registry, Florey Institute of Neuroscience and Mental Health and Department of Medicine, The University of Melbourne, Parkville, Victoria, Australia
| | - Christopher Fowler
- The Florey Institute of Neuroscience and Mental Health, Parkville, Victoria, Australia
| | - Amelia McGlade
- National Dementia Diagnostics Laboratory, The Florey Institute of Neuroscience and Mental Health, Parkville, Victoria, Australia
| | - Shiji Varghese
- National Dementia Diagnostics Laboratory, The Florey Institute of Neuroscience and Mental Health, Parkville, Victoria, Australia
| | - Parsa Ravanfar
- Neuropsychiatry, Royal Melbourne Hospital, Parkville, Victoria, Australia.,Department of Psychiatry & Melbourne Neuropsychiatry Centre, University of Melbourne, Parkville, Victoria, Australia
| | - Wendy Kelso
- Neuropsychiatry, Royal Melbourne Hospital, Parkville, Victoria, Australia
| | - Sarah Farrand
- Neuropsychiatry, Royal Melbourne Hospital, Parkville, Victoria, Australia.,Department of Psychiatry & Melbourne Neuropsychiatry Centre, University of Melbourne, Parkville, Victoria, Australia
| | - Michael Keem
- Neuropsychiatry, Royal Melbourne Hospital, Parkville, Victoria, Australia
| | - Matthew Kang
- Neuropsychiatry, Royal Melbourne Hospital, Parkville, Victoria, Australia
| | - Anita M Y Goh
- Neuropsychiatry, Royal Melbourne Hospital, Parkville, Victoria, Australia.,Department of Psychiatry & Melbourne Neuropsychiatry Centre, University of Melbourne, Parkville, Victoria, Australia
| | - Kunal Dhiman
- School of Medicine, Deakin University, Geelong, Victoria, Australia.,School of Medical and Health Sciences, Edith Cowan University, Joondalup, Western Australia, Australia
| | - Veer Gupta
- School of Medicine, Deakin University, Geelong, Victoria, Australia.,School of Medical and Health Sciences, Edith Cowan University, Joondalup, Western Australia, Australia
| | - Rosie Watson
- Population Health and Immunity Division, the Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia
| | - Nawaf Yassi
- Population Health and Immunity Division, the Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia.,Departments of Medicine and Neurology, Melbourne Brain Centre at the Royal Melbourne Hospital, University of Melbourne, Parkville, Victoria, Australia
| | - Cath Kaylor-Hughes
- Department of General Practice, Integrated Mental Health Team, University of Melbourne, Parkville, Victoria, Australia
| | - Richard Kanaan
- Department of Psychiatry, Austin Health, University of Melbourne, Heidelberg, Victoria, Australia
| | - Piero Perucca
- Department of Medicine, Austin Health, The University of Melbourne, Heidelberg, Victoria, Australia.,Comprehensive Epilepsy Program, Austin Health, The University of Melbourne, Heidelberg, Victoria, Australia.,Department of Neuroscience, Central Clinical School, The Alfred Hospital, Monash University, Melbourne, Victoria, Australia
| | - Hannah Dobson
- Neuropsychiatry, Royal Melbourne Hospital, Parkville, Victoria, Australia.,Department of Psychiatry, Alfred Health, Melbourne, Victoria, Australia
| | - Lucy Vivash
- Department of Neuroscience, Central Clinical School, The Alfred Hospital, Monash University, Melbourne, Victoria, Australia
| | - Rashida Ali
- Department of Neuroscience, Central Clinical School, The Alfred Hospital, Monash University, Melbourne, Victoria, Australia
| | - Terence J O'Brien
- Department of Neuroscience, Central Clinical School, The Alfred Hospital, Monash University, Melbourne, Victoria, Australia
| | - Oskar Hansson
- Department of Clinical Sciences Malmö, Clinical Memory Research Unit, Lund University, Lund, Sweden.,Memory Clinic, Skåne University Hospital, Malmo, Sweden
| | - Henrik Zetterberg
- Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.,Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.,Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, UK.,UK Dementia Research Institute at UCL, London, UK
| | - Kaj Blennow
- Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.,Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden
| | - Mark Walterfang
- Neuropsychiatry, Royal Melbourne Hospital, Parkville, Victoria, Australia.,Department of Psychiatry & Melbourne Neuropsychiatry Centre, University of Melbourne, Parkville, Victoria, Australia.,The Florey Institute of Neuroscience and Mental Health, Parkville, Victoria, Australia
| | - Colin L Masters
- National Dementia Diagnostics Laboratory, The Florey Institute of Neuroscience and Mental Health, Parkville, Victoria, Australia
| | - Samuel F Berkovic
- Department of Medicine, Austin Health, Epilepsy Research Centre, The University of Melbourne, Heidelberg, Victoria, Australia
| | - Steven Collins
- Australian National Creutzfeldt-Jakob Disease Registry, Florey Institute of Neuroscience and Mental Health and Department of Medicine, The University of Melbourne, Parkville, Victoria, Australia
| | - Dennis Velakoulis
- Neuropsychiatry, Royal Melbourne Hospital, Parkville, Victoria, Australia.,Department of Psychiatry & Melbourne Neuropsychiatry Centre, University of Melbourne, Parkville, Victoria, Australia
| | | |
Collapse
|
75
|
Wang T, Huynh K, Giles C, Mellett NA, Duong T, Nguyen A, Lim WLF, Smith AAT, Olshansky G, Cadby G, Hung J, Hui J, Beilby J, Watts GF, Chatterjee P, Martins I, Laws SM, Bush AI, Rowe CC, Villemagne VL, Ames D, Masters CL, Taddei K, Doré V, Fripp J, Arnold M, Kastenmüller G, Nho K, Saykin AJ, Baillie R, Han X, Martins RN, Moses EK, Kaddurah‐Daouk R, Meikle PJ. APOE ε2 resilience for Alzheimer's disease is mediated by plasma lipid species: Analysis of three independent cohort studies. Alzheimers Dement 2022; 18:2151-2166. [PMID: 35077012 PMCID: PMC9787288 DOI: 10.1002/alz.12538] [Citation(s) in RCA: 8] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/19/2021] [Revised: 10/19/2021] [Accepted: 10/25/2021] [Indexed: 01/31/2023]
Abstract
INTRODUCTION The apolipoprotein E (APOE) genotype is the strongest genetic risk factor for late-onset Alzheimer's disease. However, its effect on lipid metabolic pathways, and their mediating effect on disease risk, is poorly understood. METHODS We performed lipidomic analysis on three independent cohorts (the Australian Imaging, Biomarkers and Lifestyle [AIBL] flagship study, n = 1087; the Alzheimer's Disease Neuroimaging Initiative [ADNI] 1 study, n = 819; and the Busselton Health Study [BHS], n = 4384), and we defined associations between APOE ε2 and ε4 and 569 plasma/serum lipid species. Mediation analysis defined the proportion of the treatment effect of the APOE genotype mediated by plasma/serum lipid species. RESULTS A total of 237 and 104 lipid species were associated with APOE ε2 and ε4, respectively. Of these 68 (ε2) and 24 (ε4) were associated with prevalent Alzheimer's disease. Individual lipid species or lipidomic models of APOE genotypes mediated up to 30% and 10% of APOE ε2 and ε4 treatment effect, respectively. DISCUSSION Plasma lipid species mediate the treatment effect of APOE genotypes on Alzheimer's disease and as such represent a potential therapeutic target.
Collapse
|
76
|
Barber DJ, Masters CL. A Tale of Two Platforms. Neurology 2022; 99:973-974. [DOI: 10.1212/wnl.0000000000201532] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2022] [Accepted: 09/15/2022] [Indexed: 11/15/2022] Open
|
77
|
Morris JC, Weiner M, Xiong C, Beckett L, Coble D, Saito N, Aisen PS, Allegri R, Benzinger TLS, Berman SB, Cairns NJ, Carrillo MC, Chui HC, Chhatwal JP, Cruchaga C, Fagan AM, Farlow M, Fox NC, Ghetti B, Goate AM, Gordon BA, Graff-Radford N, Day GS, Hassenstab J, Ikeuchi T, Jack CR, Jagust WJ, Jucker M, Levin J, Massoumzadeh P, Masters CL, Martins R, McDade E, Mori H, Noble JM, Petersen RC, Ringman JM, Salloway S, Saykin AJ, Schofield PR, Shaw LM, Toga AW, Trojanowski JQ, Vöglein J, Weninger S, Bateman RJ, Buckles VD. Autosomal dominant and sporadic late onset Alzheimer's disease share a common in vivo pathophysiology. Brain 2022; 145:3594-3607. [PMID: 35580594 PMCID: PMC9989348 DOI: 10.1093/brain/awac181] [Citation(s) in RCA: 11] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2021] [Revised: 04/12/2022] [Accepted: 04/27/2022] [Indexed: 11/13/2022] Open
Abstract
The extent to which the pathophysiology of autosomal dominant Alzheimer's disease corresponds to the pathophysiology of 'sporadic' late onset Alzheimer's disease is unknown, thus limiting the extrapolation of study findings and clinical trial results in autosomal dominant Alzheimer's disease to late onset Alzheimer's disease. We compared brain MRI and amyloid PET data, as well as CSF concentrations of amyloid-β42, amyloid-β40, tau and tau phosphorylated at position 181, in 292 carriers of pathogenic variants for Alzheimer's disease from the Dominantly Inherited Alzheimer Network, with corresponding data from 559 participants from the Alzheimer's Disease Neuroimaging Initiative. Imaging data and CSF samples were reprocessed as appropriate to guarantee uniform pipelines and assays. Data analyses yielded rates of change before and after symptomatic onset of Alzheimer's disease, allowing the alignment of the ∼30-year age difference between the cohorts on a clinically meaningful anchor point, namely the participant age at symptomatic onset. Biomarker profiles were similar for both autosomal dominant Alzheimer's disease and late onset Alzheimer's disease. Both groups demonstrated accelerated rates of decline in cognitive performance and in regional brain volume loss after symptomatic onset. Although amyloid burden accumulation as determined by PET was greater after symptomatic onset in autosomal dominant Alzheimer's disease than in late onset Alzheimer's disease participants, CSF assays of amyloid-β42, amyloid-β40, tau and p-tau181 were largely overlapping in both groups. Rates of change in cognitive performance and hippocampal volume loss after symptomatic onset were more aggressive for autosomal dominant Alzheimer's disease participants. These findings suggest a similar pathophysiology of autosomal dominant Alzheimer's disease and late onset Alzheimer's disease, supporting a shared pathobiological construct.
Collapse
Affiliation(s)
- John C Morris
- Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA
| | - Michael Weiner
- Department of Radiology, University of California at San Francisco, San Francisco, CA, USA
| | - Chengjie Xiong
- Division of Biostatistics, Washington University School of Medicine, St. Louis, MO, USA
| | - Laurel Beckett
- Department of Public Health Sciences, School of Medicine, University of California; Davis, Davis, CA, USA
| | - Dean Coble
- Division of Biostatistics, Washington University School of Medicine, St. Louis, MO, USA
| | - Naomi Saito
- Department of Public Health Sciences, School of Medicine, University of California; Davis, Davis, CA, USA
| | - Paul S Aisen
- Department of Neurology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
| | - Ricardo Allegri
- Department of Cognitive Neurology, Neuropsychology and Neuropsychiatry, Institute for Neurological Research (FLENI), Buenos Aires, Argentina
| | - Tammie L S Benzinger
- Department of Radiology, Washington University School of Medicine, St. Louis, MO, USA
| | - Sarah B Berman
- Department of Neurology and Clinical and Translational Science, University of Pittsburgh, Pittsburgh, PA, USA
| | - Nigel J Cairns
- College of Medicine and Health and the Living Systems Institute, University of Exeter, Exeter, UK
| | | | - Helena C Chui
- Department of Neurology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
| | - Jasmeer P Chhatwal
- Department of Neurology, Massachusetts General Hospital, Boston, MA, USA
| | - Carlos Cruchaga
- Department of Psychiatry, Washington University School of Medicine, St. Louis, MO, USA
| | - Anne M Fagan
- Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA
| | - Martin Farlow
- Department of Neurology, Indiana University School of Medicine, Indianapolis, IN, USA
| | - Nick C Fox
- Department of Neurodegenerative Disease and UK Dementia Research Institute, UCL Institute of Neurology, London, UK
| | - Bernardino Ghetti
- Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN, USA
| | - Alison M Goate
- Ronald M. Loeb Center for Alzheimer’s Disease, Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Brian A Gordon
- Department of Radiology, Washington University School of Medicine, St. Louis, MO, USA
| | | | - Gregory S Day
- Department of Neurology, Mayo Clinic, Jacksonville, FL, USA
| | - Jason Hassenstab
- Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA
| | - Takeshi Ikeuchi
- Department of Molecular Genetics, Brain Research Institute, Niigata University, Niigata, Japan
| | | | - William J Jagust
- Helen Wills Neuroscience Institute, University of California, Berkeley, CA, USA
| | - Mathias Jucker
- Cell Biology of Neurological Diseases Group, German Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany
- Hertie Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany
| | - Johannes Levin
- DZNE Munich, Munich Cluster of Systems Neurology (SyNergy) and Ludwig-Maximilians-Universität, Munich, Germany
| | - Parinaz Massoumzadeh
- Department of Radiology, Washington University School of Medicine, St. Louis, MO, USA
| | - Colin L Masters
- Florey Institute, University of Melbourne, Melbourne, Australia
| | - Ralph Martins
- Sir James McCusker Alzheimer’s Disease Research Unit, Edith Cowan University, Nedlands, Australia
| | - Eric McDade
- Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA
| | - Hiroshi Mori
- Department of Neuroscience, Osaka City University Medical School, Osaka City, Japan
| | - James M Noble
- Department of Neurology, Taub Institute for Research on Aging Brain, Columbia University Irving Medical Center, New York, NY, USA
| | | | - John M Ringman
- Department of Neurology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
| | - Stephen Salloway
- Department of Neurology, Butler Hospital and Alpert Medical School of Brown University, Providence, RI, 02906, USA
| | - Andrew J Saykin
- Department of Radiology and Imaging Sciences and the Indiana Alzheimer’s Disease Research Center, Indiana University School of Medicine, Indianapolis, IN, USA
| | - Peter R Schofield
- Neuroscience Research Australia and School of Medical Sciences, University of New South Wales, Sydney, Australia
| | - Leslie M Shaw
- Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
| | - Arthur W Toga
- Laboratory of Neuro Imaging, Mark and Mary Stevens Neuroimaging and Informatics Institute, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
| | - John Q Trojanowski
- Center for Neurodegenerative Disease Research, Institute on Aging, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
| | - Jonathan Vöglein
- German Center for Neurodegenerative Diseases (DZNE) and Department of Neurology, Ludwig-Maximilians-Universität München, Munich, Germany
| | | | - Randall J Bateman
- Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA
| | - Virginia D Buckles
- Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA
| |
Collapse
|
78
|
Eratne D, Janelidze S, Malpas CB, Loi S, Walterfang M, Merritt A, Diouf I, Blennow K, Zetterberg H, Cilia B, Wannan C, Bousman C, Everall I, Zalesky A, Jayaram M, Thomas N, Berkovic SF, Hansson O, Velakoulis D, Pantelis C, Santillo A, Stehmann C, Cadwallader C, Fowler C, Ravanfar P, Farrand S, Keem M, Kang M, Watson R, Yassi N, Kaylor-Hughes C, Kanaan R, Perucca P, Vivash L, Ali R, O’Brien TJ, Masters CL, Collins S, Kelso W, Evans A, King A, Kwan P, Gunn J, Goranitis I, Pan T, Lewis C, Kalincik T. Plasma neurofilament light chain protein is not increased in treatment-resistant schizophrenia and first-degree relatives. Aust N Z J Psychiatry 2022; 56:1295-1305. [PMID: 35179048 DOI: 10.1177/00048674211058684] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Abstract
OBJECTIVE Schizophrenia, a complex psychiatric disorder, is often associated with cognitive, neurological and neuroimaging abnormalities. The processes underlying these abnormalities, and whether a subset of people with schizophrenia have a neuroprogressive or neurodegenerative component to schizophrenia, remain largely unknown. Examining fluid biomarkers of diverse types of neuronal damage could increase our understanding of these processes, as well as potentially provide clinically useful biomarkers, for example with assisting with differentiation from progressive neurodegenerative disorders such as Alzheimer and frontotemporal dementias. METHODS This study measured plasma neurofilament light chain protein (NfL) using ultrasensitive Simoa technology, to investigate the degree of neuronal injury in a well-characterised cohort of people with treatment-resistant schizophrenia on clozapine (n = 82), compared to first-degree relatives (an at-risk group, n = 37), people with schizophrenia not treated with clozapine (n = 13), and age- and sex-matched controls (n = 59). RESULTS We found no differences in NfL levels between treatment-resistant schizophrenia (mean NfL, M = 6.3 pg/mL, 95% confidence interval: [5.5, 7.2]), first-degree relatives (siblings, M = 6.7 pg/mL, 95% confidence interval: [5.2, 8.2]; parents, M after adjusting for age = 6.7 pg/mL, 95% confidence interval: [4.7, 8.8]), controls (M = 5.8 pg/mL, 95% confidence interval: [5.3, 6.3]) and not treated with clozapine (M = 4.9 pg/mL, 95% confidence interval: [4.0, 5.8]). Exploratory, hypothesis-generating analyses found weak correlations in treatment-resistant schizophrenia, between NfL and clozapine levels (Spearman's r = 0.258, 95% confidence interval: [0.034, 0.457]), dyslipidaemia (r = 0.280, 95% confidence interval: [0.064, 0.470]) and a negative correlation with weight (r = -0.305, 95% confidence interval: [-0.504, -0.076]). CONCLUSION Treatment-resistant schizophrenia does not appear to be associated with neuronal, particularly axonal degeneration. Further studies are warranted to investigate the utility of NfL to differentiate treatment-resistant schizophrenia from neurodegenerative disorders such as behavioural variant frontotemporal dementia, and to explore NfL in other stages of schizophrenia such as the prodome and first episode.
Collapse
Affiliation(s)
- Dhamidhu Eratne
- Neuropsychiatry, The Royal Melbourne Hospital, Parkville, VIC, Australia.,Melbourne Neuropsychiatry Centre, Department of Psychiatry, The University of Melbourne and Melbourne Health, Melbourne, VIC, Australia
| | - Shorena Janelidze
- Clinical Memory Research Unit, Department of Clinical Sciences, Faculty of Medicine, Lund University, Lund, Sweden
| | - Charles B Malpas
- Clinical Outcomes Research Unit (CORe), Department of Medicine, The Royal Melbourne Hospital, The University of Melbourne, Melbourne, VIC, Australia.,Department of Neurology, The Royal Melbourne Hospital, Melbourne, VIC, Australia.,Melbourne School of Psychological Sciences, The University of Melbourne, Melbourne, VIC, Australia
| | - Samantha Loi
- Neuropsychiatry, The Royal Melbourne Hospital, Parkville, VIC, Australia.,Melbourne Neuropsychiatry Centre, Department of Psychiatry, The University of Melbourne and Melbourne Health, Melbourne, VIC, Australia
| | - Mark Walterfang
- Neuropsychiatry, The Royal Melbourne Hospital, Parkville, VIC, Australia.,Melbourne Neuropsychiatry Centre, Department of Psychiatry, The University of Melbourne and Melbourne Health, Melbourne, VIC, Australia
| | - Antonia Merritt
- Melbourne Neuropsychiatry Centre, Department of Psychiatry, The University of Melbourne and Melbourne Health, Melbourne, VIC, Australia
| | - Ibrahima Diouf
- Clinical Outcomes Research Unit (CORe), Department of Medicine, The Royal Melbourne Hospital, The University of Melbourne, Melbourne, VIC, Australia.,Department of Neurology, The Royal Melbourne Hospital, Melbourne, VIC, Australia
| | - Kaj Blennow
- Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, Sahlgrenska University Hospital, University of Gothenburg, Mölndal, Sweden
| | - Henrik Zetterberg
- Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, Sahlgrenska University Hospital, University of Gothenburg, Mölndal, Sweden.,Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Mölndal, Sweden.,Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK.,UK Dementia Research Institute, University College London (UCL), London, UK.,Hong Kong Center for Neurodegenerative Diseases, Hong Kong, China
| | - Brandon Cilia
- The University of Melbourne, Parkville, VIC, Australia
| | - Cassandra Wannan
- Melbourne Neuropsychiatry Centre, Department of Psychiatry, The University of Melbourne and Melbourne Health, Melbourne, VIC, Australia
| | - Chad Bousman
- Departments of Medical Genetics, Psychiatry, and Physiology & Pharmacology, University of Calgary, Calgary, AB, Canada
| | - Ian Everall
- Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK
| | - Andrew Zalesky
- Melbourne Neuropsychiatry Centre, Department of Psychiatry, The University of Melbourne and Melbourne Health, Melbourne, VIC, Australia
| | - Mahesh Jayaram
- Melbourne Neuropsychiatry Centre, Department of Psychiatry, The University of Melbourne and Melbourne Health, Melbourne, VIC, Australia.,Mid West Area Mental Health Service, Melbourne Health, Sunshine, VIC, Australia
| | - Naveen Thomas
- Melbourne Neuropsychiatry Centre, Department of Psychiatry, The University of Melbourne and Melbourne Health, Melbourne, VIC, Australia.,Mid West Area Mental Health Service, Melbourne Health, Sunshine, VIC, Australia
| | - Samuel F Berkovic
- Epilepsy Research Centre, Department of Medicine, Austin Health, The University of Melbourne, Heidelberg, VIC, Australia
| | - Oskar Hansson
- Clinical Memory Research Unit, Department of Clinical Sciences, Faculty of Medicine, Lund University, Lund, Sweden
| | - Dennis Velakoulis
- Neuropsychiatry, The Royal Melbourne Hospital, Parkville, VIC, Australia.,Melbourne Neuropsychiatry Centre, Department of Psychiatry, The University of Melbourne and Melbourne Health, Melbourne, VIC, Australia
| | - Christos Pantelis
- Melbourne Neuropsychiatry Centre, Department of Psychiatry, The University of Melbourne and Melbourne Health, Melbourne, VIC, Australia.,Mid West Area Mental Health Service, Melbourne Health, Sunshine, VIC, Australia
| | - Alexander Santillo
- Clinical Memory Research Unit, Department of Clinical Sciences, Faculty of Medicine, Lund University, Lund, Sweden
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
79
|
Pedrini S, Doecke JD, Hone E, Wang P, Thota R, Bush AI, Rowe CC, Dore V, Villemagne VL, Ames D, Rainey‐Smith S, Verdile G, Sohrabi HR, Raida MR, Taddei K, Gandy S, Masters CL, Chatterjee P, Martins R. Plasma high-density lipoprotein cargo is altered in Alzheimer's disease and is associated with regional brain volume. J Neurochem 2022; 163:53-67. [PMID: 36000528 PMCID: PMC9804612 DOI: 10.1111/jnc.15681] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/09/2022] [Revised: 07/12/2022] [Accepted: 07/22/2022] [Indexed: 01/05/2023]
Abstract
Cholesterol levels have been repeatedly linked to Alzheimer's Disease (AD), suggesting that high levels could be detrimental, but this effect is likely attributed to Low-Density Lipoprotein (LDL) cholesterol. On the other hand, High-Density Lipoproteins (HDL) cholesterol levels have been associated with reduced brain amyloidosis and improved cognitive function. However, recent findings have suggested that HDL-functionality, which depends upon the HDL-cargo proteins associated with HDL, rather than HDL levels, appears to be the key factor, suggesting a quality over quantity status. In this report, we have assessed the HDL-cargo (Cholesterol, ApoA-I, ApoA-II, ApoC-I, ApoC-III, ApoD, ApoE, ApoH, ApoJ, CRP, and SAA) in stable healthy control (HC), healthy controls who will convert to MCI/AD (HC-Conv) and AD patients (AD). Compared to HC we observed an increased cholesterol/ApoA-I ratio in AD and HC-Conv, as well as an increased ApoD/ApoA-I ratio and a decreased ApoA-II/ApoA-I ratio in AD. Higher cholesterol/ApoA-I ratio was also associated with lower cortical grey matter volume and higher ventricular volume, while higher ApoA-II/ApoA-I and ApoJ/ApoA-I ratios were associated with greater cortical grey matter volume (and for ApoA-II also with greater hippocampal volume) and smaller ventricular volume. Additionally, in a clinical status-independent manner, the ApoE/ApoA-I ratio was significantly lower in APOE ε4 carriers and lowest in APOE ε4 homozygous. Together, these data indicate that in AD patients the composition of HDL is altered, which may affect HDL functionality, and such changes are associated with altered regional brain volumetric data.
Collapse
Affiliation(s)
- Steve Pedrini
- School of Medical SciencesEdith Cowan UniversityJoondalupWestern AustraliaAustralia,CRC for Mental HealthMelbourneVictoriaAustralia
| | - James D. Doecke
- Australian E‐Health Research CentreCSIROBrisbaneQueenslandAustralia
| | - Eugene Hone
- School of Medical SciencesEdith Cowan UniversityJoondalupWestern AustraliaAustralia,CRC for Mental HealthMelbourneVictoriaAustralia
| | - Penghao Wang
- College of Science, Health, Engineering and EducationMurdoch UniversityMurdochWestern AustraliaAustralia
| | - Rohith Thota
- Faculty of Medicine, Health and Human Sciences, Department of Biomedical SciencesMacquarie UniversitySydneyNew South WalesAustralia
| | - Ashley I. Bush
- CRC for Mental HealthMelbourneVictoriaAustralia,The Florey Institute, The University of MelbourneParkvilleVictoriaAustralia
| | - Christopher C. Rowe
- Department of Nuclear Medicine and Centre for PETAustin HealthHeidelbergVictoriaAustralia
| | - Vincent Dore
- Department of Nuclear Medicine and Centre for PETAustin HealthHeidelbergVictoriaAustralia
| | | | - David Ames
- National Ageing Research InstituteParkvilleVictoriaAustralia,University of Melbourne Academic unit for Psychiatry of Old AgeSt George's HospitalKewVictoriaAustralia
| | - Stephanie Rainey‐Smith
- School of Medical SciencesEdith Cowan UniversityJoondalupWestern AustraliaAustralia,Centre for Healthy Ageing, Health Futures InstituteMurdoch UniversityMurdochWestern AustraliaAustralia
| | - Giuseppe Verdile
- Curtin Medical SchoolCurtin UniversityBentleyWestern AustraliaAustralia,Curtin Health Innovation Research InstituteCurtin UniversityBentleyWestern AustraliaAustralia
| | - Hamid R. Sohrabi
- Centre for Healthy Ageing, Health Futures InstituteMurdoch UniversityMurdochWestern AustraliaAustralia
| | - Manfred R. Raida
- Life Science Institute, Singapore Lipidomics IncubatorNational University of SingaporeSingapore CitySingapore
| | - Kevin Taddei
- School of Medical SciencesEdith Cowan UniversityJoondalupWestern AustraliaAustralia,CRC for Mental HealthMelbourneVictoriaAustralia
| | - Sam Gandy
- Department of NeurologyIcahn School of Medicine at Mount SinaiNew York CityNew YorkUSA
| | - Colin L. Masters
- The Florey Institute, The University of MelbourneParkvilleVictoriaAustralia
| | - Pratishtha Chatterjee
- Faculty of Medicine, Health and Human Sciences, Department of Biomedical SciencesMacquarie UniversitySydneyNew South WalesAustralia
| | - Ralph N. Martins
- School of Medical SciencesEdith Cowan UniversityJoondalupWestern AustraliaAustralia,CRC for Mental HealthMelbourneVictoriaAustralia,Faculty of Medicine, Health and Human Sciences, Department of Biomedical SciencesMacquarie UniversitySydneyNew South WalesAustralia,School of Psychiatry and Clinical NeurosciencesUniversity of Western AustraliaCrawleyWestern AustraliaAustralia
| | | |
Collapse
|
80
|
Delaby C, Teunissen CE, Blennow K, Alcolea D, Arisi I, Amar EB, Beaume A, Bedel A, Bellomo G, Bigot‐Corbel E, Bjerke M, Blanc‐Quintin M, Boada M, Bousiges O, Chapman MD, DeMarco ML, D'Onofrio M, Dumurgier J, Dufour‐Rainfray D, Engelborghs S, Esselmann H, Fogli A, Gabelle A, Galloni E, Gondolf C, Grandhomme F, Grau‐Rivera O, Hart M, Ikeuchi T, Jeromin A, Kasuga K, Keshavan A, Khalil M, Körtvelyessy P, Kulczynska‐Przybik A, Laplanche J, Lewczuk P, Li Q, Lleó A, Malaplate C, Marquié M, Masters CL, Mroczko B, Nogueira L, Orellana A, Otto M, Oudart J, Paquet C, Paoletti FP, Parnetti L, Perret‐Liaudet A, Peoc'h K, Poesen K, Puig‐Pijoan A, Quadrio I, Quillard‐Muraine M, Rucheton B, Schraen S, Schott JM, Shaw LM, Suárez‐Calvet M, Tsolaki M, Tumani H, Udeh‐Momoh CT, Vaudran L, Verbeek MM, Verde F, Vermunt L, Vogelgsang J, Wiltfang J, Zetterberg H, Lehmann S. Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview. Alzheimers Dement 2022; 18:1868-1879. [PMID: 34936194 PMCID: PMC9787404 DOI: 10.1002/alz.12545] [Citation(s) in RCA: 14] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2021] [Revised: 10/11/2021] [Accepted: 10/25/2021] [Indexed: 01/28/2023]
Abstract
INTRODUCTION The current practice of quantifying cerebrospinal fluid (CSF) biomarkers as an aid in the diagnosis of Alzheimer's disease (AD) varies from center to center. For a same biochemical profile, interpretation and reporting of results may differ, which can lead to misunderstandings and raises questions about the commutability of tests. METHODS We obtained a description of (pre-)analytical protocols and sample reports from 40 centers worldwide. A consensus approach allowed us to propose harmonized comments corresponding to the different CSF biomarker profiles observed in patients. RESULTS The (pre-)analytical procedures were similar between centers. There was considerable heterogeneity in cutoff definitions and report comments. We therefore identified and selected by consensus the most accurate and informative comments regarding the interpretation of CSF biomarkers in the context of AD diagnosis. DISCUSSION This is the first time that harmonized reports are proposed across worldwide specialized laboratories involved in the biochemical diagnosis of AD.
Collapse
Affiliation(s)
- Constance Delaby
- LBPC‐PPCUniv MontpellierCHU MontpellierINSERMMontpellierFrance,Hospital de la Santa Creu i Sant Pau ‐ Biomedical Research Institute Sant Pau ‐ Universitat Autònoma de BarcelonaBarcelonaSpain
| | - Charlotte E. Teunissen
- Neurochemistry LabDepartment of Clinical ChemistryAmsterdam NeuroscienceAmsterdam UMCVrije Universiteit AmsterdamAmsterdamNetherlands
| | - Kaj Blennow
- Institute of Neuroscience and PhysiologyThe Sahlgrenska Academy at the University of GothenburgGothenburgSweden
| | - Daniel Alcolea
- Hospital de la Santa Creu i Sant Pau ‐ Biomedical Research Institute Sant Pau ‐ Universitat Autònoma de BarcelonaBarcelonaSpain
| | - Ivan Arisi
- European Brain Research Institute (EBRI) “Rita Levi‐Montalcini”RomaItaly
| | - Elodie Bouaziz Amar
- Université de ParisCognitive Neurology CenterGHU APHP Nord Lariboisière Fernand‐Widal HospitalParisFrance
| | | | | | - Giovanni Bellomo
- Lab of Clinical NeurochemistrySection of NeurologyDept. of Medicine and SurgeryUniversity of PerugiaPerugiaItaly
| | | | - Maria Bjerke
- Vrije Universiteit BrusselCenter for Neurosciences and Department of Clinical BiologyClinical Neurochemistry LaboratoryUniversitair Ziekenhuis BrusselBrusselsBelgium,Department of Biomedical Sciences, Institute Born‐BungeUniversity of AntwerpAntwerpBelgium
| | | | - Mercè Boada
- Research Center and Memory ClinicFundació ACEInstitut Català de Neurociències Aplicades and Universitat Internacional de Catalunya (UIC)BarcelonaSpain,Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED)Instituto de Salud Carlos IIIMadridSpain
| | - Olivier Bousiges
- Laboratoire de Biochimie et Biologie Moléculaire, et CNRSICube Laboratory UMR 7357 and FMTS (Fédération de Médecine Translationnelle de Strasbourg)Team IMISHôpitaux Universitaires de StrasbourgStrasbourgFrance
| | - Miles D Chapman
- Department of NeuroimmunologyNational Hospital for Neurology and Neurosurgery, UCL Queen SquareLondonUK
| | - Mari L. DeMarco
- Department of Pathology and Laboratory MedicineSt. Paul's Hospital, Providence Health Care, Vancouver, Canada & Department of Pathology & Laboratory MedicineUniversity of British ColumbiaVancouverCanada
| | - Mara D'Onofrio
- European Brain Research Institute (EBRI) “Rita Levi‐Montalcini”RomaItaly
| | - Julien Dumurgier
- Université de ParisCognitive Neurology CenterGHU APHP Nord Lariboisière Fernand‐Widal HospitalParisFrance
| | | | - Sebastiaan Engelborghs
- Department of Biomedical Sciences, Institute Born‐BungeUniversity of AntwerpAntwerpBelgium,Vrije Universiteit BrusselUniversitair Ziekenhuis BrusselCenter for Neurosciences and Department of NeurologyBrusselsBelgium
| | - Hermann Esselmann
- Department of Psychiatry and PsychotherapyUniversity Medical Center Goettingen (UMGGoettingenGermany
| | - Anne Fogli
- CHU Clermont‐FerrandClermont‐FerrandFrance
| | - Audrey Gabelle
- LBPC‐PPCUniv MontpellierCHU MontpellierINSERMMontpellierFrance
| | | | | | | | - Oriol Grau‐Rivera
- Barcelonaβeta Brain Research Center (BBRC)Pasqual Maragall FoundationBarcelonaSpain,Servei de NeurologiaHospital del MarUnitat de deteriorament cognitiu i transtorns del movimentBarcelonaSpain,IMIM (Hospital del Mar Medical Research Institute)BarcelonaSpain,Centro de Investigación Biomédica en Red de Fragilidad y Envejecimiento Saludable (CIBERFES)MadridSpain
| | - Melanie Hart
- Department of NeuroimmunologyNational Hospital for Neurology and Neurosurgery, UCL Queen SquareLondonUK
| | - Takeshi Ikeuchi
- Dept. of Molecular GeneticsCenter for BioresourcesBrain Research InstituteNiigata UniversityNiigataJapan
| | | | - Kensaku Kasuga
- Dept. of Molecular GeneticsCenter for BioresourcesBrain Research InstituteNiigata UniversityNiigataJapan
| | - Ashvini Keshavan
- Dementia Research CentreUCL Queen Square Institute of NeurologyLondonUK
| | | | - Peter Körtvelyessy
- Freie Universität Berlin and Humboldt‐Universität zu BerlinDepartment of NeurologyGerman Center for Neurodegenerative Diseases, Magdeburg, Germany and Charité‐Universitäts medizin BerlinBerlinGermany
| | | | - Jean‐Louis Laplanche
- Université de ParisCognitive Neurology CenterGHU APHP Nord Lariboisière Fernand‐Widal HospitalParisFrance
| | - Piotr Lewczuk
- Department of Neurodegeneration DiagnosticsMedical University of BialystokBialystokPoland,Lab for Clinical Neurochemistry and Neurochemical Dementia DiagnosticsUniversitätsklinikum Erlangen and Friedrich‐Alexander Universität Erlangen‐NürnbergErlangenGermany
| | - Qiao‐Xin Li
- Florey Institute and The University of MelbourneMelbourneVictoriaAustralia
| | - Alberto Lleó
- Hospital de la Santa Creu i Sant Pau ‐ Biomedical Research Institute Sant Pau ‐ Universitat Autònoma de BarcelonaBarcelonaSpain
| | - Catherine Malaplate
- CHRU de NancyLaboratoire de BiochimieBiologie Moléculaire et Nutrition/ Université de LorraineNancyFrance
| | - Marta Marquié
- Research Center and Memory ClinicFundació ACEInstitut Català de Neurociències Aplicades and Universitat Internacional de Catalunya (UIC)BarcelonaSpain,Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED)Instituto de Salud Carlos IIIMadridSpain
| | - Colin L. Masters
- Florey Institute and The University of MelbourneMelbourneVictoriaAustralia
| | - Barbara Mroczko
- Department of Neurodegeneration DiagnosticsMedical University of BialystokBialystokPoland
| | - Léonor Nogueira
- Laboratoire de Biologie Cellulaire et CytologieCHU PURPANToulouseFrance
| | - Adelina Orellana
- Research Center and Memory ClinicFundació ACEInstitut Català de Neurociències Aplicades and Universitat Internacional de Catalunya (UIC)BarcelonaSpain,Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED)Instituto de Salud Carlos IIIMadridSpain
| | - Markus Otto
- Department of Neurology and CSF LaboratoryUniversity of UlmUlmGermany
| | | | - Claire Paquet
- Université de ParisCognitive Neurology CenterGHU APHP Nord Lariboisière Fernand‐Widal HospitalParisFrance
| | - Federico Paolini Paoletti
- Lab of Clinical NeurochemistrySection of NeurologyDept. of Medicine and SurgeryUniversity of PerugiaPerugiaItaly
| | - Lucilla Parnetti
- Lab of Clinical NeurochemistrySection of NeurologyDept. of Medicine and SurgeryUniversity of PerugiaPerugiaItaly
| | - Armand Perret‐Liaudet
- Lyon Neuroscience Research Center BIORAN Team ‐ CNRS UMR 5292INSERM U1028Lyon University HospitalLyonFrance
| | - Katell Peoc'h
- Université de Paris GHU APHP Nord Beaujon HospitalParisFrance
| | - Koen Poesen
- Laboratory for Molecular Neurobiomarker Research (LaMoN)Department of NeurosciencesKU LeuvenLeuven Brain InstituteLeuvenBelgium
| | - Albert Puig‐Pijoan
- Servei de NeurologiaHospital del MarUnitat de deteriorament cognitiu i transtorns del movimentBarcelonaSpain,IMIM (Hospital del Mar Medical Research Institute)BarcelonaSpain
| | - Isabelle Quadrio
- Lyon Neuroscience Research Center BIORAN Team ‐ CNRS UMR 5292INSERM U1028Lyon University HospitalLyonFrance
| | - Muriel Quillard‐Muraine
- UNIROUENRouen University HospitalDepartment of Clinical biologyBiochemistry laboratoryNormandie UnivRouenFrance
| | | | - Susanna Schraen
- InsermCHU LilleU1172‐LilNCogLICENDLabEx DISTALZUniversité de LilleLilleFrance
| | | | - Leslie M. Shaw
- Department of Pathology and Laboratory Medicine HospitalUniversity of PennsylvaniaPennsylvaniaUSA
| | - Marc Suárez‐Calvet
- Barcelonaβeta Brain Research Center (BBRC)Pasqual Maragall FoundationBarcelonaSpain,Servei de NeurologiaHospital del MarUnitat de deteriorament cognitiu i transtorns del movimentBarcelonaSpain,IMIM (Hospital del Mar Medical Research Institute)BarcelonaSpain,Centro de Investigación Biomédica en Red de Fragilidad y Envejecimiento Saludable (CIBERFES)MadridSpain
| | - Magda Tsolaki
- 1st Department of NeurologySchool of MedicineFaculty of Health of SciencesAristotle University of ThessalonikiThessalonikiGreece
| | - Hayrettin Tumani
- Department of Neurology and CSF LaboratoryUniversity of UlmUlmGermany
| | | | | | - Marcel M Verbeek
- Donders Institute for Brain, Cognition and BehaviourRadboud Alzheimer CentreDepartments of Neurology and Laboratory MedicineRadboud University Medical CenterNijmegenThe Netherlands
| | - Federico Verde
- Department of Neurology ‐ Stroke Unit and Laboratory of NeuroscienceIRCCS Istituto Auxologico ItalianoMilanItaly,Department of Pathophysiology and Transplantation“Dino Ferrari” Center, Università degli Studi di MilanoMilanItaly
| | - Lisa Vermunt
- Neurochemistry LabDepartment of Clinical ChemistryAmsterdam NeuroscienceAmsterdam UMCVrije Universiteit AmsterdamAmsterdamNetherlands
| | - Jonathan Vogelgsang
- Department of Psychiatry and PsychotherapyUniversity Medical Center Goettingen (UMGGoettingenGermany,McLean HospitalTranslational Neuroscience LaboratoryHarvard Medical SchoolBelmontMassachusettsUSA
| | - Jens Wiltfang
- Department of Psychiatry and PsychotherapyUniversity Medical Center Goettingen (UMGGoettingenGermany,German Center for Neurodegenerative Diseases (DZNE)GoettingenGermany,Neurosciences and Signaling GroupInstitute of Biomedicine (iBiMED)Department of Medical SciencesUniversity of AveiroAveiroPortugal
| | - Henrik Zetterberg
- Institute of Neuroscience and PhysiologyThe Sahlgrenska Academy at the University of GothenburgGothenburgSweden,Clinical Neurochemistry LaboratorySahlgrenska University HospitalMölndalSweden,UK Dementia Research Institute at UCLLondonUK,Department of Neurodegenerative DiseaseUCL Institute of NeurologyLondonUK
| | - Sylvain Lehmann
- LBPC‐PPCUniv MontpellierCHU MontpellierINSERMMontpellierFrance
| |
Collapse
|
81
|
Buckles VD, Xiong C, Bateman RJ, Hassenstab J, Allegri R, Berman SB, Chhatwal JP, Danek A, Fagan AM, Ghetti B, Goate A, Graff-Radford N, Jucker M, Levin J, Marcus DS, Masters CL, McCue L, McDade E, Mori H, Moulder KL, Noble JM, Paumier K, Preische O, Ringman JM, Fox NC, Salloway S, Schofield PR, Martins R, Vöglein J, Morris JC. Different rates of cognitive decline in autosomal dominant and late-onset Alzheimer disease. Alzheimers Dement 2022; 18:1754-1764. [PMID: 34854530 PMCID: PMC9160203 DOI: 10.1002/alz.12505] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/07/2021] [Revised: 08/13/2021] [Accepted: 09/22/2021] [Indexed: 01/28/2023]
Abstract
As prevention trials advance with autosomal dominant Alzheimer disease (ADAD) participants, understanding the similarities and differences between ADAD and "sporadic" late-onset AD (LOAD) is critical to determine generalizability of findings between these cohorts. Cognitive trajectories of ADAD mutation carriers (MCs) and autopsy-confirmed LOAD individuals were compared to address this question. Longitudinal rates of change on cognitive measures were compared in ADAD MCs (n = 310) and autopsy-confirmed LOAD participants (n = 163) before and after symptom onset (estimated/observed). LOAD participants declined more rapidly in the presymptomatic (preclinical) period and performed more poorly at symptom onset than ADAD participants on a cognitive composite. After symptom onset, however, the younger ADAD MCs declined more rapidly. The similar but not identical cognitive trajectories (declining but at different rates) for ADAD and LOAD suggest common AD pathologies but with some differences.
Collapse
Affiliation(s)
- Virginia D. Buckles
- Department of Neurology, Washington University School of Medicine, St. Louis, MO, 63110, USA
| | - Chengjie Xiong
- Division of Biostatistics, Washington University School of Medicine, St. Louis, MO, 63110, USA
| | - Randall J. Bateman
- Department of Neurology, Washington University School of Medicine, St. Louis, MO, 63110, USA
| | - Jason Hassenstab
- Department of Neurology, Washington University School of Medicine, St. Louis, MO, 63110, USA
| | - Ricardo Allegri
- Institute for Neurological Research (FLENI), Buenos Aires, Argentina
| | - Sarah B. Berman
- Department of Neurology and Clinical and Translational Science, University of Pittsburgh, Pittsburgh, PA, 15213, USA
| | - Jasmeer P. Chhatwal
- Department of Neurology, Massachusetts General Hospital, Boston, MA, 02129, USA
| | - Adrian Danek
- Neurologische Klinik und Poliklinik, Klinikum der Universität München, Munich Germany
| | - Anne M Fagan
- Department of Neurology, Washington University School of Medicine, St. Louis, MO, 63110, USA
| | - Bernardino Ghetti
- Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN, 46202, USA
| | - Alison Goate
- Department of Neuroscience, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | | | - Mathias Jucker
- DZNE Tuebingen & Hertie Institute for Clinical Brain Research, University of Tuebingen, Tuebingen, Germany
| | - Johannes Levin
- DZNE Munich, Munich Cluster of systems neurology (SyNergy) & Ludwig-Maximilians-Universität, Munich, Germany
| | - Daniel S Marcus
- Department of Radiology, Washington University School of Medicine, St. Louis, MO, 63110, USA
| | | | - Lena McCue
- Division of Biostatistics, Washington University School of Medicine, St. Louis, MO, 63110, USA
| | - Eric McDade
- Department of Neurology, Washington University School of Medicine, St. Louis, MO, 63110, USA
| | - Hiroshi Mori
- Department of Neuroscience, Osaka City University Medical School, Osaka City, Japan
| | - Krista L. Moulder
- Department of Neurology, Washington University School of Medicine, St. Louis, MO, 63110, USA
| | - James M Noble
- Department of Neurology, Taub Institute for Research on Aging Brain, Columbia University Irving Medical Center, New York, NY, 10032, USA
| | - Katrina Paumier
- Department of Neurology, Washington University School of Medicine, St. Louis, MO, 63110, USA
| | - Oliver Preische
- DZNE Tuebingen & University of Tuebingen, Tuebingen, Germany
| | - John M. Ringman
- Department of Neurology, Keck School of Medicine, University of Southern California, Los Angeles, CA, 90033, USA
| | - Nick C Fox
- Department of Neurodegenerative Disease & UK Dementia Research Institute, Institute of Neurology, London, UK
| | - Stephen Salloway
- Department of Neurology, Butler Hospital & Alpert Medical School of Brown University, Providence, RI, 02906, USA
| | - Peter R. Schofield
- Neuroscience Research Australia & School of Medical Sciences, University of New South Wales, Sydney, Australia
| | - Ralph Martins
- Sir James McCusker Alzheimer’s Disease Research Unit, Edith Cowan University, Nedlands, Australia
| | - Jonathan Vöglein
- German Center for Neurodegenerative Diseases (DZNE) and Department of Neurology, Ludwig-Maximilians Universität München; Munich, Germany
| | - John C. Morris
- Department of Neurology, Washington University School of Medicine, St. Louis, MO, 63110, USA
| | | |
Collapse
|
82
|
Atkins KJ, Evered L, Scott DA, Fowler C, Masters CL, Silbert B. Cerebrospinal fluid sampling for research of Alzheimer’s disease and other neurodegenerative diseases when lumbar punctures are performed by anaesthetists. BMJ Neurol Open 2022; 4:e000335. [PMID: 36110925 PMCID: PMC9445826 DOI: 10.1136/bmjno-2022-000335] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 08/11/2022] [Indexed: 11/03/2022] Open
Abstract
ObjectivesAn increasing number of people are undergoing lumbar puncture (LP) for the purposes of research. Performing LP for research purposes introduces considerations that differ from LP performed for clinical, diagnostic or therapeutic reasons. The demand for research LP will greatly increase as biomarkers are used to both diagnose and monitor disease progression in clinical trials. Minimising adverse events is paramount because research participants receive no clinical benefit and often need repeat procedures. We describe the experience of performing LP for research by anaesthetists.MethodsWe reviewed the clinical protocol and incidence of adverse events in 326 research LP in an anaesthesia department.ResultsThere was a lower incidence of adverse events compared with previous reports when LP was undertaken for clinical reasons. The incidence of severe post-LP headache was 1.3% when an atraumatic spinal needle with a 27 gauge tip and a 22 gauge shaft was used.ConclusionsWe describe the practice to sample cerebrospinal fluid (CSF) by LP for research purposes. Specific practices include the sitting position of the participant, aspiration rather than passive CSF withdrawal, attention to the sterility of the procedure, monitoring of vital signs and importantly the use of 22/27 gauge microtip spinal needle.Trial registration numbersACTRN12612000493842, NCT04623242.
Collapse
Affiliation(s)
- Kelly J Atkins
- Department of Anaesthesia and Acute Pain Medicine, St Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia
- Department of Critical Care, Melbourne Medical School, The University of Melbourne, Melbourne, Victoria, Australia
| | - Lisbeth Evered
- Department of Anaesthesia and Acute Pain Medicine, St Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia
- Department of Critical Care, Melbourne Medical School, The University of Melbourne, Melbourne, Victoria, Australia
- Department of Anesthesiology, Weill Cornell Medicine, New York, New York, USA
| | - David A Scott
- Department of Anaesthesia and Acute Pain Medicine, St Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia
- Department of Critical Care, Melbourne Medical School, The University of Melbourne, Melbourne, Victoria, Australia
| | - Christopher Fowler
- The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Melbourne, Victoria, Australia
| | - Colin L Masters
- The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Melbourne, Victoria, Australia
| | - Brendan Silbert
- Department of Anaesthesia and Acute Pain Medicine, St Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia
- Department of Critical Care, Melbourne Medical School, The University of Melbourne, Melbourne, Victoria, Australia
| |
Collapse
|
83
|
Ruwanpathirana GP, Williams RC, Masters CL, Rowe CC, Johnston LA, Davey CE. Mapping the association between tau-PET and Aβ-amyloid-PET using deep learning. Sci Rep 2022; 12:14797. [PMID: 36042256 PMCID: PMC9427855 DOI: 10.1038/s41598-022-18963-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/04/2022] [Accepted: 08/23/2022] [Indexed: 11/26/2022] Open
Abstract
In Alzheimer’s disease, the molecular pathogenesis of the extracellular Aβ-amyloid (Aβ) instigation of intracellular tau accumulation is poorly understood. We employed a high-resolution PET scanner, with low detection thresholds, to examine the Aβ-tau association using a convolutional neural network (CNN), and compared results to a standard voxel-wise linear analysis. The full range of Aβ Centiloid values was highly predicted by the tau topography using the CNN (training R2 = 0.86, validation R2 = 0.75, testing R2 = 0.72). Linear models based on tau-SUVR identified widespread positive correlations between tau accumulation and Aβ burden throughout the brain. In contrast, CNN analysis identified focal clusters in the bilateral medial temporal lobes, frontal lobes, precuneus, postcentral gyrus and middle cingulate. At low Aβ levels, information from the middle cingulate, frontal lobe and precuneus regions was more predictive of Aβ burden, while at high Aβ levels, the medial temporal regions were more predictive of Aβ burden. The data-driven CNN approach revealed new associations between tau topography and Aβ burden.
Collapse
Affiliation(s)
- Gihan P Ruwanpathirana
- Department of Biomedical Engineering, The University of Melbourne, Melbourne, VIC, Australia.,Melbourne Brain Centre Imaging Unit, The University of Melbourne, Melbourne, VIC, Australia
| | - Robert C Williams
- Melbourne Brain Centre Imaging Unit, The University of Melbourne, Melbourne, VIC, Australia
| | - Colin L Masters
- Florey Institute of Neuroscience and Mental Health, Melbourne, VIC, Australia.,Florey Department of Neuroscience and Mental Health, The University of Melbourne, Melbourne, VIC, Australia
| | - Christopher C Rowe
- Department of Molecular Imaging and Therapy, Austin Health, Melbourne, VIC, Australia.,Florey Institute of Neuroscience and Mental Health, Melbourne, VIC, Australia.,Florey Department of Neuroscience and Mental Health, The University of Melbourne, Melbourne, VIC, Australia
| | - Leigh A Johnston
- Department of Biomedical Engineering, The University of Melbourne, Melbourne, VIC, Australia.,Melbourne Brain Centre Imaging Unit, The University of Melbourne, Melbourne, VIC, Australia
| | - Catherine E Davey
- Department of Biomedical Engineering, The University of Melbourne, Melbourne, VIC, Australia. .,Melbourne Brain Centre Imaging Unit, The University of Melbourne, Melbourne, VIC, Australia.
| |
Collapse
|
84
|
Stehmann C, Senesi M, Sarros S, McGlade A, Lewis V, Simpson M, Klug G, McLean C, Masters CL, Collins S. Creutzfeldt-Jakob disease surveillance in Australia: update to 31 December 2021. Commun Dis Intell (2018) 2022; 46. [DOI: 10.33321/cdi.2022.46.53] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Abstract Nationwide surveillance of Creutzfeldt-Jakob disease (CJD) and other human prion diseases is performed by the Australian National Creutzfeldt-Jakob Disease Registry (ANCJDR). National surveillance encompasses the period since 1 January 1970, with prospective surveillance occurring from 1 October 1993. Over this prospective surveillance period, considerable developments have occurred in pre-mortem diagnostics; in the delineation of new disease subtypes; and in a heightened awareness of prion diseases in healthcare settings. Surveillance practices of the ANCJDR have evolved and adapted accordingly. This report summarises the activities of the ANCJDR during 2021. Since the ANCJDR began offering diagnostic cerebrospinal fluid (CSF) 14-3-3 protein testing in Australia in September 1997, the annual number of referrals has steadily increased. In 2021, a total of 548 domestic CSF specimens were referred for 14-3-3 protein testing; 73 persons with suspected human prion disease were formally added to the national register. As of 31 December 2021, just over half of the 73 suspect case notifications (37/73) remain classified as ‘incomplete’; 17 cases were classified as ‘definite’ and 13 as ‘probable’ prion disease; six cases were excluded through either detailed clinical follow-up (two cases) or neuropathological examination (four cases). For 2021, sixty-four percent of all suspected human-prion-disease-related deaths in Australia underwent neuropathological examination. No cases of variant or iatrogenic CJD were identified. The SARS-CoV-2 pandemic did not affect prion disease surveillance outcomes in Australia.
Collapse
|
85
|
Woodward M, Brodaty H, McCabe M, Masters CL, Naismith SL, Morris P, Rowe CC, Walker P, Yates M. Nationally Informed Recommendations on Approaching the Detection, Assessment, and Management of Mild Cognitive Impairment. J Alzheimers Dis 2022; 89:803-809. [PMID: 35964184 PMCID: PMC9535556 DOI: 10.3233/jad-220288] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Prior to the usual clinical symptoms of dementia, there can be subtle changes in cognitive function that differ from the normal age-related cognitive decline, which has been termed mild cognitive impairment (MCI). The increase in the numbers of individuals with possible MCI presenting to health care professionals, notably, General Practitioners (GPs), is going to rise dramatically in the coming years. With ever increasing demands on GPs, it is therefore timely to provide information that can be accessed by health care professionals to assist them in making appropriate diagnoses and to provide the most relevant, evidence-based treatment options. We have provided a comprehensive list of recommendations that aim to address key aspects of MCI in primary care. Specifically, these relate to detection and diagnosis; sharing the diagnosis, monitoring, and follow up; practical interventions to potentially delay progression; and personalizing care—planning, engagement, and patient motivation for the long term.
Collapse
Affiliation(s)
| | - Henry Brodaty
- Centre for Healthy Brain Ageing (CHeBA), University of New South Wales, Sydney, Australia
| | - Maree McCabe
- Dementia Australia, Parkville, Victoria, Australia
| | - Colin L Masters
- Florey Institute and The University of Melbourne, Victoria, Australia
| | - Sharon L Naismith
- School of Psychology, The University of Sydney, New South Wales, Australia
| | - Philip Morris
- Faculty of Health Sciences and Medicine, Bond University, Queensland, Australia
| | - Christopher C Rowe
- Austin Health, University of Melbourne, Victoria, Australia.,Florey Institute and The University of Melbourne, Victoria, Australia
| | | | - Mark Yates
- Grampians Health, Deakin University, Victoria, Australia
| |
Collapse
|
86
|
Huq AJ, Thompson B, Bennett MF, Bournazos A, Bommireddipalli S, Gorelik A, Schultz J, Sexton A, Purvis R, West K, Cotter M, Valente G, Hughes A, Riaz M, Walsh M, Farrand S, Loi SM, Kilpatrick T, Brodtmann A, Darby D, Eratne D, Walterfang M, Delatycki MB, Storey E, Fahey M, Cooper S, Lacaze P, Masters CL, Velakoulis D, Bahlo M, James PA, Winship I. Clinical impact of whole-genome sequencing in patients with early-onset dementia. J Neurol Neurosurg Psychiatry 2022; 93:jnnp-2021-328146. [PMID: 35906014 DOI: 10.1136/jnnp-2021-328146] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/30/2021] [Accepted: 06/07/2022] [Indexed: 11/04/2022]
Abstract
BACKGROUND In the clinical setting, identification of the genetic cause in patients with early-onset dementia (EOD) is challenging due to multiple types of genetic tests required to arrive at a diagnosis. Whole-genome sequencing (WGS) has the potential to serve as a single diagnostic platform, due to its superior ability to detect common, rare and structural genetic variation. METHODS WGS analysis was performed in 50 patients with EOD. Point mutations, small insertions/deletions, as well as structural variants (SVs) and short tandem repeats (STRs), were analysed. An Alzheimer's disease (AD)-related polygenic risk score (PRS) was calculated in patients with AD. RESULTS Clinical genetic diagnosis was achieved in 7 of 50 (14%) of the patients, with a further 8 patients (16%) found to have established risk factors which may have contributed to their EOD. Two pathogenic variants were identified through SV analysis. No expanded STRs were found in this study cohort, but a blinded analysis with a positive control identified a C9orf72 expansion accurately. Approximately 37% (7 of 19) of patients with AD had a PRS equivalent to >90th percentile risk. DISCUSSION WGS acts as a single genetic test to identify different types of clinically relevant genetic variations in patients with EOD. WGS, if used as a first-line clinical diagnostic test, has the potential to increase the diagnostic yield and reduce time to diagnosis for EOD.
Collapse
Affiliation(s)
- Aamira J Huq
- Department of Genomic Medicine, Royal Melbourne Hospital City Campus, Parkville, Victoria, Australia
- Department of Clinical Genetics, Austin Health, Heidelberg, Victoria, Australia
- Department of Medicine, University of Melbourne, Parkville, Victoria, Australia
| | - Bryony Thompson
- Department of Genomic Medicine, Royal Melbourne Hospital City Campus, Parkville, Victoria, Australia
- Department of Pathology, Royal Melbourne Hospital, Parkville, Victoria, Australia
| | - Mark F Bennett
- Population Health and Immunity Division, Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia
| | - Adam Bournazos
- Institute for Neuroscience and Muscle Research, Children's Hospital at Westmead, Sydney, New South Wales, Australia
- The University of Sydney, Sydney, New South Wales, Australia
| | - Shobhana Bommireddipalli
- Institute for Neuroscience and Muscle Research, Children's Hospital at Westmead, Sydney, New South Wales, Australia
- The University of Sydney, Sydney, New South Wales, Australia
| | - Alexandra Gorelik
- Department of Medicine, University of Melbourne, Parkville, Victoria, Australia
| | - Joshua Schultz
- Department of Genomic Medicine, Royal Melbourne Hospital City Campus, Parkville, Victoria, Australia
| | - Adrienne Sexton
- Department of Genomic Medicine, Royal Melbourne Hospital City Campus, Parkville, Victoria, Australia
| | - Rebecca Purvis
- Department of Genomic Medicine, Royal Melbourne Hospital City Campus, Parkville, Victoria, Australia
| | - Kirsty West
- Department of Genomic Medicine, Royal Melbourne Hospital City Campus, Parkville, Victoria, Australia
| | - Megan Cotter
- Department of Clinical Genetics, Austin Health, Heidelberg, Victoria, Australia
| | - Giulia Valente
- Department of Clinical Genetics, Austin Health, Heidelberg, Victoria, Australia
| | - Andrew Hughes
- Department of Clinical Genetics, Austin Health, Heidelberg, Victoria, Australia
| | - Moeen Riaz
- Public Health and Preventative Medicine, Monash University Faculty of Medicine, Nursing and Health Sciences, Melbourne, Victoria, Australia
| | - Maie Walsh
- Department of Genomic Medicine, Royal Melbourne Hospital City Campus, Parkville, Victoria, Australia
| | - Sarah Farrand
- Neuropsychiatry Unit, Royal Melbourne Hospital, Melbourne, Victoria, Australia
| | - Samantha M Loi
- Neuropsychiatry Unit, Royal Melbourne Hospital, Melbourne, Victoria, Australia
| | - Trevor Kilpatrick
- Department of Medicine, University of Melbourne, Parkville, Victoria, Australia
| | - Amy Brodtmann
- Department of Medicine, University of Melbourne, Parkville, Victoria, Australia
- Florey Institute of Neuroscience and Mental Health, University of Melbourne, Heidelberg, Victoria, Australia
- Florey Neurosciences Institutes, University of Melbourne, Carlton South, Victoria, Australia
| | - David Darby
- Florey Institute of Neuroscience and Mental Health, University of Melbourne, Heidelberg, Victoria, Australia
- Mental Health Research Institute, University of Melbourne, Parkville, Victoria, Australia
| | - Dhamidhu Eratne
- Neuropsychiatry Unit, Royal Melbourne Hospital, Melbourne, Victoria, Australia
| | - Mark Walterfang
- Neuropsychiatry Unit, Royal Melbourne Hospital, Melbourne, Victoria, Australia
| | | | - Elsdon Storey
- Department of Genomic Medicine, Royal Melbourne Hospital City Campus, Parkville, Victoria, Australia
- Neuroscience, Alfred Health, Melbourne, Victoria, Australia
| | - Michael Fahey
- Royal Melbourne Hospital City Campus, Parkville, Victoria, Australia
| | - Sandra Cooper
- Institute for Neuroscience and Muscle Research, Children's Hospital at Westmead, Sydney, New South Wales, Australia
- The University of Sydney, Sydney, New South Wales, Australia
| | - Paul Lacaze
- Public Health and Preventative Medicine, Monash University Faculty of Medicine, Nursing and Health Sciences, Melbourne, Victoria, Australia
| | - Colin L Masters
- Florey Institute of Neuroscience and Mental Health, University of Melbourne, Melbourne, Victoria, Australia
| | - Dennis Velakoulis
- Neuropsychiatry Unit, Royal Melbourne Hospital, Melbourne, Victoria, Australia
| | - Melanie Bahlo
- Population Health and Immunity Division, Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia
| | - Paul A James
- Department of Genomic Medicine, Royal Melbourne Hospital City Campus, Parkville, Victoria, Australia
| | - Ingrid Winship
- Department of Genomic Medicine, Royal Melbourne Hospital City Campus, Parkville, Victoria, Australia
- Department of Medicine, University of Melbourne, Parkville, Victoria, Australia
| |
Collapse
|
87
|
Piccirella S, Van Neste L, Fowler C, Masters CL, Fripp J, Doecke JD, Xiong C, Uberti D, Kinnon P. A Conformational Variant of p53 (U-p53AZ) as Blood-Based Biomarker for the Prediction of the Onset of Symptomatic Alzheimer's Disease. J Prev Alzheimers Dis 2022; 9:469-479. [PMID: 35841248 DOI: 10.14283/jpad.2022.52] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
BACKGROUND Ongoing research seeks to identify blood-based biomarkers able to predict onset and progression of Alzheimer's disease (AD). OBJECTIVE The unfolded conformational variant of p53 (U-p53AZ), previously observed in AD individuals, was evaluated in plasma samples from individuals participating in the Australian Imaging, Biomarkers and Lifestyle (AIBL) cohort for diagnostic and prognostic assessment, validated on a neuropsychological-based diagnosis, over the course of six years. DESIGN Retrospective Longitudinal Prognostic biomarker study. SETTING Single-center study based on the AIBL cohort. PARTICIPANTS 482 participants of the AIBL cohort, aged 60-85 years, without uncontrolled diabetes, vascular disease, severe depression or psychiatric illnesses. MEASUREMENTS The AlzoSure® Predict test, consisting of immunoprecipitation (IP) followed by liquid chromatography (LC) tandem mass spectrometry (MS/MS), was performed to quantify the AZ 284® peptide as readout of U-p53AZ and compared with an independent neuropsychological diagnosis. The amyloid load via amyloid β-positron emission tomography (Aβ-PET) and supporting clinical information were included where possible. RESULTS U-p53AZ diagnostic and prognostic performance was assessed in both time-independent and time-dependent (36, 72 and 90 months following initial sampling) analyses. Prognostic performance of Aβ-PET and survival analyses with different risk factors (gender, Aβ-PET and APOE ε4 allele status) were also performed. U-p53AZ differentiated neuropsychologically graded AD from non-AD samples, and its detection at intermediate/high levels precisely identified present and future symptomatic AD. In both time-independent and time-dependent prognostic analyses U-p53AZ achieved area under the curve (AUC) >98%, significantly higher than Aβ-PET AUCs (between 84% and 93%, P respectively <0.0001 and <0.001). As single factor, U-p53AZ could clearly determine the risk of AD neuropsychological diagnosis over time (low versus intermediate/high U-p53AZ hazard ratio=2.99). Proportional hazards regression analysis identified U-p53AZ levels as a major independent predictor of AD onset. CONCLUSIONS These findings support use of U-p53AZ as blood-based biomarker predicting whether individuals would reach neuropsychologically-defined AD within six years prior to AD diagnosis. Integration of U-p53AZ in screening processes could support refined participant stratification for interventional studies.
Collapse
|
88
|
Li Y, Huang X, Fowler C, Lim YY, Laws SM, Faux N, Doecke JD, Trounson B, Pertile K, Rumble R, Doré V, Villemagne VL, Rowe CC, Wiley JS, Maruff P, Masters CL, Gu BJ. Identification of Leukocyte Surface P2X7 as a Biomarker Associated with Alzheimer's Disease. Int J Mol Sci 2022; 23:ijms23147867. [PMID: 35887215 PMCID: PMC9322488 DOI: 10.3390/ijms23147867] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/17/2022] [Revised: 07/10/2022] [Accepted: 07/12/2022] [Indexed: 02/04/2023] Open
Abstract
Alzheimer's disease (AD) has shown altered immune responses in the periphery. We studied P2X7 (a proinflammatory receptor and a scavenger receptor) and two integrins, CD11b and CD11c, on the surface of circulating leukocytes and analysed their associations with Aβ-PET, brain atrophy, neuropsychological assessments, and cerebrospinal fluid (CSF) biomarkers. Total 287 age-matched, sex-balanced participants were recruited in a discovery cohort and two validation cohorts through the AIBL study and studied using tri-colour flow cytometry. Our results demonstrated reduced expressions of P2X7, CD11b, and CD11c on leukocytes, particularly monocytes, in Aβ +ve cases compared with Aβ -ve controls. P2X7 and integrin downregulation was observed at pre-clinical stage of AD and stayed low throughout disease course. We further constructed a polygenic risk score (PRS) model based on 12 P2RX7 risk alleles to assess the genetic impact on P2X7 function in AIBL and ADNI cohorts. No significant association was identified between the P2RX7 gene and AD, indicating that P2X7 downregulation in AD is likely caused by environmental changes rather than genetic factors. In conclusion, the downregulation of P2X7 and integrins at pre-clinical stage of AD indicates altered pro-inflammatory responses, phagocytic functions, and migrating capabilities of circulating monocytes in early AD pathogenesis. Our study not only improves our understanding of peripheral immune involvement in early stage of AD but also provides more insights into novel biomarker development, diagnosis, and prognosis of AD.
Collapse
Affiliation(s)
- Yihan Li
- The Florey Institute, The University of Melbourne, 30 Royal Parade, Parkville, VIC 3052, Australia; (Y.L.); (X.H.); (C.F.); (B.T.); (K.P.); (R.R.); (J.S.W.); (P.M.); (C.L.M.)
| | - Xin Huang
- The Florey Institute, The University of Melbourne, 30 Royal Parade, Parkville, VIC 3052, Australia; (Y.L.); (X.H.); (C.F.); (B.T.); (K.P.); (R.R.); (J.S.W.); (P.M.); (C.L.M.)
| | - Christopher Fowler
- The Florey Institute, The University of Melbourne, 30 Royal Parade, Parkville, VIC 3052, Australia; (Y.L.); (X.H.); (C.F.); (B.T.); (K.P.); (R.R.); (J.S.W.); (P.M.); (C.L.M.)
| | - Yen Y. Lim
- School of Psychological Sciences, Turner Institute for Brain and Mental Health, Monash University, Clayton, VIC 3168, Australia; (Y.Y.L.); (V.D.)
| | - Simon M. Laws
- School of Medical and Health Sciences, Edith Cowan University, 270 Joondalup Drive, Joondalup, WA 6027, Australia;
| | - Noel Faux
- Melbourne Data Analytics Platform, Petascale Campus Initiative, The University of Melbourne, 21 Bedford St., North Melbourne, VIC 3051, Australia;
| | - James D. Doecke
- The Australian e-Health Research Centre, CSIRO, Brisbane, QLD 4029, Australia;
| | - Brett Trounson
- The Florey Institute, The University of Melbourne, 30 Royal Parade, Parkville, VIC 3052, Australia; (Y.L.); (X.H.); (C.F.); (B.T.); (K.P.); (R.R.); (J.S.W.); (P.M.); (C.L.M.)
| | - Kelly Pertile
- The Florey Institute, The University of Melbourne, 30 Royal Parade, Parkville, VIC 3052, Australia; (Y.L.); (X.H.); (C.F.); (B.T.); (K.P.); (R.R.); (J.S.W.); (P.M.); (C.L.M.)
| | - Rebecca Rumble
- The Florey Institute, The University of Melbourne, 30 Royal Parade, Parkville, VIC 3052, Australia; (Y.L.); (X.H.); (C.F.); (B.T.); (K.P.); (R.R.); (J.S.W.); (P.M.); (C.L.M.)
| | - Vincent Doré
- School of Psychological Sciences, Turner Institute for Brain and Mental Health, Monash University, Clayton, VIC 3168, Australia; (Y.Y.L.); (V.D.)
- Department of Molecular Imaging & Therapy, Austin Health, Melbourne, VIC 3084, Australia; (V.L.V.); (C.C.R.)
- Department of Medicine, The University of Melbourne, Melbourne, VIC 3084, Australia
| | - Victor L. Villemagne
- Department of Molecular Imaging & Therapy, Austin Health, Melbourne, VIC 3084, Australia; (V.L.V.); (C.C.R.)
- Department of Medicine, The University of Melbourne, Melbourne, VIC 3084, Australia
- Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA 15260, USA
| | - Christopher C. Rowe
- Department of Molecular Imaging & Therapy, Austin Health, Melbourne, VIC 3084, Australia; (V.L.V.); (C.C.R.)
- Department of Medicine, The University of Melbourne, Melbourne, VIC 3084, Australia
| | - James S. Wiley
- The Florey Institute, The University of Melbourne, 30 Royal Parade, Parkville, VIC 3052, Australia; (Y.L.); (X.H.); (C.F.); (B.T.); (K.P.); (R.R.); (J.S.W.); (P.M.); (C.L.M.)
| | - Paul Maruff
- The Florey Institute, The University of Melbourne, 30 Royal Parade, Parkville, VIC 3052, Australia; (Y.L.); (X.H.); (C.F.); (B.T.); (K.P.); (R.R.); (J.S.W.); (P.M.); (C.L.M.)
- CogState Ltd., Melbourne, VIC 3001, Australia
| | - Colin L. Masters
- The Florey Institute, The University of Melbourne, 30 Royal Parade, Parkville, VIC 3052, Australia; (Y.L.); (X.H.); (C.F.); (B.T.); (K.P.); (R.R.); (J.S.W.); (P.M.); (C.L.M.)
| | - Ben J. Gu
- The Florey Institute, The University of Melbourne, 30 Royal Parade, Parkville, VIC 3052, Australia; (Y.L.); (X.H.); (C.F.); (B.T.); (K.P.); (R.R.); (J.S.W.); (P.M.); (C.L.M.)
- National Clinical Research Center for Aging and Medicine, Huashan Hospital, Fudan University, Shanghai 200040, China
- Correspondence: ; Tel.: +61-3-9035-6317
| |
Collapse
|
89
|
Krishnadas N, Huang K, Schultz SA, Doré V, Bourgeat P, Goh AM, Lamb F, Bozinovski S, Burnham SC, Robertson JS, Laws SM, Maruff P, Masters CL, Villemagne VL, Rowe CC. Visually Identified Tau 18F-MK6240 PET Patterns in Symptomatic Alzheimer’s Disease. J Alzheimers Dis 2022; 88:1627-1637. [PMID: 35811517 PMCID: PMC9484111 DOI: 10.3233/jad-215558] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Background: In Alzheimer’s disease, heterogeneity has been observed in the postmortem distribution of tau neurofibrillary tangles. Visualizing the topography of tau in vivo may facilitate clinical trials and clinical practice. Objective: This study aimed to investigate whether tau distribution patterns that are limited to mesial temporal lobe (MTL)/limbic regions, and those that spare MTL regions, can be visually identified using 18F-MK6240, and whether these patterns are associated with different demographic and cognitive profiles. Methods: Tau 18F-MK6240 PET images of 151 amyloid-β positive participants with mild cognitive impairment (MCI) and dementia were visually rated as: tau negative, limbic predominant (LP), MTL-sparing, and Typical by two readers. Groups were evaluated for differences in age, APOE ɛ4 carriage, hippocampal volumes, and cognition (MMSE, composite memory and non-memory scores). Voxel-wise contrasts were also performed. Results: Visual rating resulted in 59.6% classified as Typical, 17.9% as MTL-sparing, 9.9% LP, and 12.6% as tau negative. Intra-rater and inter-rater reliability was strong (Cohen’s kappa values of 0.89 and 0.86 respectively). Tracer retention in a “hook”-like distribution on sagittal sequences was observed in the LP and Typical groups. The visually classified MTL-sparing group had lower APOE ɛ4 carriage and relatively preserved hippocampal volumes. Higher MTL tau was associated with greater amnestic cognitive impairment. High cortical tau was associated with greater impairments on non-memory domains of cognition, and individuals with high cortical tau were more likely to have dementia than MCI. Conclusion: Tau distribution patterns can be visually identified using 18F-MK6240 PET and are associated with differences in APOE ɛ4 carriage, hippocampal volumes, and cognition.
Collapse
Affiliation(s)
- Natasha Krishnadas
- Florey Department of Neurosciences & Mental Health, The University of Melbourne, Parkville, VIC, Australia
- Department of Molecular Imaging & Therapy, Austin Health, Heidelberg, VIC, Australia
| | - Kun Huang
- Department of Molecular Imaging & Therapy, Austin Health, Heidelberg, VIC, Australia
| | - Stephanie A. Schultz
- Department of Molecular Imaging & Therapy, Austin Health, Heidelberg, VIC, Australia
| | - Vincent Doré
- Department of Molecular Imaging & Therapy, Austin Health, Heidelberg, VIC, Australia
- Health and Biosecurity Flagship, The Australian eHealth Research Centre, Melbourne, Victoria, Australia
| | - Pierrick Bourgeat
- Health and Biosecurity Flagship, The Australian eHealth Research Centre, Brisbane, QLD, Australia
| | - Anita M.Y. Goh
- Department of Psychiatry, The University of Melbourne, Parkville, VIC, Australia
- National Ageing Research Institute, Parkville, VIC, Australia
| | - Fiona Lamb
- Department of Molecular Imaging & Therapy, Austin Health, Heidelberg, VIC, Australia
| | - Svetlana Bozinovski
- Department of Molecular Imaging & Therapy, Austin Health, Heidelberg, VIC, Australia
| | - Samantha C. Burnham
- Health and Biosecurity Flagship, The Australian eHealth Research Centre, Melbourne, Victoria, Australia
| | - Joanne S. Robertson
- Florey Institute of Neurosciences & Mental Health, Parkville, VIC, Australia
| | - Simon M. Laws
- Centre for Precision Health, Edith Cowan University, Perth, WA, Australia
- Collaborative Genomics and Translation Group, School of Medical and Health Sciences, Edith Cowan University, Perth, WA, Australia
| | - Paul Maruff
- Florey Institute of Neurosciences & Mental Health, Parkville, VIC, Australia
| | - Colin L. Masters
- Florey Institute of Neurosciences & Mental Health, Parkville, VIC, Australia
| | - Victor L. Villemagne
- Department of Molecular Imaging & Therapy, Austin Health, Heidelberg, VIC, Australia
- Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA, USA
| | - Christopher C. Rowe
- Florey Department of Neurosciences & Mental Health, The University of Melbourne, Parkville, VIC, Australia
- Department of Molecular Imaging & Therapy, Austin Health, Heidelberg, VIC, Australia
- Florey Institute of Neurosciences & Mental Health, Parkville, VIC, Australia
| |
Collapse
|
90
|
Eratne D, Li QX, Loi SM, Walterfang M, Farrand S, Evans A, Mocellin R, Masters CL, Collins S, Velakoulis D. Cerebrospinal fluid Alzheimer disease biomarkers for assessing cognitive and neuropsychiatric symptoms: Expanding the 'toolkit' in the psychiatrist's diagnostic armamentarium. Aust N Z J Psychiatry 2022; 56:865-866. [PMID: 35257595 DOI: 10.1177/00048674221084245] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Affiliation(s)
- Dhamidhu Eratne
- Neuropsychiatry, The Royal Melbourne Hospital, Parkville, VIC, Australia.,Melbourne Neuropsychiatry Centre, The University of Melbourne & NorthWestern Mental Health, Melbourne, VIC, Australia.,Department of Psychiatry, The University of Melbourne, Melbourne, VIC, Australia.,National Dementia Diagnostics Laboratory, Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, VIC, Australia
| | - Qiao-Xin Li
- National Dementia Diagnostics Laboratory, Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, VIC, Australia
| | - Samantha M Loi
- Neuropsychiatry, The Royal Melbourne Hospital, Parkville, VIC, Australia.,Melbourne Neuropsychiatry Centre, The University of Melbourne & NorthWestern Mental Health, Melbourne, VIC, Australia.,Department of Psychiatry, The University of Melbourne, Melbourne, VIC, Australia
| | - Mark Walterfang
- Neuropsychiatry, The Royal Melbourne Hospital, Parkville, VIC, Australia.,Melbourne Neuropsychiatry Centre, The University of Melbourne & NorthWestern Mental Health, Melbourne, VIC, Australia.,Department of Psychiatry, The University of Melbourne, Melbourne, VIC, Australia
| | - Sarah Farrand
- Neuropsychiatry, The Royal Melbourne Hospital, Parkville, VIC, Australia.,Melbourne Neuropsychiatry Centre, The University of Melbourne & NorthWestern Mental Health, Melbourne, VIC, Australia
| | - Andrew Evans
- Neuropsychiatry, The Royal Melbourne Hospital, Parkville, VIC, Australia
| | | | - Colin L Masters
- National Dementia Diagnostics Laboratory, Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, VIC, Australia
| | - Steven Collins
- National Dementia Diagnostics Laboratory, Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, VIC, Australia.,Department of Medicine, The Royal Melbourne Hospital, The University of Melbourne, Melbourne, VIC, Australia
| | - Dennis Velakoulis
- Neuropsychiatry, The Royal Melbourne Hospital, Parkville, VIC, Australia.,Melbourne Neuropsychiatry Centre, The University of Melbourne & NorthWestern Mental Health, Melbourne, VIC, Australia.,Department of Psychiatry, The University of Melbourne, Melbourne, VIC, Australia
| |
Collapse
|
91
|
Jiang Y, Zhou X, Wong HY, Ouyang L, Ip FCF, Chau VMN, Lau SF, Wu W, Wong DYK, Seo H, Fu WY, Lai NCH, Chen Y, Chen Y, Tong EPS, Mok VCT, Kwok TCY, Mok KY, Shoai M, Lehallier B, Losada PM, O'Brien E, Porter T, Laws SM, Hardy J, Wyss-Coray T, Masters CL, Fu AKY, Ip NY. An IL1RL1 genetic variant lowers soluble ST2 levels and the risk effects of APOE-ε4 in female patients with Alzheimer's disease. Nat Aging 2022; 2:616-634. [PMID: 37117777 PMCID: PMC10154240 DOI: 10.1038/s43587-022-00241-9] [Citation(s) in RCA: 10] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/16/2021] [Accepted: 05/23/2022] [Indexed: 04/30/2023]
Abstract
Changes in the levels of circulating proteins are associated with Alzheimer's disease (AD), whereas their pathogenic roles in AD are unclear. Here, we identified soluble ST2 (sST2), a decoy receptor of interleukin-33-ST2 signaling, as a new disease-causing factor in AD. Increased circulating sST2 level is associated with more severe pathological changes in female individuals with AD. Genome-wide association analysis and CRISPR-Cas9 genome editing identified rs1921622 , a genetic variant in an enhancer element of IL1RL1, which downregulates gene and protein levels of sST2. Mendelian randomization analysis using genetic variants, including rs1921622 , demonstrated that decreased sST2 levels lower AD risk and related endophenotypes in females carrying the Apolipoprotein E (APOE)-ε4 genotype; the association is stronger in Chinese than in European-descent populations. Human and mouse transcriptome and immunohistochemical studies showed that rs1921622 /sST2 regulates amyloid-beta (Aβ) pathology through the modulation of microglial activation and Aβ clearance. These findings demonstrate how sST2 level is modulated by a genetic variation and plays a disease-causing role in females with AD.
Collapse
Affiliation(s)
- Yuanbing Jiang
- Division of Life Science, State Key Laboratory of Molecular Neuroscience, Molecular Neuroscience Center, The Hong Kong University of Science and Technology, Clear Water Bay, Hong Kong, China
- Hong Kong Center for Neurodegenerative Diseases, Hong Kong Science Park, Hong Kong, China
| | - Xiaopu Zhou
- Division of Life Science, State Key Laboratory of Molecular Neuroscience, Molecular Neuroscience Center, The Hong Kong University of Science and Technology, Clear Water Bay, Hong Kong, China
- Hong Kong Center for Neurodegenerative Diseases, Hong Kong Science Park, Hong Kong, China
- Guangdong Provincial Key Laboratory of Brain Science, Disease and Drug Development; Shenzhen-Hong Kong Institute of Brain Science, HKUST Shenzhen Research Institute, Shenzhen, China
| | - Hiu Yi Wong
- Division of Life Science, State Key Laboratory of Molecular Neuroscience, Molecular Neuroscience Center, The Hong Kong University of Science and Technology, Clear Water Bay, Hong Kong, China
- Hong Kong Center for Neurodegenerative Diseases, Hong Kong Science Park, Hong Kong, China
| | - Li Ouyang
- Division of Life Science, State Key Laboratory of Molecular Neuroscience, Molecular Neuroscience Center, The Hong Kong University of Science and Technology, Clear Water Bay, Hong Kong, China
- Hong Kong Center for Neurodegenerative Diseases, Hong Kong Science Park, Hong Kong, China
| | - Fanny C F Ip
- Division of Life Science, State Key Laboratory of Molecular Neuroscience, Molecular Neuroscience Center, The Hong Kong University of Science and Technology, Clear Water Bay, Hong Kong, China
- Hong Kong Center for Neurodegenerative Diseases, Hong Kong Science Park, Hong Kong, China
- Guangdong Provincial Key Laboratory of Brain Science, Disease and Drug Development; Shenzhen-Hong Kong Institute of Brain Science, HKUST Shenzhen Research Institute, Shenzhen, China
| | - Vicky M N Chau
- Division of Life Science, State Key Laboratory of Molecular Neuroscience, Molecular Neuroscience Center, The Hong Kong University of Science and Technology, Clear Water Bay, Hong Kong, China
- Hong Kong Center for Neurodegenerative Diseases, Hong Kong Science Park, Hong Kong, China
| | - Shun-Fat Lau
- Division of Life Science, State Key Laboratory of Molecular Neuroscience, Molecular Neuroscience Center, The Hong Kong University of Science and Technology, Clear Water Bay, Hong Kong, China
- Hong Kong Center for Neurodegenerative Diseases, Hong Kong Science Park, Hong Kong, China
| | - Wei Wu
- Division of Life Science, State Key Laboratory of Molecular Neuroscience, Molecular Neuroscience Center, The Hong Kong University of Science and Technology, Clear Water Bay, Hong Kong, China
- Hong Kong Center for Neurodegenerative Diseases, Hong Kong Science Park, Hong Kong, China
| | - Daniel Y K Wong
- Division of Life Science, State Key Laboratory of Molecular Neuroscience, Molecular Neuroscience Center, The Hong Kong University of Science and Technology, Clear Water Bay, Hong Kong, China
- Hong Kong Center for Neurodegenerative Diseases, Hong Kong Science Park, Hong Kong, China
| | - Heukjin Seo
- Division of Life Science, State Key Laboratory of Molecular Neuroscience, Molecular Neuroscience Center, The Hong Kong University of Science and Technology, Clear Water Bay, Hong Kong, China
| | - Wing-Yu Fu
- Division of Life Science, State Key Laboratory of Molecular Neuroscience, Molecular Neuroscience Center, The Hong Kong University of Science and Technology, Clear Water Bay, Hong Kong, China
- Hong Kong Center for Neurodegenerative Diseases, Hong Kong Science Park, Hong Kong, China
| | - Nicole C H Lai
- Division of Life Science, State Key Laboratory of Molecular Neuroscience, Molecular Neuroscience Center, The Hong Kong University of Science and Technology, Clear Water Bay, Hong Kong, China
- Hong Kong Center for Neurodegenerative Diseases, Hong Kong Science Park, Hong Kong, China
| | - Yuewen Chen
- Division of Life Science, State Key Laboratory of Molecular Neuroscience, Molecular Neuroscience Center, The Hong Kong University of Science and Technology, Clear Water Bay, Hong Kong, China
- Guangdong Provincial Key Laboratory of Brain Science, Disease and Drug Development; Shenzhen-Hong Kong Institute of Brain Science, HKUST Shenzhen Research Institute, Shenzhen, China
- The Brain Cognition and Brain Disease Institute, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences; Shenzhen-Hong Kong Institute of Brain Science-Shenzhen Fundamental Research Institutions, Shenzhen, China
| | - Yu Chen
- Division of Life Science, State Key Laboratory of Molecular Neuroscience, Molecular Neuroscience Center, The Hong Kong University of Science and Technology, Clear Water Bay, Hong Kong, China
- Guangdong Provincial Key Laboratory of Brain Science, Disease and Drug Development; Shenzhen-Hong Kong Institute of Brain Science, HKUST Shenzhen Research Institute, Shenzhen, China
- The Brain Cognition and Brain Disease Institute, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences; Shenzhen-Hong Kong Institute of Brain Science-Shenzhen Fundamental Research Institutions, Shenzhen, China
| | - Estella P S Tong
- Division of Life Science, State Key Laboratory of Molecular Neuroscience, Molecular Neuroscience Center, The Hong Kong University of Science and Technology, Clear Water Bay, Hong Kong, China
- Hong Kong Center for Neurodegenerative Diseases, Hong Kong Science Park, Hong Kong, China
| | - Vincent C T Mok
- Gerald Choa Neuroscience Centre, Lui Che Woo Institute of Innovative Medicine, Therese Pei Fong Chow Research Centre for Prevention of Dementia, Division of Neurology, Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, China
| | - Timothy C Y Kwok
- Therese Pei Fong Chow Research Centre for Prevention of Dementia, Division of Geriatrics, Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, China
| | - Kin Y Mok
- Division of Life Science, State Key Laboratory of Molecular Neuroscience, Molecular Neuroscience Center, The Hong Kong University of Science and Technology, Clear Water Bay, Hong Kong, China
- Hong Kong Center for Neurodegenerative Diseases, Hong Kong Science Park, Hong Kong, China
- Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK
- UK Dementia Research Institute, University College London, London, UK
| | - Maryam Shoai
- Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK
- UK Dementia Research Institute, University College London, London, UK
| | - Benoit Lehallier
- Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California, USA
- Alkahest Inc, San Carlos, California, USA
| | - Patricia Morán Losada
- Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California, USA
- Wu Tsai Neurosciences Institute, Stanford University, Stanford, California, USA
| | - Eleanor O'Brien
- Centre for Precision Health, Edith Cowan University, Joondalup, Australia
- Collaborative Genomics and Translation Group, School of Medical and Health Sciences, Edith Cowan University, Joondalup, Australia
| | - Tenielle Porter
- Centre for Precision Health, Edith Cowan University, Joondalup, Australia
- Collaborative Genomics and Translation Group, School of Medical and Health Sciences, Edith Cowan University, Joondalup, Australia
- School of Pharmacy and Biomedical Sciences, Faculty of Health Sciences, Curtin Health Innovation Research Institute, Curtin University, Bentley, Australia
| | - Simon M Laws
- Centre for Precision Health, Edith Cowan University, Joondalup, Australia
- Collaborative Genomics and Translation Group, School of Medical and Health Sciences, Edith Cowan University, Joondalup, Australia
- School of Pharmacy and Biomedical Sciences, Faculty of Health Sciences, Curtin Health Innovation Research Institute, Curtin University, Bentley, Australia
| | - John Hardy
- Hong Kong Center for Neurodegenerative Diseases, Hong Kong Science Park, Hong Kong, China
- Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK
- UK Dementia Research Institute, University College London, London, UK
- Institute for Advanced Study, The Hong Kong University of Science and Technology, Clear Water Bay, Hong Kong, China
| | - Tony Wyss-Coray
- Hong Kong Center for Neurodegenerative Diseases, Hong Kong Science Park, Hong Kong, China
- Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California, USA
- Wu Tsai Neurosciences Institute, Stanford University, Stanford, California, USA
- The Phil and Penny Knight Initiative for Brain Resilience, Stanford University, Stanford, California, USA
| | - Colin L Masters
- The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Melbourne, Australia
| | - Amy K Y Fu
- Division of Life Science, State Key Laboratory of Molecular Neuroscience, Molecular Neuroscience Center, The Hong Kong University of Science and Technology, Clear Water Bay, Hong Kong, China
- Hong Kong Center for Neurodegenerative Diseases, Hong Kong Science Park, Hong Kong, China
- Guangdong Provincial Key Laboratory of Brain Science, Disease and Drug Development; Shenzhen-Hong Kong Institute of Brain Science, HKUST Shenzhen Research Institute, Shenzhen, China
| | - Nancy Y Ip
- Division of Life Science, State Key Laboratory of Molecular Neuroscience, Molecular Neuroscience Center, The Hong Kong University of Science and Technology, Clear Water Bay, Hong Kong, China.
- Hong Kong Center for Neurodegenerative Diseases, Hong Kong Science Park, Hong Kong, China.
- Guangdong Provincial Key Laboratory of Brain Science, Disease and Drug Development; Shenzhen-Hong Kong Institute of Brain Science, HKUST Shenzhen Research Institute, Shenzhen, China.
| |
Collapse
|
92
|
Kellie JF, Campbell BCV, Watson R, Praeger AJ, Nair G, Murugasu A, Rowe CC, Masters CL, Collins S, McLean C, Yassi N. Amyloid-β (Aβ)-Related Cerebral Amyloid Angiopathy Causing Lobar Hemorrhage Decades After Childhood Neurosurgery. Stroke 2022; 53:e369-e374. [PMID: 35770667 DOI: 10.1161/strokeaha.121.038364] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
BACKGROUND Recent reports raise the possibility of cerebral amyloid angiopathy (CAA) leading to intracerebral hemorrhage in young adults following childhood neurosurgery, suggesting transmission of amyloid-β (Aβ) through neurosurgical procedures including dura mater grafting. Parenchymal Aβ deposition, and to a lesser extent tau aggregation, similar to that seen in Alzheimer disease, have also been described. METHODS We conducted a database review of 634 consecutive intracerebral hemorrhage patients aged <65 years at a tertiary stroke center over 20 years to identify such patients. RESULTS We identified 3 patients aged in their thirties who presented with spontaneous lobar intracerebral hemorrhage, with imaging or neuropathology consistent with CAA, and a history of childhood neurosurgery. Two of these patients had undergone a dural repair using cadaveric dura mater (Lyodura). In addition to CAA, both patients had neuropathologically confirmed parenchymal Aβ and tau deposits, characteristic of Alzheimer disease. CONCLUSIONS Our findings support the concept of neurosurgical Aβ transmission but suggest that such cases are rare in standard clinical practice.
Collapse
Affiliation(s)
- Jeremy F Kellie
- Departments of Medicine and Neurology, Melbourne Brain Centre at The Royal Melbourne Hospital, University of Melbourne, Australia (J.F.K., B.C.V.C., N.Y.)
| | - Bruce C V Campbell
- Departments of Medicine and Neurology, Melbourne Brain Centre at The Royal Melbourne Hospital, University of Melbourne, Australia (J.F.K., B.C.V.C., N.Y.)
| | - Rosie Watson
- Department of Medicine, The Royal Melbourne Hospital, University of Melbourne, Australia (R.W., S.C.).,Population Health and Immunity Division, The Walter and Eliza Hall Institute of Medical Research, Australia (R.W., N.Y.)
| | - Adrian J Praeger
- Department of Neurosurgery, The Royal Melbourne Hospital, Australia. (A.J.P., G.N.)
| | - Girish Nair
- Department of Neurosurgery, The Royal Melbourne Hospital, Australia. (A.J.P., G.N.)
| | - Anand Murugasu
- Department of Pathology, The Royal Melbourne Hospital, Australia. (A.M.)
| | - Christopher C Rowe
- Department of Molecular Imaging and Therapy, Austin Health, Australia (C.C.R.)
| | - Colin L Masters
- The Florey Institute of Neuroscience and Mental Health, Australia (C.L.M., S.C.)
| | - Steven Collins
- Department of Medicine, The Royal Melbourne Hospital, University of Melbourne, Australia (R.W., S.C.).,The Florey Institute of Neuroscience and Mental Health, Australia (C.L.M., S.C.)
| | - Catriona McLean
- Department of Anatomical Pathology, The Alfred Hospital, Australia (C.M.)
| | - Nawaf Yassi
- Departments of Medicine and Neurology, Melbourne Brain Centre at The Royal Melbourne Hospital, University of Melbourne, Australia (J.F.K., B.C.V.C., N.Y.).,Population Health and Immunity Division, The Walter and Eliza Hall Institute of Medical Research, Australia (R.W., N.Y.)
| |
Collapse
|
93
|
Aschenbrenner AJ, Hassenstab J, Wang G, Li Y, Xiong C, McDade E, Clifford DB, Salloway S, Farlow M, Yaari R, Cheng EYJ, Holdridge KC, Mummery CJ, Masters CL, Hsiung GY, Surti G, Day GS, Weintraub S, Honig LS, Galvin JE, Ringman JM, Brooks WS, Fox NC, Snyder PJ, Suzuki K, Shimada H, Gräber S, Bateman RJ. Avoid or Embrace? Practice Effects in Alzheimer's Disease Prevention Trials. Front Aging Neurosci 2022; 14:883131. [PMID: 35783127 PMCID: PMC9244171 DOI: 10.3389/fnagi.2022.883131] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/24/2022] [Accepted: 05/19/2022] [Indexed: 12/02/2022] Open
Abstract
Demonstrating a slowing in the rate of cognitive decline is a common outcome measure in clinical trials in Alzheimer's disease (AD). Selection of cognitive endpoints typically includes modeling candidate outcome measures in the many, richly phenotyped observational cohort studies available. An important part of choosing cognitive endpoints is a consideration of improvements in performance due to repeated cognitive testing (termed "practice effects"). As primary and secondary AD prevention trials are comprised predominantly of cognitively unimpaired participants, practice effects may be substantial and may have considerable impact on detecting cognitive change. The extent to which practice effects in AD prevention trials are similar to those from observational studies and how these potential differences impact trials is unknown. In the current study, we analyzed data from the recently completed DIAN-TU-001 clinical trial (TU) and the associated DIAN-Observational (OBS) study. Results indicated that asymptomatic mutation carriers in the TU exhibited persistent practice effects on several key outcomes spanning the entire trial duration. Critically, these practice related improvements were larger on certain tests in the TU relative to matched participants from the OBS study. Our results suggest that the magnitude of practice effects may not be captured by modeling potential endpoints in observational studies where assessments are typically less frequent and drug expectancy effects are absent. Using alternate instrument forms (represented in our study by computerized tasks) may partly mitigate practice effects in clinical trials but incorporating practice effects as outcomes may also be viable. Thus, investigators must carefully consider practice effects (either by minimizing them or modeling them directly) when designing cognitive endpoint AD prevention trials by utilizing trial data with similar assessment frequencies.
Collapse
Affiliation(s)
| | - Jason Hassenstab
- Washington University in St. Louis School of Medicine, St. Louis, MO, United States
| | - Guoqiao Wang
- Washington University in St. Louis School of Medicine, St. Louis, MO, United States
| | - Yan Li
- Washington University in St. Louis School of Medicine, St. Louis, MO, United States
| | - Chengjie Xiong
- Washington University in St. Louis School of Medicine, St. Louis, MO, United States
| | - Eric McDade
- Washington University in St. Louis School of Medicine, St. Louis, MO, United States
| | - David B. Clifford
- Washington University in St. Louis School of Medicine, St. Louis, MO, United States
| | - Stephen Salloway
- Warren Alpert Medical School of Brown University, Providence, RI, United States
| | - Martin Farlow
- Indiana University School of Medicine, Indianapolis, IN, United States
| | - Roy Yaari
- Eli Lilly and Company, Indianapolis, IN, United States
| | | | | | | | | | | | - Ghulam Surti
- The University of Rhode Island, Kingston, RI, United States
| | | | - Sandra Weintraub
- Feiniberg School of Medicine, Northwestern University, Chicago, IL, United States
| | - Lawrence S. Honig
- Columbia University Irving Medical Center, New York, NY, United States
| | - James E. Galvin
- Miller School of Medicine, University of Miami, Miami, FL, United States
| | - John M. Ringman
- University of Southern California, Los Angeles, CA, United States
| | - William S. Brooks
- Neuroscience Research Australia, University of New South Wales Medicine, Randwick, NSW, Australia
| | - Nick C. Fox
- Dementia Research Center, University College London, London, United Kingdom
| | | | | | | | - Susanne Gräber
- German Center for Neurodegenerative Disease (DZNE), Tübingen, Germany
| | - Randall J. Bateman
- Washington University in St. Louis School of Medicine, St. Louis, MO, United States
| |
Collapse
|
94
|
Cadby G, Giles C, Melton PE, Huynh K, Mellett NA, Duong T, Nguyen A, Cinel M, Smith A, Olshansky G, Wang T, Brozynska M, Inouye M, McCarthy NS, Ariff A, Hung J, Hui J, Beilby J, Dubé MP, Watts GF, Shah S, Wray NR, Lim WLF, Chatterjee P, Martins I, Laws SM, Porter T, Vacher M, Bush AI, Rowe CC, Villemagne VL, Ames D, Masters CL, Taddei K, Arnold M, Kastenmüller G, Nho K, Saykin AJ, Han X, Kaddurah-Daouk R, Martins RN, Blangero J, Meikle PJ, Moses EK. Comprehensive genetic analysis of the human lipidome identifies loci associated with lipid homeostasis with links to coronary artery disease. Nat Commun 2022; 13:3124. [PMID: 35668104 PMCID: PMC9170690 DOI: 10.1038/s41467-022-30875-7] [Citation(s) in RCA: 26] [Impact Index Per Article: 13.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2021] [Accepted: 05/17/2022] [Indexed: 12/26/2022] Open
Abstract
We integrated lipidomics and genomics to unravel the genetic architecture of lipid metabolism and identify genetic variants associated with lipid species putatively in the mechanistic pathway for coronary artery disease (CAD). We quantified 596 lipid species in serum from 4,492 individuals from the Busselton Health Study. The discovery GWAS identified 3,361 independent lipid-loci associations, involving 667 genomic regions (479 previously unreported), with validation in two independent cohorts. A meta-analysis revealed an additional 70 independent genomic regions associated with lipid species. We identified 134 lipid endophenotypes for CAD associated with 186 genomic loci. Associations between independent lipid-loci with coronary atherosclerosis were assessed in ∼456,000 individuals from the UK Biobank. Of the 53 lipid-loci that showed evidence of association (P < 1 × 10-3), 43 loci were associated with at least one lipid endophenotype. These findings illustrate the value of integrative biology to investigate the aetiology of atherosclerosis and CAD, with implications for other complex diseases.
Collapse
Affiliation(s)
- Gemma Cadby
- School of Population and Global Health, University of Western Australia, Crawley, WA, Australia
| | - Corey Giles
- Baker Heart and Diabetes Institute, Melbourne, VIC, Australia
- Baker Department of Cardiometabolic Health, University of Melbourne, Melbourne, VIC, Australia
| | - Phillip E Melton
- School of Population and Global Health, University of Western Australia, Crawley, WA, Australia
- Menzies Research Institute, University of Tasmania, Hobart, TAS, Australia
| | - Kevin Huynh
- Baker Heart and Diabetes Institute, Melbourne, VIC, Australia
- Baker Department of Cardiometabolic Health, University of Melbourne, Melbourne, VIC, Australia
| | | | - Thy Duong
- Baker Heart and Diabetes Institute, Melbourne, VIC, Australia
| | - Anh Nguyen
- Baker Heart and Diabetes Institute, Melbourne, VIC, Australia
| | - Michelle Cinel
- Baker Heart and Diabetes Institute, Melbourne, VIC, Australia
| | - Alex Smith
- Baker Heart and Diabetes Institute, Melbourne, VIC, Australia
| | - Gavriel Olshansky
- Baker Heart and Diabetes Institute, Melbourne, VIC, Australia
- Baker Department of Cardiometabolic Health, University of Melbourne, Melbourne, VIC, Australia
| | - Tingting Wang
- Baker Heart and Diabetes Institute, Melbourne, VIC, Australia
- Baker Department of Cardiometabolic Health, University of Melbourne, Melbourne, VIC, Australia
| | - Marta Brozynska
- Baker Heart and Diabetes Institute, Melbourne, VIC, Australia
| | - Mike Inouye
- Baker Heart and Diabetes Institute, Melbourne, VIC, Australia
| | - Nina S McCarthy
- School of Biomedical Sciences, University of Western Australia, Crawley, WA, Australia
| | - Amir Ariff
- School of Women's and Children's Health, University of New South Wales, Sydney, NSW, Australia
| | - Joseph Hung
- School of Medicine, The University of Western Australia, Crawley, WA, Australia
- Department of Cardiovascular Medicine, Sir Charles Gairdner Hospital, Perth, WA, Australia
- Busselton Population Medical Research Institute Inc., Perth, WA, Australia
| | - Jennie Hui
- Busselton Population Medical Research Institute Inc., Perth, WA, Australia
- PathWest Laboratory Medicine WA, Perth, WA, Australia
| | - John Beilby
- Busselton Population Medical Research Institute Inc., Perth, WA, Australia
- PathWest Laboratory Medicine WA, Perth, WA, Australia
| | - Marie-Pierre Dubé
- Université de Montréal Beaulieu-Saucier Pharmacogenomics Centre, Montreal Heart Institute, Montreal, QC, Canada
| | - Gerald F Watts
- School of Medicine, The University of Western Australia, Crawley, WA, Australia
- Lipid Disorders Clinic, Department of Cardiology, Royal Perth Hospital, Perth, WA, Australia
| | - Sonia Shah
- Institute for Molecular Biosciences, University of Queensland, Brisbane, QLD, Australia
| | - Naomi R Wray
- Institute for Molecular Biosciences, University of Queensland, Brisbane, QLD, Australia
- Queensland Brain Institute, University of Queensland, Brisbane, QLD, Australia
| | - Wei Ling Florence Lim
- School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia
- Cooperative research Centre (CRC) for Mental Health, Joondalup, WA, Australia
| | - Pratishtha Chatterjee
- School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia
- Department of Biomedical Sciences, Macquarie University, North Ryde, NSW, Australia
- KaRa Institute of Neurological Disease, Sydney, Macquarie Park, NSW, Australia
| | - Ian Martins
- School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia
| | - Simon M Laws
- Centre for Precision Health, Edith Cowan University, Joondalup, WA, Australia
- Collaborative Genomics Group, School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia
- Curtin Health Innovation Research Institute, Curtin University, Perth, WA, Australia
| | - Tenielle Porter
- Centre for Precision Health, Edith Cowan University, Joondalup, WA, Australia
- Collaborative Genomics Group, School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia
- Curtin Health Innovation Research Institute, Curtin University, Perth, WA, Australia
| | - Michael Vacher
- Centre for Precision Health, Edith Cowan University, Joondalup, WA, Australia
- Collaborative Genomics Group, School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia
- The Australian e-Health Research Centre, Health and Biosecurity, CSIRO, Floreat, WA, Australia
| | - Ashley I Bush
- The Florey Department of Neuroscience and Mental Health, The University of Melbourne, Melbourne, VIC, Australia
| | - Christopher C Rowe
- The Florey Department of Neuroscience and Mental Health, The University of Melbourne, Melbourne, VIC, Australia
- Department of Molecular Imaging and Therapy, Austin Health, Heidelberg, VIC, Australia
| | - Victor L Villemagne
- Department of Molecular Imaging and Therapy, Austin Health, Heidelberg, VIC, Australia
- Department of Medicine, Austin Health, The University of Melbourne, Heidelberg, VIC, Australia
| | - David Ames
- National Ageing Research Institute, Parkville, VIC, Australia
- University of Melbourne Academic Unit for Psychiatry of Old Age, St George's Hospital, Kew, VIC, Australia
| | - Colin L Masters
- The Florey Department of Neuroscience and Mental Health, The University of Melbourne, Melbourne, VIC, Australia
| | - Kevin Taddei
- School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia
| | - Matthias Arnold
- Department of Psychiatry and Behavioral Sciences, Duke University, Durham, NC, USA
- Institute of Computational Biology, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany
| | - Gabi Kastenmüller
- Institute of Computational Biology, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany
| | - Kwangsik Nho
- Department of Radiology and Imaging Sciences, Indiana University School of Medicine, Indianapolis, IN, USA
- Center for Computational Biology and Bioinformatics, Indiana University School of Medicine, Indianapolis, IN, USA
- Indiana Alzheimer's Disease Research Center, Indiana University School of Medicine, Indianapolis, IN, USA
| | - Andrew J Saykin
- Department of Radiology and Imaging Sciences, Indiana University School of Medicine, Indianapolis, IN, USA
- Indiana Alzheimer's Disease Research Center, Indiana University School of Medicine, Indianapolis, IN, USA
- Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN, USA
| | - Xianlin Han
- Barshop Institute for Longevity and Aging Studies, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA
| | - Rima Kaddurah-Daouk
- Department of Psychiatry and Behavioral Sciences, Duke University, Durham, NC, USA
- Duke Institute of Brain Sciences, Duke University, Durham, NC, USA
- Department of Medicine, Duke University, Durham, NC, USA
| | - Ralph N Martins
- School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia
- Cooperative research Centre (CRC) for Mental Health, Joondalup, WA, Australia
- Department of Biomedical Sciences, Macquarie University, North Ryde, NSW, Australia
- KaRa Institute of Neurological Disease, Sydney, Macquarie Park, NSW, Australia
| | - John Blangero
- South Texas Diabetes and Obesity Institute, The University of Texas Rio Grande Valley, Brownsville, TX, USA
| | - Peter J Meikle
- Baker Heart and Diabetes Institute, Melbourne, VIC, Australia.
- Baker Department of Cardiometabolic Health, University of Melbourne, Melbourne, VIC, Australia.
- Monash University, Melbourne, VIC, Australia.
| | - Eric K Moses
- Menzies Research Institute, University of Tasmania, Hobart, TAS, Australia.
- School of Biomedical Sciences, University of Western Australia, Crawley, WA, Australia.
| |
Collapse
|
95
|
Milicic L, Vacher M, Porter T, Doré V, Burnham SC, Bourgeat P, Shishegar R, Doecke J, Armstrong NJ, Tankard R, Maruff P, Masters CL, Rowe CC, Villemagne VL, Laws SM. Comprehensive analysis of epigenetic clocks reveals associations between disproportionate biological ageing and hippocampal volume. GeroScience 2022; 44:1807-1823. [PMID: 35445885 PMCID: PMC9213584 DOI: 10.1007/s11357-022-00558-8] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2022] [Accepted: 03/30/2022] [Indexed: 12/21/2022] Open
Abstract
The concept of age acceleration, the difference between biological age and chronological age, is of growing interest, particularly with respect to age-related disorders, such as Alzheimer's Disease (AD). Whilst studies have reported associations with AD risk and related phenotypes, there remains a lack of consensus on these associations. Here we aimed to comprehensively investigate the relationship between five recognised measures of age acceleration, based on DNA methylation patterns (DNAm age), and cross-sectional and longitudinal cognition and AD-related neuroimaging phenotypes (volumetric MRI and Amyloid-β PET) in the Australian Imaging, Biomarkers and Lifestyle (AIBL) and the Alzheimer's Disease Neuroimaging Initiative (ADNI). Significant associations were observed between age acceleration using the Hannum epigenetic clock and cross-sectional hippocampal volume in AIBL and replicated in ADNI. In AIBL, several other findings were observed cross-sectionally, including a significant association between hippocampal volume and the Hannum and Phenoage epigenetic clocks. Further, significant associations were also observed between hippocampal volume and the Zhang and Phenoage epigenetic clocks within Amyloid-β positive individuals. However, these were not validated within the ADNI cohort. No associations between age acceleration and other Alzheimer's disease-related phenotypes, including measures of cognition or brain Amyloid-β burden, were observed, and there was no association with longitudinal change in any phenotype. This study presents a link between age acceleration, as determined using DNA methylation, and hippocampal volume that was statistically significant across two highly characterised cohorts. The results presented in this study contribute to a growing literature that supports the role of epigenetic modifications in ageing and AD-related phenotypes.
Collapse
Affiliation(s)
- Lidija Milicic
- Centre for Precision Health, Edith Cowan University, 270 Joondalup Drive, Joondalup, Western Australia, 6027, Australia
- Collaborative Genomics and Translation Group, School of Medical and Health Sciences, Edith Cowan University, Joondalup, Western Australia, 6027, Australia
| | - Michael Vacher
- Centre for Precision Health, Edith Cowan University, 270 Joondalup Drive, Joondalup, Western Australia, 6027, Australia
- Collaborative Genomics and Translation Group, School of Medical and Health Sciences, Edith Cowan University, Joondalup, Western Australia, 6027, Australia
- CSIRO Health and Biosecurity, Australian E-Health Research Centre, Floreat, Western Australia, 6014, Australia
| | - Tenielle Porter
- Centre for Precision Health, Edith Cowan University, 270 Joondalup Drive, Joondalup, Western Australia, 6027, Australia
- Collaborative Genomics and Translation Group, School of Medical and Health Sciences, Edith Cowan University, Joondalup, Western Australia, 6027, Australia
- School of Pharmacy and Biomedical Sciences, Faculty of Health Sciences, Curtin Health Innovation Research Institute, Curtin University, Bentley, Western Australia, 6102, Australia
| | - Vincent Doré
- Australian E-Health Research Centre, CSIRO, Parkville, Victoria, 3052, Australia
- Department of Molecular Imaging and Therapy and Centre for PET, Austin Health, Heidelberg, Victoria, Australia
| | - Samantha C Burnham
- Centre for Precision Health, Edith Cowan University, 270 Joondalup Drive, Joondalup, Western Australia, 6027, Australia
- Australian E-Health Research Centre, CSIRO, Parkville, Victoria, 3052, Australia
| | - Pierrick Bourgeat
- Australian E-Health Research Centre, CSIRO, Herston, Queensland, 4029, Australia
| | - Rosita Shishegar
- Australian E-Health Research Centre, CSIRO, Parkville, Victoria, 3052, Australia
- School of Psychological Sciences and Turner Institute for Brain and Mental Health, Monash University, Melbourne, VIC, Australia
| | - James Doecke
- Centre for Precision Health, Edith Cowan University, 270 Joondalup Drive, Joondalup, Western Australia, 6027, Australia
- Australian E-Health Research Centre, CSIRO, Herston, Queensland, 4029, Australia
| | - Nicola J Armstrong
- Department of Mathematics and Statistics, Curtin University, Bentley, Western Australia, Australia
| | - Rick Tankard
- School of Mathematics and Statistics, Murdoch University, Perth, Western Australia, Australia
| | - Paul Maruff
- Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, VIC, 3052, Australia
- Cogstate Ltd, Melbourne, VIC, Australia
| | - Colin L Masters
- Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, VIC, 3052, Australia
| | - Christopher C Rowe
- Department of Molecular Imaging and Therapy and Centre for PET, Austin Health, Heidelberg, Victoria, Australia
- Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, VIC, 3052, Australia
| | - Victor L Villemagne
- Centre for Precision Health, Edith Cowan University, 270 Joondalup Drive, Joondalup, Western Australia, 6027, Australia
- Department of Molecular Imaging and Therapy and Centre for PET, Austin Health, Heidelberg, Victoria, Australia
- Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA, USA
| | - Simon M Laws
- Centre for Precision Health, Edith Cowan University, 270 Joondalup Drive, Joondalup, Western Australia, 6027, Australia.
- Collaborative Genomics and Translation Group, School of Medical and Health Sciences, Edith Cowan University, Joondalup, Western Australia, 6027, Australia.
- School of Pharmacy and Biomedical Sciences, Faculty of Health Sciences, Curtin Health Innovation Research Institute, Curtin University, Bentley, Western Australia, 6102, Australia.
| |
Collapse
|
96
|
Cespedes M, Jacobs KR, Maruff P, Rembach A, Fowler CJ, Trounson B, Pertile KK, Rumble RL, Rainey-Smithe SR, Rowe CC, Villemagne VL, Bourgeat P, Lim CK, Chatterjee P, Martins RN, Ittner A, Masters CL, Doecke JD, Guillemin GJ, Lovejoy DB. Systemic perturbations of the kynurenine pathway precede progression to dementia independently of amyloid-β. Neurobiol Dis 2022; 171:105783. [DOI: 10.1016/j.nbd.2022.105783] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/24/2021] [Revised: 05/30/2022] [Accepted: 06/01/2022] [Indexed: 11/16/2022] Open
|
97
|
Vacher M, Doré V, Porter T, Milicic L, Villemagne VL, Bourgeat P, Burnham SC, Cox T, Masters CL, Rowe CC, Fripp J, Doecke JD, Laws SM. Assessment of a polygenic hazard score for the onset of pre-clinical Alzheimer's disease. BMC Genomics 2022; 23:401. [PMID: 35619096 PMCID: PMC9134703 DOI: 10.1186/s12864-022-08617-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2022] [Accepted: 05/09/2022] [Indexed: 11/29/2022] Open
Abstract
Abstract Background With a growing number of loci associated with late-onset (sporadic) Alzheimer’s disease (AD), the polygenic contribution to AD is now well established. The development of polygenic risk score approaches have shown promising results for identifying individuals at higher risk of developing AD, thereby facilitating the development of preventative and therapeutic strategies. A polygenic hazard score (PHS) has been proposed to quantify age-specific genetic risk for AD. In this study, we assessed the predictive power and transferability of this PHS in an independent cohort, to support its clinical utility. Results Using genotype and imaging data from 780 individuals enrolled in the Australian Imaging, Biomarkers and Lifestyle (AIBL) study, we investigated associations between the PHS and several AD-related traits, including 1) cross-sectional Aβ-amyloid (Aβ) deposition, 2) longitudinal brain atrophy, 3) longitudinal cognitive decline, 4) age of onset. Except in the cognitive domain, we obtained results that were consistent with previously published findings. The PHS was associated with increased Aβ burden, faster regional brain atrophy and an earlier age of onset. Conclusion Overall, the results support the predictive power of a PHS, however, with only marginal improvement compared to apolipoprotein E alone. Supplementary Information The online version contains supplementary material available at 10.1186/s12864-022-08617-2.
Collapse
Affiliation(s)
- Michael Vacher
- Australian e-Health Research Centre, CSIRO, Floreat, Western Australia, 6014, Australia. .,Centre for Precision Health, Edith Cowan University, Joondalup, Western Australia, 6027, Australia. .,Collaborative Genomics and Translation Group, School of Medical and Health Sciences, Edith Cowan University, Joondalup, 6027, Western Australia.
| | - Vincent Doré
- Australian e-Health Research Centre, CSIRO, Parkville, Victoria, 3052, Australia.,Department of Molecular Imaging & Therapy and Centre for PET, Austin Health, Heidelberg, Victoria, Australia
| | - Tenielle Porter
- Centre for Precision Health, Edith Cowan University, Joondalup, Western Australia, 6027, Australia.,Collaborative Genomics and Translation Group, School of Medical and Health Sciences, Edith Cowan University, Joondalup, 6027, Western Australia.,Curtin Health Innovation Research Institute, Curtin University, Bentley, 6102, Western Australia
| | - Lidija Milicic
- Centre for Precision Health, Edith Cowan University, Joondalup, Western Australia, 6027, Australia.,Collaborative Genomics and Translation Group, School of Medical and Health Sciences, Edith Cowan University, Joondalup, 6027, Western Australia
| | - Victor L Villemagne
- Centre for Precision Health, Edith Cowan University, Joondalup, Western Australia, 6027, Australia.,Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA, USA
| | - Pierrick Bourgeat
- Australian e-Health Research Centre, CSIRO, Herston, Queensland, 4029, Australia
| | - Sam C Burnham
- Centre for Precision Health, Edith Cowan University, Joondalup, Western Australia, 6027, Australia.,Australian e-Health Research Centre, CSIRO, Parkville, Victoria, 3052, Australia
| | - Timothy Cox
- Australian e-Health Research Centre, CSIRO, Parkville, Victoria, 3052, Australia
| | - Colin L Masters
- Florey Institute, The University of Melbourne, Parkville, VIC, 3052, Australia
| | - Christopher C Rowe
- Department of Molecular Imaging & Therapy and Centre for PET, Austin Health, Heidelberg, Victoria, Australia
| | - Jurgen Fripp
- Australian e-Health Research Centre, CSIRO, Herston, Queensland, 4029, Australia
| | - James D Doecke
- Centre for Precision Health, Edith Cowan University, Joondalup, Western Australia, 6027, Australia.,Australian e-Health Research Centre, CSIRO, Herston, Queensland, 4029, Australia
| | - Simon M Laws
- Centre for Precision Health, Edith Cowan University, Joondalup, Western Australia, 6027, Australia.,Collaborative Genomics and Translation Group, School of Medical and Health Sciences, Edith Cowan University, Joondalup, 6027, Western Australia.,Curtin Health Innovation Research Institute, Curtin University, Bentley, 6102, Western Australia
| |
Collapse
|
98
|
Rosenich E, Bransby L, Yassi N, Fripp J, Laws SM, Martins RN, Fowler C, Rainey-Smith SR, Rowe CC, Masters CL, Maruff P, Lim YY. Differential Effects of APOE and Modifiable Risk Factors on Hippocampal Volume Loss and Memory Decline in Aβ- and Aβ+ Older Adults. Neurology 2022; 98:e1704-e1715. [PMID: 35169009 PMCID: PMC9071368 DOI: 10.1212/wnl.0000000000200118] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2021] [Accepted: 01/11/2022] [Indexed: 11/15/2022] Open
Abstract
BACKGROUND AND OBJECTIVES This prospective study sought to determine the association of modifiable/nonmodifiable components included in the Cardiovascular Risk Factors, Aging, and Incidence of Dementia (CAIDE) risk score with hippocampal volume (HV) loss and episodic memory (EM) decline in cognitively normal (CN) older adults classified as brain β-amyloid (Aβ) negative (Aβ-) or positive (Aβ+). METHODS Australian Imaging, Biomarkers and Lifestyle study participants (age 58-91 years) who completed ≥2 neuropsychological assessments and a brain Aβ PET scan (n = 592) were included in this study. We computed the CAIDE risk score (age, sex, APOE ε4 status, education, hypertension, body mass index [BMI], hypercholesterolemia, physical inactivity) and a modifiable CAIDE risk score (CAIDE-MR; education, hypertension, BMI, hypercholesterolemia, physical inactivity) for each participant. Aβ+ was classified using Centiloid >25. Linear mixed models assessed interactions between each CAIDE score, Aβ group, and time on HV loss and EM decline. Age, sex, and APOE ε4 were included as separate predictors in CAIDE-MR models to assess differential associations. Exploratory analyses examined relationships between individual modifiable risk factors and outcomes in Aβ- cognitively normal (CN) adults. RESULTS We observed a significant Aβ group × CAIDE × time interaction on HV loss (β [SE] = -0.04 [0.01]; p < 0.000) but not EM decline (β [SE] = -2.33 [9.96]; p = 0.98). Decomposition revealed a significant CAIDE × time interaction in Aβ+ participants only. When modifiable/nonmodifiable CAIDE components were considered separately, we observed a significant Aβ group × CAIDE-MR × time interaction on EM decline only (β [SE] = 3.03 [1.18]; p = 0.01). A significant CAIDE-MR score × time interaction was observed in Aβ- participants only. Significant interactions between APOE ε4 and age × time on HV loss and EM decline were observed in both groups. Exploratory analyses in Aβ- CN participants revealed a significant interaction between BMI × time on EM decline (β [SE] = -3.30 [1.43]; p = 0.02). DISCUSSION These results are consistent with studies showing that increasing age and APOE ε4 are associated with increased rates of HV loss and EM decline. In Aβ- CN adults, lower prevalence of modifiable cardiovascular risk factors was associated with less HV loss and EM decline over ∼10 years, suggesting interventions to reduce modifiable cardiovascular risk factors could be beneficial in this group.
Collapse
Affiliation(s)
- Emily Rosenich
- From the Turner Institute for Brain and Mental Health, School of Psychological Sciences (E.R., L.B., P.M., Y.Y.L.), Monash University, Clayton; Departments of Medicine and Neurology, Melbourne Brain Centre at The Royal Melbourne Hospital (N.Y., C.C.R.), and Florey Institute of Neuroscience and Mental Health (C.F., C.L.M., P.M.), University of Melbourne; Population Health and Immunity Division (N.Y.), The Walter and Eliza Hall Institute of Medical Research, Parkville; CSIRO Health and Biosecurity (J.F.), Australian e-Health Research Centre, Brisbane; Collaborative Genomics and Translation Group, School of Medical and Health Sciences (S.M.L.), and Centre of Excellence for Alzheimer's Disease Research and Care (R.N.M.), Edith Cowan University, Joondalup; School of Pharmacy and Biomedical Sciences, Faculty of Health Sciences (S.M.L.), Curtin Health Innovation Research Institute, Curtin University, Bentley; Centre for Healthy Ageing, Health Futures Institute (S.R.R.-G.), Murdoch University; Australian Alzheimer's Research Foundation (S.R.R.-G.), Sarich Neuroscience Research Institute, Nedlands; Department of Nuclear Medicine and Centre for PET (C.C.R.), Austin Health, Heidelberg; Department of Medicine (C.C.R.), Austin Health, University of Melbourne; and Cogstate Ltd. (P.M.), Melbourne, Australia
| | - Lisa Bransby
- From the Turner Institute for Brain and Mental Health, School of Psychological Sciences (E.R., L.B., P.M., Y.Y.L.), Monash University, Clayton; Departments of Medicine and Neurology, Melbourne Brain Centre at The Royal Melbourne Hospital (N.Y., C.C.R.), and Florey Institute of Neuroscience and Mental Health (C.F., C.L.M., P.M.), University of Melbourne; Population Health and Immunity Division (N.Y.), The Walter and Eliza Hall Institute of Medical Research, Parkville; CSIRO Health and Biosecurity (J.F.), Australian e-Health Research Centre, Brisbane; Collaborative Genomics and Translation Group, School of Medical and Health Sciences (S.M.L.), and Centre of Excellence for Alzheimer's Disease Research and Care (R.N.M.), Edith Cowan University, Joondalup; School of Pharmacy and Biomedical Sciences, Faculty of Health Sciences (S.M.L.), Curtin Health Innovation Research Institute, Curtin University, Bentley; Centre for Healthy Ageing, Health Futures Institute (S.R.R.-G.), Murdoch University; Australian Alzheimer's Research Foundation (S.R.R.-G.), Sarich Neuroscience Research Institute, Nedlands; Department of Nuclear Medicine and Centre for PET (C.C.R.), Austin Health, Heidelberg; Department of Medicine (C.C.R.), Austin Health, University of Melbourne; and Cogstate Ltd. (P.M.), Melbourne, Australia
| | - Nawaf Yassi
- From the Turner Institute for Brain and Mental Health, School of Psychological Sciences (E.R., L.B., P.M., Y.Y.L.), Monash University, Clayton; Departments of Medicine and Neurology, Melbourne Brain Centre at The Royal Melbourne Hospital (N.Y., C.C.R.), and Florey Institute of Neuroscience and Mental Health (C.F., C.L.M., P.M.), University of Melbourne; Population Health and Immunity Division (N.Y.), The Walter and Eliza Hall Institute of Medical Research, Parkville; CSIRO Health and Biosecurity (J.F.), Australian e-Health Research Centre, Brisbane; Collaborative Genomics and Translation Group, School of Medical and Health Sciences (S.M.L.), and Centre of Excellence for Alzheimer's Disease Research and Care (R.N.M.), Edith Cowan University, Joondalup; School of Pharmacy and Biomedical Sciences, Faculty of Health Sciences (S.M.L.), Curtin Health Innovation Research Institute, Curtin University, Bentley; Centre for Healthy Ageing, Health Futures Institute (S.R.R.-G.), Murdoch University; Australian Alzheimer's Research Foundation (S.R.R.-G.), Sarich Neuroscience Research Institute, Nedlands; Department of Nuclear Medicine and Centre for PET (C.C.R.), Austin Health, Heidelberg; Department of Medicine (C.C.R.), Austin Health, University of Melbourne; and Cogstate Ltd. (P.M.), Melbourne, Australia
| | - Jurgen Fripp
- From the Turner Institute for Brain and Mental Health, School of Psychological Sciences (E.R., L.B., P.M., Y.Y.L.), Monash University, Clayton; Departments of Medicine and Neurology, Melbourne Brain Centre at The Royal Melbourne Hospital (N.Y., C.C.R.), and Florey Institute of Neuroscience and Mental Health (C.F., C.L.M., P.M.), University of Melbourne; Population Health and Immunity Division (N.Y.), The Walter and Eliza Hall Institute of Medical Research, Parkville; CSIRO Health and Biosecurity (J.F.), Australian e-Health Research Centre, Brisbane; Collaborative Genomics and Translation Group, School of Medical and Health Sciences (S.M.L.), and Centre of Excellence for Alzheimer's Disease Research and Care (R.N.M.), Edith Cowan University, Joondalup; School of Pharmacy and Biomedical Sciences, Faculty of Health Sciences (S.M.L.), Curtin Health Innovation Research Institute, Curtin University, Bentley; Centre for Healthy Ageing, Health Futures Institute (S.R.R.-G.), Murdoch University; Australian Alzheimer's Research Foundation (S.R.R.-G.), Sarich Neuroscience Research Institute, Nedlands; Department of Nuclear Medicine and Centre for PET (C.C.R.), Austin Health, Heidelberg; Department of Medicine (C.C.R.), Austin Health, University of Melbourne; and Cogstate Ltd. (P.M.), Melbourne, Australia
| | - Simon M Laws
- From the Turner Institute for Brain and Mental Health, School of Psychological Sciences (E.R., L.B., P.M., Y.Y.L.), Monash University, Clayton; Departments of Medicine and Neurology, Melbourne Brain Centre at The Royal Melbourne Hospital (N.Y., C.C.R.), and Florey Institute of Neuroscience and Mental Health (C.F., C.L.M., P.M.), University of Melbourne; Population Health and Immunity Division (N.Y.), The Walter and Eliza Hall Institute of Medical Research, Parkville; CSIRO Health and Biosecurity (J.F.), Australian e-Health Research Centre, Brisbane; Collaborative Genomics and Translation Group, School of Medical and Health Sciences (S.M.L.), and Centre of Excellence for Alzheimer's Disease Research and Care (R.N.M.), Edith Cowan University, Joondalup; School of Pharmacy and Biomedical Sciences, Faculty of Health Sciences (S.M.L.), Curtin Health Innovation Research Institute, Curtin University, Bentley; Centre for Healthy Ageing, Health Futures Institute (S.R.R.-G.), Murdoch University; Australian Alzheimer's Research Foundation (S.R.R.-G.), Sarich Neuroscience Research Institute, Nedlands; Department of Nuclear Medicine and Centre for PET (C.C.R.), Austin Health, Heidelberg; Department of Medicine (C.C.R.), Austin Health, University of Melbourne; and Cogstate Ltd. (P.M.), Melbourne, Australia
| | - Ralph N Martins
- From the Turner Institute for Brain and Mental Health, School of Psychological Sciences (E.R., L.B., P.M., Y.Y.L.), Monash University, Clayton; Departments of Medicine and Neurology, Melbourne Brain Centre at The Royal Melbourne Hospital (N.Y., C.C.R.), and Florey Institute of Neuroscience and Mental Health (C.F., C.L.M., P.M.), University of Melbourne; Population Health and Immunity Division (N.Y.), The Walter and Eliza Hall Institute of Medical Research, Parkville; CSIRO Health and Biosecurity (J.F.), Australian e-Health Research Centre, Brisbane; Collaborative Genomics and Translation Group, School of Medical and Health Sciences (S.M.L.), and Centre of Excellence for Alzheimer's Disease Research and Care (R.N.M.), Edith Cowan University, Joondalup; School of Pharmacy and Biomedical Sciences, Faculty of Health Sciences (S.M.L.), Curtin Health Innovation Research Institute, Curtin University, Bentley; Centre for Healthy Ageing, Health Futures Institute (S.R.R.-G.), Murdoch University; Australian Alzheimer's Research Foundation (S.R.R.-G.), Sarich Neuroscience Research Institute, Nedlands; Department of Nuclear Medicine and Centre for PET (C.C.R.), Austin Health, Heidelberg; Department of Medicine (C.C.R.), Austin Health, University of Melbourne; and Cogstate Ltd. (P.M.), Melbourne, Australia
| | - Christopher Fowler
- From the Turner Institute for Brain and Mental Health, School of Psychological Sciences (E.R., L.B., P.M., Y.Y.L.), Monash University, Clayton; Departments of Medicine and Neurology, Melbourne Brain Centre at The Royal Melbourne Hospital (N.Y., C.C.R.), and Florey Institute of Neuroscience and Mental Health (C.F., C.L.M., P.M.), University of Melbourne; Population Health and Immunity Division (N.Y.), The Walter and Eliza Hall Institute of Medical Research, Parkville; CSIRO Health and Biosecurity (J.F.), Australian e-Health Research Centre, Brisbane; Collaborative Genomics and Translation Group, School of Medical and Health Sciences (S.M.L.), and Centre of Excellence for Alzheimer's Disease Research and Care (R.N.M.), Edith Cowan University, Joondalup; School of Pharmacy and Biomedical Sciences, Faculty of Health Sciences (S.M.L.), Curtin Health Innovation Research Institute, Curtin University, Bentley; Centre for Healthy Ageing, Health Futures Institute (S.R.R.-G.), Murdoch University; Australian Alzheimer's Research Foundation (S.R.R.-G.), Sarich Neuroscience Research Institute, Nedlands; Department of Nuclear Medicine and Centre for PET (C.C.R.), Austin Health, Heidelberg; Department of Medicine (C.C.R.), Austin Health, University of Melbourne; and Cogstate Ltd. (P.M.), Melbourne, Australia
| | - Stephanie R Rainey-Smith
- From the Turner Institute for Brain and Mental Health, School of Psychological Sciences (E.R., L.B., P.M., Y.Y.L.), Monash University, Clayton; Departments of Medicine and Neurology, Melbourne Brain Centre at The Royal Melbourne Hospital (N.Y., C.C.R.), and Florey Institute of Neuroscience and Mental Health (C.F., C.L.M., P.M.), University of Melbourne; Population Health and Immunity Division (N.Y.), The Walter and Eliza Hall Institute of Medical Research, Parkville; CSIRO Health and Biosecurity (J.F.), Australian e-Health Research Centre, Brisbane; Collaborative Genomics and Translation Group, School of Medical and Health Sciences (S.M.L.), and Centre of Excellence for Alzheimer's Disease Research and Care (R.N.M.), Edith Cowan University, Joondalup; School of Pharmacy and Biomedical Sciences, Faculty of Health Sciences (S.M.L.), Curtin Health Innovation Research Institute, Curtin University, Bentley; Centre for Healthy Ageing, Health Futures Institute (S.R.R.-G.), Murdoch University; Australian Alzheimer's Research Foundation (S.R.R.-G.), Sarich Neuroscience Research Institute, Nedlands; Department of Nuclear Medicine and Centre for PET (C.C.R.), Austin Health, Heidelberg; Department of Medicine (C.C.R.), Austin Health, University of Melbourne; and Cogstate Ltd. (P.M.), Melbourne, Australia
| | - Christopher C Rowe
- From the Turner Institute for Brain and Mental Health, School of Psychological Sciences (E.R., L.B., P.M., Y.Y.L.), Monash University, Clayton; Departments of Medicine and Neurology, Melbourne Brain Centre at The Royal Melbourne Hospital (N.Y., C.C.R.), and Florey Institute of Neuroscience and Mental Health (C.F., C.L.M., P.M.), University of Melbourne; Population Health and Immunity Division (N.Y.), The Walter and Eliza Hall Institute of Medical Research, Parkville; CSIRO Health and Biosecurity (J.F.), Australian e-Health Research Centre, Brisbane; Collaborative Genomics and Translation Group, School of Medical and Health Sciences (S.M.L.), and Centre of Excellence for Alzheimer's Disease Research and Care (R.N.M.), Edith Cowan University, Joondalup; School of Pharmacy and Biomedical Sciences, Faculty of Health Sciences (S.M.L.), Curtin Health Innovation Research Institute, Curtin University, Bentley; Centre for Healthy Ageing, Health Futures Institute (S.R.R.-G.), Murdoch University; Australian Alzheimer's Research Foundation (S.R.R.-G.), Sarich Neuroscience Research Institute, Nedlands; Department of Nuclear Medicine and Centre for PET (C.C.R.), Austin Health, Heidelberg; Department of Medicine (C.C.R.), Austin Health, University of Melbourne; and Cogstate Ltd. (P.M.), Melbourne, Australia
| | - Colin L Masters
- From the Turner Institute for Brain and Mental Health, School of Psychological Sciences (E.R., L.B., P.M., Y.Y.L.), Monash University, Clayton; Departments of Medicine and Neurology, Melbourne Brain Centre at The Royal Melbourne Hospital (N.Y., C.C.R.), and Florey Institute of Neuroscience and Mental Health (C.F., C.L.M., P.M.), University of Melbourne; Population Health and Immunity Division (N.Y.), The Walter and Eliza Hall Institute of Medical Research, Parkville; CSIRO Health and Biosecurity (J.F.), Australian e-Health Research Centre, Brisbane; Collaborative Genomics and Translation Group, School of Medical and Health Sciences (S.M.L.), and Centre of Excellence for Alzheimer's Disease Research and Care (R.N.M.), Edith Cowan University, Joondalup; School of Pharmacy and Biomedical Sciences, Faculty of Health Sciences (S.M.L.), Curtin Health Innovation Research Institute, Curtin University, Bentley; Centre for Healthy Ageing, Health Futures Institute (S.R.R.-G.), Murdoch University; Australian Alzheimer's Research Foundation (S.R.R.-G.), Sarich Neuroscience Research Institute, Nedlands; Department of Nuclear Medicine and Centre for PET (C.C.R.), Austin Health, Heidelberg; Department of Medicine (C.C.R.), Austin Health, University of Melbourne; and Cogstate Ltd. (P.M.), Melbourne, Australia
| | - Paul Maruff
- From the Turner Institute for Brain and Mental Health, School of Psychological Sciences (E.R., L.B., P.M., Y.Y.L.), Monash University, Clayton; Departments of Medicine and Neurology, Melbourne Brain Centre at The Royal Melbourne Hospital (N.Y., C.C.R.), and Florey Institute of Neuroscience and Mental Health (C.F., C.L.M., P.M.), University of Melbourne; Population Health and Immunity Division (N.Y.), The Walter and Eliza Hall Institute of Medical Research, Parkville; CSIRO Health and Biosecurity (J.F.), Australian e-Health Research Centre, Brisbane; Collaborative Genomics and Translation Group, School of Medical and Health Sciences (S.M.L.), and Centre of Excellence for Alzheimer's Disease Research and Care (R.N.M.), Edith Cowan University, Joondalup; School of Pharmacy and Biomedical Sciences, Faculty of Health Sciences (S.M.L.), Curtin Health Innovation Research Institute, Curtin University, Bentley; Centre for Healthy Ageing, Health Futures Institute (S.R.R.-G.), Murdoch University; Australian Alzheimer's Research Foundation (S.R.R.-G.), Sarich Neuroscience Research Institute, Nedlands; Department of Nuclear Medicine and Centre for PET (C.C.R.), Austin Health, Heidelberg; Department of Medicine (C.C.R.), Austin Health, University of Melbourne; and Cogstate Ltd. (P.M.), Melbourne, Australia
| | - Yen Ying Lim
- From the Turner Institute for Brain and Mental Health, School of Psychological Sciences (E.R., L.B., P.M., Y.Y.L.), Monash University, Clayton; Departments of Medicine and Neurology, Melbourne Brain Centre at The Royal Melbourne Hospital (N.Y., C.C.R.), and Florey Institute of Neuroscience and Mental Health (C.F., C.L.M., P.M.), University of Melbourne; Population Health and Immunity Division (N.Y.), The Walter and Eliza Hall Institute of Medical Research, Parkville; CSIRO Health and Biosecurity (J.F.), Australian e-Health Research Centre, Brisbane; Collaborative Genomics and Translation Group, School of Medical and Health Sciences (S.M.L.), and Centre of Excellence for Alzheimer's Disease Research and Care (R.N.M.), Edith Cowan University, Joondalup; School of Pharmacy and Biomedical Sciences, Faculty of Health Sciences (S.M.L.), Curtin Health Innovation Research Institute, Curtin University, Bentley; Centre for Healthy Ageing, Health Futures Institute (S.R.R.-G.), Murdoch University; Australian Alzheimer's Research Foundation (S.R.R.-G.), Sarich Neuroscience Research Institute, Nedlands; Department of Nuclear Medicine and Centre for PET (C.C.R.), Austin Health, Heidelberg; Department of Medicine (C.C.R.), Austin Health, University of Melbourne; and Cogstate Ltd. (P.M.), Melbourne, Australia
| |
Collapse
|
99
|
Krishnadas N, Doré V, Groot C, Lamb F, Bourgeat P, Burnham SC, Huang K, Goh AMY, Masters CL, Villemagne VL, Rowe CC. Mesial temporal tau in amyloid-β-negative cognitively normal older persons. Alzheimers Res Ther 2022; 14:51. [PMID: 35395950 PMCID: PMC8991917 DOI: 10.1186/s13195-022-00993-x] [Citation(s) in RCA: 10] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2021] [Accepted: 03/23/2022] [Indexed: 11/17/2022]
Abstract
BACKGROUND Tau deposition in the mesial temporal lobe (MTL) in the absence of amyloid-β (Aβ-) occurs with aging. The tau PET tracer 18F-MK6240 has low non-specific background binding so is well suited to exploration of early-stage tau deposition. The aim of this study was to investigate the associations between MTL tau, age, hippocampal volume (HV), cognition, and neocortical tau in Aβ- cognitively unimpaired (CU) individuals. METHODS One hundred and ninety-nine Aβ- participants (Centiloid < 25) who were CU underwent 18F-MK6240 PET at age 75 ± 5.2 years. Tau standardized uptake value ratio (SUVR) was estimated in mesial temporal (Me), temporoparietal (Te), and rest of the neocortex (R) regions and four Me sub-regions. Tau SUVR were analyzed as continuous variables and compared between high and low MTL SUVR groups. RESULTS In this cohort with a stable clinical classification of CU for a mean of 5.3 years prior to and at the time of tau PET, MTL tau was visually observed in 9% of the participants and was limited to Braak stages I-II. MTL tau was correlated with age (r = 0.24, p < 0.001). Age contributed to the variance in cognitive scores but MTL tau did not. MTL tau was not greater with subjective memory complaint, nor was there a correlation between MTL tau and Aβ Centiloid value, but high tau was associated with smaller HV. Participants with MTL tau had higher tau SUVR in the neocortex but this was driven by the cerebellar reference region and was not present when using white matter normalization. CONCLUSIONS In an Aβ- CU cohort, tau tracer binding in the mesial temporal lobe was age-related and associated with smaller hippocampi, but not with subjective or objective cognitive impairment.
Collapse
Affiliation(s)
- Natasha Krishnadas
- Florey Department of Neurosciences & Mental Health, The University of Melbourne, Parkville, VIC, 3052, Australia
- Department of Molecular Imaging & Therapy, Austin Health, 145 Studley Rd, Heidelberg, VIC, 3084, Australia
| | - Vincent Doré
- Department of Molecular Imaging & Therapy, Austin Health, 145 Studley Rd, Heidelberg, VIC, 3084, Australia
- Health and Biosecurity Flagship, The Australian eHealth Research Centre, Melbourne, Victoria, Australia
| | - Colin Groot
- Department of Molecular Imaging & Therapy, Austin Health, 145 Studley Rd, Heidelberg, VIC, 3084, Australia
| | - Fiona Lamb
- Department of Molecular Imaging & Therapy, Austin Health, 145 Studley Rd, Heidelberg, VIC, 3084, Australia
| | - Pierrick Bourgeat
- Health and Biosecurity Flagship, The Australian eHealth Research Centre, Brisbane, QLD, Australia
| | - Samantha C Burnham
- Health and Biosecurity Flagship, The Australian eHealth Research Centre, Melbourne, Victoria, Australia
| | - Kun Huang
- Department of Molecular Imaging & Therapy, Austin Health, 145 Studley Rd, Heidelberg, VIC, 3084, Australia
| | - Anita M Y Goh
- Department of Psychiatry, The University of Melbourne, Parkville, VIC, 3010, Australia
- National Ageing Research Institute, Parkville, VIC, 3052, Australia
| | - Colin L Masters
- Florey Institute of Neuroscience & Mental Health, Parkville, VIC, 3052, Australia
| | | | - Christopher C Rowe
- Florey Department of Neurosciences & Mental Health, The University of Melbourne, Parkville, VIC, 3052, Australia.
- Department of Molecular Imaging & Therapy, Austin Health, 145 Studley Rd, Heidelberg, VIC, 3084, Australia.
- Florey Institute of Neuroscience & Mental Health, Parkville, VIC, 3052, Australia.
| |
Collapse
|
100
|
Bu XL, Sun PY, Fan DY, Wang J, Sun HL, Cheng Y, Zeng GH, Chen DW, Li HY, Yi X, Shen YY, Miles LA, Maruff P, Gu BJ, Fowler CJ, Masters CL, Wang YJ. Associations of plasma soluble CD22 levels with brain amyloid burden and cognitive decline in Alzheimer's disease. Sci Adv 2022; 8:eabm5667. [PMID: 35363517 PMCID: PMC10938586 DOI: 10.1126/sciadv.abm5667] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/27/2021] [Accepted: 02/10/2022] [Indexed: 06/14/2023]
Abstract
CD22 has been suggested to contribute to Alzheimer's disease (AD) pathogenesis by inhibiting microglial amyloid β (Aβ) phagocytosis. Soluble CD22 (sCD22) generated by cleavage from cell membranes may be a marker of inflammation and microglial dysfunction; but alterations of sCD22 levels in AD and their correlation with AD biomarkers remain unclear. Plasma sCD22 levels were measured in cognitively normal non-AD participants and patients with preclinical AD and AD dementia from a Chinese cohort and the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing. Plasma sCD22 levels were elevated in patients with preclinical and dementia AD. Plasma sCD22 levels were negatively correlated with cerebrospinal fluid (CSF) Aβ42 levels and Aβ42/Aβ40, and positively correlated with CSF phosphorylated tau levels and brain Aβ burden, but negatively correlated with cognitive function. Moreover, higher plasma sCD22 levels were associated with faster cognitive decline during follow-up. These findings suggest that CD22 plays important roles in AD development, and that sCD22 is a potential biomarker for AD.
Collapse
Affiliation(s)
- Xian-Le Bu
- Department of Neurology and Centre for Clinical Neuroscience, Daping Hospital, Third Military Medical University, Chongqing, China
- Institute of Brain and Intelligence, Third Military Medical University, Chongqing, China
- Chongqing Key Laboratory of Ageing and Brain Diseases, Chongqing, China
| | - Pu-Yang Sun
- Department of Neurology and Centre for Clinical Neuroscience, Daping Hospital, Third Military Medical University, Chongqing, China
- Chongqing Key Laboratory of Ageing and Brain Diseases, Chongqing, China
| | - Dong-Yu Fan
- Department of Neurology and Centre for Clinical Neuroscience, Daping Hospital, Third Military Medical University, Chongqing, China
- Chongqing Key Laboratory of Ageing and Brain Diseases, Chongqing, China
- Shigatse Branch, Xinqiao Hospital, Third Military Medical University, Shigatse, China
| | - Jun Wang
- Department of Neurology and Centre for Clinical Neuroscience, Daping Hospital, Third Military Medical University, Chongqing, China
- Chongqing Key Laboratory of Ageing and Brain Diseases, Chongqing, China
| | - Hao-Lun Sun
- Shigatse Branch, Xinqiao Hospital, Third Military Medical University, Shigatse, China
| | - Yuan Cheng
- Department of Neurology and Centre for Clinical Neuroscience, Daping Hospital, Third Military Medical University, Chongqing, China
- Chongqing Key Laboratory of Ageing and Brain Diseases, Chongqing, China
| | - Gui-Hua Zeng
- Department of Neurology and Centre for Clinical Neuroscience, Daping Hospital, Third Military Medical University, Chongqing, China
- Chongqing Key Laboratory of Ageing and Brain Diseases, Chongqing, China
| | - Dong-Wan Chen
- Department of Neurology and Centre for Clinical Neuroscience, Daping Hospital, Third Military Medical University, Chongqing, China
- Chongqing Key Laboratory of Ageing and Brain Diseases, Chongqing, China
| | - Hui-Yun Li
- Department of Neurology and Centre for Clinical Neuroscience, Daping Hospital, Third Military Medical University, Chongqing, China
- Chongqing Key Laboratory of Ageing and Brain Diseases, Chongqing, China
| | - Xu Yi
- Department of Neurology and Centre for Clinical Neuroscience, Daping Hospital, Third Military Medical University, Chongqing, China
- Chongqing Key Laboratory of Ageing and Brain Diseases, Chongqing, China
| | - Ying-Ying Shen
- Department of Neurology and Centre for Clinical Neuroscience, Daping Hospital, Third Military Medical University, Chongqing, China
- Chongqing Key Laboratory of Ageing and Brain Diseases, Chongqing, China
| | - Luke A. Miles
- The Florey Institute, The University of Melbourne, Parkville, Victoria, Australia
| | - Paul Maruff
- The Florey Institute, The University of Melbourne, Parkville, Victoria, Australia
- CogState, Melbourne, Victoria, Australia
| | - Ben J. Gu
- The Florey Institute, The University of Melbourne, Parkville, Victoria, Australia
| | | | - Colin L. Masters
- The Florey Institute, The University of Melbourne, Parkville, Victoria, Australia
| | - Yan-Jiang Wang
- Department of Neurology and Centre for Clinical Neuroscience, Daping Hospital, Third Military Medical University, Chongqing, China
- Institute of Brain and Intelligence, Third Military Medical University, Chongqing, China
- Chongqing Key Laboratory of Ageing and Brain Diseases, Chongqing, China
- State Key Laboratory of Trauma, Burns and Combined Injury, Third Military Medical University, Chongqing, China
- Center for Excellence in Brain Science and Intelligence Technology, Chinese Academy of Sciences, Shanghai, China
| |
Collapse
|